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Abstract 
 
Background 
The prevalence of hearing impairment in infants born prematurely or with low birth weight 
is around 1-2%, up to 10 times higher than babies born at term. The aetiology of which is 
poorly understood; risk factors are likely to be interrelated. Susceptibility to the audiological 
toxicity of gentamicin, frequently given to newborn babies, is increased in the presence of 
m.1555A>G, a mitochondrial mutation.  
Objectives 
This study aims to investigate the aetiology of hearing loss in infants following neonatal 
intensive care, and the burden that m.1555A>G represents to deafness in children born at 
less than 32 weeks gestational age. 
Method 
This was a case control study of preterm children with hearing loss in Greater London. 
Controls (up to 5 per case) had normal hearing and were matched for sex, gestational age 
and hospital in which they received neonatal care. Saliva samples were taken from all 
children for genetic screening of m.1555A>G. Audiological, pharmacological and clinical data 
were abstracted from medical notes.  
Results 
Two hundred and thirty seven children, 57 children with hearing loss, were recruited to the 
study. Independent risks included low gestational age, low birthweight, patent ductus 
arteriosus, acquired brain injury, the use of inotrope, steroid, vancomycin, furosemide, 
elevated bilirubin and creatinine levels. Cumulative doses of gentamicin, vancomycin, and 
furosemide also increased the risk of impaired hearing. One child with normal hearing had 
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the m.1555A>G mutation and had been exposed to aminoglycosides. A high frequency 
hearing loss has since been detected. 
Discussion 
The prevalence of m.1555A>G was 0.41%, and is unlikely to explain the increased rate of 
hearing loss in preterm infants. Children with hearing loss were exposed to a greater number 
of interacting risk factors across a timeline of care. Cumulative ototoxic medication in 
particular, increased the likelihood of hearing loss, warranting closer monitoring throughout 
neonatal care. 
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1 Chapter 1: Introduction 
1.1 Hearing loss in preterm infants 
Substantial advances in neonatal care have improved the survival rates of infants born very 
prematurely. This has primarily led to reduced mortality at extremely low gestations but also 
to increases in the proportion of survivors without disability, at the cost of a small increase 
in the numbers of children with moderate or severe impairments in motor, cognitive, visual 
and hearing domains [1]. In particular there has been no discernible change in the uncommon 
but important prevalence of hearing loss in this group. 
The prevalence of hearing loss in newborn infants in the general population is around 1 in 
700-1000 [2], which increases to 2.7 per 1000 children before the age of 5 years [3]. The 
incidence of hearing loss in children born prematurely is estimated to be up to 10 times 
higher than the normal paediatric population [4]; hence this thesis will examine potential 
acquired causes for hearing loss after birth. However, it should be noted that prevalence 
rates vary greatly between studies, which show significant methodological heterogeneity. In 
general NICU populations including term and preterm infants, there is a range of 0.07-11% 
between different studies (Appendix 1), which may increase up to 54% when looking at 
specific groups of infants within the NICU population (Appendix 2). The range of reported 
prevalence between studies indicate differences in gestation, severity of illness, and 
definition and measurement of hearing loss. 
Childhood deafness has broad long term implications including social and emotional 
development, educational achievement, and later vocational opportunities, even in mild 
cases of unilateral or bilateral hearing loss [5]. Dependent on the age of onset, hearing 
impairment can be described as prelingual (prior to the development of speech) or 
postlingual (following speech development) [6]. Early identification is essential and likely to 
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lead to a reduction in the wider complications of growing up deaf; current policy is for all 
infants to be screened prior to discharge from hospital 
(https://www.gov.uk/government/publications/newborn-hearing-screening-care-
pathways). Screening failures are then rapidly evaluated to come to a firm diagnosis and 
commence early interventions. 
Following preterm birth, permanent hearing loss is of two main types, sensorineural hearing 
loss (SNHL) and auditory neuropathy spectrum disorder (ANSD). SNHL is a result of damage 
to the outer hair cells of the cochlea, but the inner hair cells, auditory nerve and brainstem 
are intact. These outer hair cells are unable to regenerate and any impairment cannot 
therefore be reversed. SNHL can be congenital (present at birth) or acquired during the 
lifetime. Probable causes of hearing impairment include sepsis, hypoxia, 
hyperbilirubinaemia, noise and drug-induced ototoxicity. Furthermore, risk factors are likely 
to be interrelated, such as interactions between genetic and environmental risk factors which 
can be a further cause of hearing loss (discussed in section 1.3.2). However, due to the 
complexity of these relationships, aetiology remains inconclusive. 
In contrast, ANSD is typically “retrocochlear”, and can be an impairment of the eighth cranial 
nerve or the inner hair cells. The outer cochlear hair cells are functional but brainstem 
responses are abnormal or absent [7]. A reduction in the number of neurons, or a disordered 
neural signal are thought to underlie the disrupted responses [8]; most cases appear to result 
from an impaired auditory nerve or inner hair cells. In some individuals with ANSD, genetic 
abnormalities may predispose to hearing impairment, such as mutations in the otoferlin gene 
(OTOF). The localisation of ANSD may differ depending on the site of the lesion and therefore 
provides a varying clinical picture between individuals. ANSD emerged in the 1980’s as a 
separate condition from SNHL, but did not become a separate diagnosis until the mid 1990’s, 
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therefore most of the older studies will not have differentiated between the two conditions. 
Furthermore, there remain studies that still consider ANSD to be a form of SNHL. 
The Newborn Hearing Screening Programme (NHSP) was introduced across the UK in 2006. 
All infants born in the UK are screened for a hearing impairment shortly after birth, and 
preterm infants prior to being discharged home. Initial screening for all infants assesses the 
functioning of cochlear outer hair cells using otoacoustic emissions (OAEs). OAEs are the 
responses of outer cochlear hair cells following an auditory stimulus (either a click or 
simultaneous tones of differing frequency) which generates a sound detected by a 
microphone in the ear canal [9]. OAEs are dependent on the functioning of the cochlear outer 
hair cells and provide no indication of the inner hair cells, auditory nerve or brainstem 
pathways.  
The other commonly used method of hearing assessment is auditory brainstem responses 
(ABR). This detects abnormalities from the inner hair cells, to the auditory nerve or auditory 
brainstem pathway by measuring the electric field potentials produced by the brainstem 
following rapid clicks or tone pips which stimulate the cochlea. Generated field potentials 
produce a waveform response with the auditory stimulus being decreased until the waves 
are absent. Waves I and II demonstrate activity of the distal and proximal auditory nerve, 
with waves III, IV and V indicating activity from the auditory brainstem structures [10]. The 
number of neurons firing (amplitude) and the speed at which waves are detected (latency) 
are also monitored.  
Hearing function is measured using auditory thresholds, which are the quietest sounds that 
can be detected. Sound levels are measured in decibels hearing level (dB HL), with a normal 
threshold at 0 dB HL up to 20 dB HL. The severity of hearing impairment is usually categorised 
as mild (20-40 dB HL), moderate (41-70 dB HL), severe (71-95 dB HL), or profound (>95 dB 
HL), ranging from low frequency (250 Hz) to high frequency (8000 Hz).  
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Whilst early screening is essential for early recognition and timely intervention, it is not 
always effective at identifying all forms of hearing loss. For example, SNHL may have a 
delayed onset [11], and could be a progressive loss [12], which may not be detectable from 
birth. Furthermore, ANSD shows normal OAEs but abnormal or absent ABRs [13], and would 
not be detectable by routine newborn hearing screening which relies on OAE responses. 
Some children with ANSD may therefore be missed at initial screening giving false negative 
results, and there is some debate as to which method should be used for the first test, 
although for preterm or ‘at risk’ infants, both tests are now used.  
As well as differences in clinical presentation and method of diagnosis, prevalence rates 
between SNHL and ANSD also vary. Research has reliably shown the rates of ANSD to be 
lower than SNHL, although inconsistences in population samples and methodology lead to a 
marked variance in rates between studies. For example, in an American study of 4250 NICU 
infants, the incidence of ANSD was 5.6/1000; much lower in comparison to SNHL which had 
a rate of 16.7/1000 [14]. However, in a UK based study of 45 050 infants that looked 
specifically at severe to profound hearing loss the difference between prevalence rates of 
SNHL and ANSD was much smaller (0.67/1000 and 0.27/1000, respectively) [15]. 
Comparisons between prevalence rates vary with selected populations. 
Children with prelingual SNHL and ANSD, are at risk of significant speech perception 
difficulties and speech and language development problems. Both forms of hearing 
impairment can be irreversible and treatment consists of hearing aids to amplify sound. 
When hearing aids are insufficient, a cochlear implant (CI) may be considered. Following the 
detection of sound, CI provides an electrical stimulation directly to the auditory nerve for the 
transduction of a neural signal. Although hearing aids and CI do not restore normal hearing 
they enable speech to be perceived; children with hearing loss in receipt of early treatment 
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will often develop near normal speech and language, especially if there are no additional 
problems. 
There is much uncertainty as to the causal pathway of hearing loss and a range of risk factors 
have been described, which in turn contribute to current understanding of deafness in 
relation to neonatal events and treatments. 
1.1.1 Risk factors for hearing loss 
The Joint Committee on Infant Hearing (JCIH) identified 10 risk factors associated with 
hearing loss [16]. These were: family history of hearing loss, congenital infections, 
craniofacial abnormalities, low birth weight (less than 1500g), hyperbilirubinaemia, ototoxic 
medications, bacterial meningitis, low Apgar scores at 1 or 5 minutes, assisted ventilation for 
5 days or more, and syndromes associated with hearing loss. Additional risk factors have also 
been proposed, including gastrointestinal surgery, cardiac surgery, treatment for 
hypotension, hyponatremia, the administration of furosemide (including with simultaneous 
elevated creatinine levels), prolonged oxygen use and noise [12]. Despite continual 
improvements in neonatal care, many of these risk factors have not decreased in prevalence 
including necrotising enterocolitis (NEC) and bronchopulmonary dysplasia (BPD) [17]. 
Interactions between risk factors have also been established [4].  
The aetiology of hearing loss in the general population can be categorised as genetic 
(syndromic or non syndromic) or non genetic, with approximately 50% being attributed to 
each [3]. However, recent population based studies have found genetic and non genetic 
causes to be less common than originally estimated; between 24 and 45% of children appear 
to have hearing loss of unknown aetiology [18-21].  
I will now review studies that have evaluated potential causation of hearing loss in babies 
following neonatal intensive care, starting with non genetic risk factors.  
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1.2 Non genetic risk factors for hearing loss 
Clinical risk factors for hearing loss in infants include gestational age and birthweight, 
hypoxia, respiratory support, acquired brain injury, hyperbilirubinaemia, infection, noise, and 
medication, which will be considered in the following sections. 
1.2.1 Gestational age and birth weight 
Very preterm infants (<32 weeks of gestation), and those with the most immature gestational 
ages and lowest birth weights in particular, often have a complicated neonatal course. A 
preterm infant is defined as an infant born before 37 completed weeks of gestation, with 
subcategories of moderate to late preterm (from 32-37 weeks of gestation), very preterm 
(between 28 and 32 weeks of gestation) and extremely preterm (born below 28 weeks of 
gestation). Despite many studies using gestational week as a cut off for inclusion, some, 
particularly early, studies adopt low birth weight as an alternative inclusion criterion. Low 
birth weight (LBW) is defined as an infant weighing less than 2500g at birth, very low birth 
weight (VLBW) is below 1500g and extremely low birth weight (ELBW) is less than 1000g. 
Additionally, there are infants who are small for gestational age (SGA) who are born with a 
birthweight below the 10th percentile for gestational age. Subsequently, these babies face 
additional risk for adverse outcome. Gestational age is preferential over birthweight as the 
most important predictor of preterm survival [17]. Prematurity and low birth weight are 
intimately related and have both been associated with hearing loss. 
In a large study of 18 564 infants born at less than 32 weeks of gestation, the prevalence of 
hearing loss was measured according to week of gestation and category of birth weight (250g 
intervals between 750g and 1500g) [22]. Birth weight and gestational age were both found 
to be independent predictors of hearing loss, with hearing loss increasing gradually with 
decreasing week of gestation and decreasing birth weight. Interestingly, the frequency of 
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hearing loss remained relatively stable above 26 weeks of gestation. An interaction between 
gestational age and sex was also found, with females at a greater risk at less than 28 weeks, 
whilst males were at a greater risk of hearing loss when born at a gestational age of 30 weeks 
or below. This is supported by previous research that has found a male susceptibility to 
neonatal illness with increased risk of morbidities and poorer neurological outcome [23, 24]. 
Additionally there was an added risk conferred by being SGA, particularly for babies born 
below 27 weeks of gestation. This study considered infants born at 24 weeks and above, and 
it would be valuable to understand how hearing impairment may be more prevalent in 
survivors of more extremely preterm birth given the increase in survival rates (less than 24 
weeks). It would also be of benefit to consider gestational age and birth weight for 
gestational age in context with illness.  
The classification of hearing loss has also been investigated in relation to gestational age and 
birthweight. In a study of 24 infants with ANSD, 71 with SNHL and 95 normal hearing matched 
controls, the clinical characteristics of ANSD were examined in comparison to the other 
groups. The very smallest babies were the most likely to have a diagnosis of ANSD [14]. In 
the context of additional illness, both groups of infants were more likely to have had 
prolonged ventilation and BPD in comparison to the control group. It is difficult to disentangle 
the risks attributable to gestational age, birthweight and being small for dates from other 
factors which become more common as each decreases. Due to the 10 fold increase in risk 
of acquired hearing loss in preterm infants in comparison to term born babies, the inclusion 
criteria for the current study concentrated on babies born at less than 32 weeks of gestation. 
1.2.2 Hypoxia 
Hearing loss has been associated with hypoxia in both term and preterm infants. A lack of 
oxygenation and perfusion within the cochlea, specifically the outer hair cells and stria 
vascularis, results in decreased functioning [9]. Hypoxia limits the amount of energy available 
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for the sodium-potassium pump to generate the endocochlear potential within the stria 
vascularis. In the face of a reduced oxygen supply, the positive charge of the endocochlear 
potential (+80mV) decreases which causes a reduction of potassium moving from the 
endolymph into the hair cells, therefore lowering the sensitivity of hair cells within the 
cochlear [25]. Subsequently, audiological sensitivity is reduced leading to an elevation in 
hearing threshold [26].  
The majority of studies focusing on hypoxia consider babies born at term, although several 
important studies have evaluated preterm infants, with contrasting results.  
The clinical condition of the baby around the time of birth is increasingly thought to be a 
predictor of later outcome [27]. Hille et al (2007) found severe birth asphyxia was associated 
with hearing loss in 71 children from a nationwide cohort of 2186, born at less than 30 weeks 
of gestation and/or birth weight <1000g [28]. Although it is unclear as to how birth asphyxia 
was measured, a study looking at acidosis immediately after birth found similar results [29]. 
More specifically, a blood pH level below 7.25 in the first two hours following birth or on two 
or more days during treatment, was thought to have a crucial impact on cochlear perfusion 
and subsequent hearing impairment. Apgar scores also provide an indicator of clinical 
condition following birth and while preterm infants with SNHL have a higher incidence of low 
Apgar scores (at 1 minute) [30], studies using similar populations of preterm infants have not 
observed the same findings [31-33].  
Postnatal hypoxia has also been associated with hearing loss in preterm infants. In a study of 
preterm (24-34 weeks) and very low birth weight babies (<1500g), hearing loss was 
associated with a greater number of episodes of low pH and hypoxemia [31]. Level of illness 
was also taken into account in this study, with infants grouped according to the number of 
variables representing their neonatal illness. All hearing impaired infants fell exclusively 
within the group of most unwell babies. Comparisons between infants within this group 
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showed the babies with SNHL to have a higher gestational age and birthweight but 
nevertheless, remained the most unwell with the highest illness scores. Although there were 
only 12 infants with SNHL, this may be suggestive of level of illness and associated treatments 
influencing hypoxia and therefore hearing loss. Similarly, Abramovich et al (1979) concluded 
that hearing loss in very low birth weight infants was likely to be a result of perinatal illness 
inducing hypoxia [34]. Apnoea requiring intubation and ventilation was the most significant 
predictor of hearing loss. Seven of the ten children with hearing loss had additional 
developmental deficits indicative of cerebral damage which suggests the hearing impairment 
could be related to the hypoxia, brain injury or both.  
The definition of hypoxia can be somewhat ambiguous between studies with varying 
measures being used, including Apgar scores (different cut offs at 1, 5, 10 and 20 minutes 
[18, 33]), acidotic blood levels (with varying cut offs for pH and timing of acidosis [33, 34]), 
the number or length of apnoeic episodes [31], and apnoea requiring intubation and 
ventilation [34], causing difficulties in making direct comparisons between studies.  
Literature has not identified at which point hypoxia becomes detrimental to hearing. Jiang et 
al (1995) investigated the effect of perinatal and postnatal hypoxia [26]. Comparisons were 
made between 3 groups of infants: perinatal asphyxia (based on 1 and 5 min Apgar scores 
with no neurological deficits), perinatal asphyxia (20 minute Apgar scores or seizures with 
signs of neurological deficits), and postnatal asphyxia (prolonged asphyxia between 3 and 12 
months of age including respiratory failure and aspiration, all with neurodevelopmental 
deficits). Infants were excluded if they had postnatal complications unrelated to asphyxia 
that could cause hearing loss, although this was not defined. Prolonged wave V latencies and 
hearing loss at low intensities were identified, with permanent hearing loss occurring more 
frequently following asphyxia in the perinatal groups than in the postnatally asphyxiated 
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group. As hearing loss is markedly less common after 3 months of age it is possible that 
immaturity of the cochlea could increase susceptibility to damage via hypoxic insult. 
Hearing impairment also shows a trend towards being less common following treatment with 
therapeutic hypothermia (figure 1-1). Therapeutic hypothermia is used to treat near term 
infants with hypoxic-ischaemic encephalopathy (HIE), by cooling the temperature of the 
head, the body or both to 33-34oC. In four of five randomised controlled trials there was a 1-
13% decrease in the number of children with hearing loss following therapeutic hypothermia 
[35-38]. Interestingly, selective head cooling was used in the cool-cap trial in comparison to 
whole body cooling in the other trials and had a higher rate of hearing loss in the cooled 
group [39]. Differences in technique in this study may have led to a lower temperature within 
the inner ear, which may explain the discrepancy in the hearing outcome. A meta-analysis of 
the five studies with two additional studies, one adopting whole body cooling and the other 
head cooling only ([40, 41] respectively), showed no significant effect of therapeutic 
hypothermia on SNHL [42]. Nevertheless, the two studies using selective head cooling 
indicated an increased number of children from the cooled groups, presenting with impaired 
hearing at neurodevelopmental follow up appointments. Cooling reduces cellular secondary 
energy failure following the hypoxic insult, potentially decreasing the period of cochlear 
sensitivity following birth, but selective head cooling may increase the risk of hearing 
impairment.   
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Figure 1-1: Sensorineural hearing loss comparison between cooled and non-cooled infants 
with hypoxic-ischaemic encephalopathy, in 5 randomised controlled trials 
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In animal models, decreased auditory function has been observed following prolonged 
episodes of hypoxia [43]. Oxygenation, and circulation within the cochlea were reduced and 
importantly, systemic blood pressure also dropped producing a local and central response to 
the hypoxic episode. Hypoxia and changes in cerebral circulation are also related to IVH, 
which will be discussed in section 1.2.4. Hypoxia, asphyxia and ischaemia are likely to have 
differing effects which will affect term and preterm infants in varying ways. 
1.2.3 Respiratory support 
Respiratory support is inextricably associated with hypoxia, sepsis and therefore medication 
use, and, indeed surgical interventions such as ligation of Patent Ductus Arteriosus (PDA). 
Respiratory support can include conventional positive pressure ventilation, high frequency 
oscillation (HFO), continuous positive airway pressure (CPAP), high flow and low flow oxygen. 
As an individual cause of hearing loss respiratory support has been debated with inconclusive 
results, mainly due to the differing ways of measuring respiratory support, such as number 
of days ventilated or more directly related to the categorical clinical condition requiring the 
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additional support such as bronchopulmonary dysplasia (BPD, defined as an infant being in 
oxygen at 28 days and in air at 36 weeks corrected gestational age, <30% oxygen at 36 weeks 
gestational age, or >30% oxygen at 36 weeks gestational age) [44]. Prolonged ventilation can 
cause persistent inflammation of the lungs which can contribute to BPD. 
The risk of hearing loss is higher in infants following persistent pulmonary hypertension 
(PPHN), for which the need for high levels of respiratory support is crucial [45]. PPHN is 
associated with a number of causes including meconium aspiration and congenital 
diaphragmatic hernia (CDH). Treatment in some centres often involves hyperventilation with 
high levels of oxygen therapy which subsequently can cause cerebral vasoconstriction [46]. 
Conditions requiring this level of respiratory support can also cause neonatal hypoxia 
(discussed in section 1.2.2), and the two can be difficult to separate.  
Robertson et al (2002) investigated SNHL in 90 survivors of respiratory failure at four years 
of age in a multicentre study in Canada [47]. An unusually high number of babies were found 
to have a hearing impairment; all 15 term or near term infants with CDH were found to have 
SNHL, and 15 (21%) infants with severe respiratory failure but without CDH had SNHL at two 
years of age which doubled by the age of four (42%). However, there was no difference 
between the groups in terms of respiratory support, inclusive of high frequency ventilation, 
the administration of inhaled nitric oxide or extracorporeal membrane oxygenation (ECMO). 
There is a strong likelihood that these infants had other antecedents for hearing loss such as 
ototoxic medication and diuretics, yet risk factors for hearing impairment other than 
respiratory failure were not explored in the study. Despite this, the rate of SNHL remains 
surprisingly high, which could be related to the selected sample of infants and the severity of 
illness as these results have not been found by other studies [48]. Rather than respiratory 
failure or support as a predictor of hearing loss, it could be the simultaneous risks that are 
incurred as a consequence.  
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The introduction of antenatal steroids and surfactant replacement therapy have reduced the 
prevalence and severity of respiratory distress syndrome (RDS) and improved lung function 
in preterm infants [44]. Subsequently, a reduction in further neonatal morbidities has seen 
both medications as being protective of hearing loss [49], however, severe respiratory failure 
continues to be associated with hearing loss in these populations. In a study of 1279 infants 
born at 28 weeks gestational age or less with a birth weight of 1250g or less, severe or 
profound hearing loss was found in 40 (3%) babies [12]. Significantly more babies with 
bilateral hearing loss received oxygen until 36 weeks corrected gestation. Prolonged 
ventilation is concordant with ligation of PDA and medical or surgical treatment of NEC, both 
of which were also predictors of hearing loss. Thus it is difficult to isolate which are the 
independent or combined causes of hearing impairment. 
Bergman et al (1985) demonstrated that the maximum number of days requiring respiratory 
support was a significant predictor of hearing loss in a study of 72 children (36 NICU 
graduates with SNHL, 36 control) [32]. This study had a relatively small sample size with an 
equivalent number of controls whereas many studies have an increased number of controls 
to achieve statistical power. However, similar findings were found in an Italian study of 532 
infants, 84 at high risk for hearing loss [50], and a Mexican study of 418 NICU infants, whereby 
both studies found number of days receiving mechanical ventilation (>9.6 days) was also 
significantly higher in a group of infants with hearing loss in comparison to controls [49]. 
Meningitis and intraventricular haemorrhage were other significant characteristics and the 
duration of ventilation could be related to a lower birthweight and more severe level of 
illness, both of which were more prevalent in the hearing loss group.  
In a comparison of 24 infants with ANSD and 71 infants with SNHL and 95 matched control 
infants with normal hearing, the number of days requiring mechanical ventilation was 
specifically associated with ANSD in a comparison to infants with SNHL and normal hearing 
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[14]. In contrast, SNHL was more common in survivors of high frequency oscillation. BPD was 
associated with hearing loss in both groups but was also significantly greater in the babies 
with ANSD in comparison to SNHL. In a cohort of preterm infants with a birthweight of <750g, 
BPD was found in 5 of 6 of the infants with SNHL [51]. However, mechanical ventilation and 
the use of furosemide were also evident within the clinical history, both of which are 
additional antecedents to hearing loss. Although respiratory support is unlikely to be toxic to 
the auditory system, potential causation may be via ventilator noise, frequent hypoxic 
episodes or concomitant treatments.   
Thus several studies have found increased risk of hearing loss among babies with neonatal 
lung disease but few have attempted to tease out factors which may drive this association. 
1.2.4 Acquired brain injury 
Although intraventricular haemorrhage (IVH) is not listed as a risk factor for hearing loss, it 
has been considered as such in many studies. Cranial ultrasound is used to diagnosis and 
monitor IVH and grades of IVH severity have been classified as follows. A grade I IVH is a 
subependymal haemorrhage confined to the germinal matrix. The germinal matrix in 
preterm infants is highly vascular but has a poor capillary support network, increasing 
vulnerability to brain injury. In particular, germinal matrix IVH causes damage to the glial 
precursor cells during their migration to cortical layers, impacting cortical development and 
therefore resulting in a greater likelihood of neurodevelopmental deficits [52]. Grade II is a 
germinal matrix haemorrhage that has ruptured through the ependymal lining to the lateral 
ventricles but has not caused ventricular distension, grade III involves ventricular dilatation 
as a result of blood filling the ventricular space, and a grade IV means there is an associated 
haemorrhagic parenchymal infarction [53]. Babies born below 32 weeks of gestation are the 
most at risk of IVH along with very low birth weight babies. An IVH will typically occur within 
the first 72 hours after birth [54]. Possible risk factors aside from prematurity, include a 
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vulnerability to changes in cerebral blood volume, cerebral vascular immaturity resulting in 
a propensity to bleed, and an immature respiratory system increasing the risk of acidosis and 
hypoxia.  
Periventricular leukomalacia (PVL) is a further form of acquired brain injury, and previous 
studies have also included it as a risk factor for hearing loss. PVL is characterised by damage 
to the cerebral white matter surrounding the ventricles resulting in poor 
neurodevelopmental outcome. Aetiology of PVL is complex but is likely to be impacted by 
hypoxic ischaemic injury and may take longer to diagnose than an IVH. 
Research into the relationship between acquired brain injury and hearing loss has provided 
mixed results. Studies vary in approach from including the smallest gestations and 
birthweights to the nature of hearing impairment and the severity of the bleed. Meyer et al 
(1999) found the most severe intracranial haemorrhages, at grade III or IV, or PVL, were not 
a significant risk factor in a comparison of 777 infants, 41 with hearing loss and the remainder 
with normal hearing [55]. All children enrolled to the study had at least one of the ten risk 
factors for hearing loss as determined by the JCIH, with the addition of severe IVH, maternal 
substance abuse and PPHN. None of these factors were associated with hearing loss, 
however the number of infants with a severe intracranial haemorrhage was small and the 
population included term babies who are less likely to have this complication. Nevertheless, 
similar results were also found by Salamy et al (1989), in a study of 224 premature infants 
(born between 24-34 weeks of gestation), with a low birthweight (below 1500g), 12 with 
hearing loss [31]. This study considered a number of influences on hearing impairment, but 
the number of affected children was low, and both studies are underpowered.  
The pathogenesis of hearing loss following a cerebral bleed was investigated by Slack et al 
(1989) in a post-mortem study [56]. It was speculated that there might be direct injury to the 
cochlea from blood tracking into the middle ear in association with IVH. Of 3 preterm babies, 
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two had IVH and in one blood had tracked into the inner ear and was associated with a 
markedly reduced number of cochlear hair cells.  They speculate that, had this child survived, 
there may have been SNHL. Also noteworthy, is the exposure to additional risk factors for 
hearing loss during treatment, including cardiac arrest and pneumothorax which could 
indicate acidosis/hypoxia, and sepsis and necrotising entercolitis treated with 
aminoglycoside antibiotics. This emphasises the difficultly in extracting specific predictors of 
hearing impairment in infants who are likely to have experienced multiple illnesses 
simultaneously.  
Lower grades of haemorrhage have also been associated with SNHL [30]. As the most 
commonly diagnosed neurological abnormality in extremely low birthweight infants, the 
effects of grade I-II IVH was investigated in a neurodevelopmental follow up study of babies 
born <1000g [52]. Of the 362 infants in the study, 104 had a grade I-II IVH, these infants were 
significantly more likely to have either a unilateral or bilateral hearing impairment at their 20 
month neurodevelopmental assessment in comparison to the children with no cranial 
ultrasound abnormalities. Interestingly, due to lower use of antenatal steroids, there was 
also a higher rate of BPD than babies with a normal cranial ultrasound, suggestive of a 
relationship between low birth weight, respiratory support and IVH, demonstrating the 
challenges of isolating potential aetiological factors for hearing loss.  
The protective effect of antenatal steroids and pulmonary surfactant was also found in a 
study of 418 NICU babies with and without hearing loss (OR 0.38, 95% CI 0.19-0.73 and OR 
0.33, 95% CI 0.18-0.58 respectively) [49]. Hypoxia is a known antecedent for IVH, as is 
hypotension. Treatment for hypotension with bolus fluids, inotropes or steroid may also 
increase the risk of both higher severities of IVH, and hearing loss in extremely low 
birthweight babies [57]. Subsequently, this raises questions in relation to whether the causes 
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of hearing impairment in a population with IVH are much more subtle and in a multifaceted 
nature. 
The role of IVH in the outcome of hearing loss remains inconclusive, although given that the 
rate of hearing loss in very preterm infants remains relatively unchanged over the last few 
decades whilst the frequency of IVH have decreased, it appears unlikely that IVH is an 
independent risk factor for hearing impairment. It is possible that the localisation of the bleed 
and the contributing factors involved in causing the IVH, rather than the presence or severity 
of a bleed play a role in the loss of hearing. 
1.2.5 Hyperbilirubinaemia 
Hearing loss is the most common symptom of kernicterus or severe bilirubin encephalopathy 
[58], and although kernicterus is now far more uncommon than it once was due to improved 
monitoring and early intervention, it can still occur [59]. The prevalence of severe 
hyperbilrubinaemia in the UK and Republic of Ireland was 7.1/100 000 live births over a two 
year period (95% CI 5.8-8.6) [60]. Kernicterus is the yellow staining of the brain tissue caused 
by unbound unconjugated bilirubin crossing the blood-brain barrier and reflects areas of 
brain injury [61]. The clinical tetrad for kernicterus involves athetoid cerebral palsy, impaired 
hearing, failure of upward gaze and hypoplasia of the dental enamel. Hyperbilirubinaemia is 
thought to cause an imbalance in neuronal homeostasis damaging the brainstem auditory 
nuclei and possibly the cells of the spiral ganglion and auditory nerve [62], raising the 
sensitivity of the auditory system to bilirubin induced neurotoxicity. Furthermore, auditory 
dysfunction has been noted at levels below the exchange criterion [63]. Hyperbilirubinaemia 
has also been emphasised as a cause of auditory neuropathy [64] whereby the inner hair cells 
may function but there is an abnormal response (prolonged latencies and threshold 
increases) between the cochlea and the brain stem. 
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Attempts to assess the contribution of hyperbilirubinaemia to hearing loss has produced 
inconclusive results. In one of the largest neurodevelopmental outcome studies reporting 
hyperbilirubinaemia, high bilirubin levels were not associated with the prevalence of hearing 
loss [65]. However, the study was not designed specifically to consider hearing impairment 
with term and preterm infants being grouped together; preterm infants are thought to be 
more susceptible to the effects of bilirubin encephalopathy. Studies show marked 
methodological variance in terms of population sample, the age at which hearing loss is 
measured, the cut off for severe hyperbilirubinaemia, and how conclusions are drawn as to 
what is considered a risk, inclusive of the use of prevalence rates and statistical differences 
between groups.  
An example of this, is the use of total serum bilirubin (TSB). TSB is used as a marker for the 
commencement of phototherapy, although the definitive intervention for 
hyperbilirubinaemia is exchange transfusion. The levels at which treatment begins varies 
depending on the gestational age of the baby, and also by protocol which varies across 
neonatal units. Exchange transfusions have been associated both as being a risk factor for 
hearing loss [49], and as being protective of hearing loss [32]. It was postulated that an early 
exchange transfusion may prevent the level of damage caused to the auditory system in very 
preterm infants as there are a number of variables that prevent bilirubin binding to albumin, 
which early treatment would avoid. Studies are inconclusive in their findings in terms of this 
being a risk factor or protective for hearing impairment, probably due to the varying clinical 
requirements to trigger an exchange transfusion between different neonatal units. Variation 
between neonatal protocol for phototherapy and exchange transfusion was highlighted by a 
UK study of 263 hospitals, finding a wide disparity of treatment commencement for week of 
gestation, sickness criteria, and the use of conjugated and unconjugated bilirubin [66]. 
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In Rhee et al’s (1999) study, hyperbilirubinaemia requiring exchange transfusion was 
associated with hearing loss in infants born at less than 31 weeks gestation [67]. Despite 
sample size being small (11 infants, 10 of which were male, with severe hyperbilirubinaemia) 
and co existing risk factors not being considered, this study raises interesting points. Firstly, 
all infants had peak serum bilirubin levels which were > 26mg/dL, which is above the 
suggested level for considering kernicterus (20mg/dL) [61], yet there were only 4 infants of 
11 with hearing loss and 2 displayed improvement at follow up. Some patients with signs of 
the auditory damage caused by elevated bilirubin levels have been observed to resolve with 
age [62], although this is not always the case, leading to questions surrounding why only 2 of 
the children showed evidence of hearing impairment at follow up. Secondly, the timing of 
the treatment may be influential. Infants in the hearing loss group had exchange transfusions 
slightly later than the normal hearing group (6.8 and 5.3 mean days, respectively), suggesting 
that earlier transfusions might be protective which would coincide with previous research 
[32]. Thirdly, the displacement of bilirubin from albumin causing toxicity can be affected by 
several other risk factors for hearing loss, such as aminoglycoside antibiotics and acidosis. 
Two of the infants had septicaemia and would have received antibiotics, therefore the 
maximum level of bilirubin may not be independently indicative of hearing loss. Coexisting 
risk factors at the time of the maximum total bilirubin may have revealed other confounding 
factors that cause a marked reduction in bilirubin binding capacity, and therefore the 
permanent loss of hearing. Lastly, the measurement of bilirubin itself, in particular peak 
serum bilirubin levels. As a biochemical marker, total serum bilirubin is thought to lack 
sensitivity both as a predictor for neural toxicity and as a predictor of ANSD in infants with 
high levels [68]. As only unbound bilirubin is able to cross the blood brain barrier reflecting 
potential toxicity. Free bilirubin may be a more reliable predictor of ANSD in late preterm 
and term babies: unbound levels has been shown to be higher in patients with ANSD than 
normal hearing patients, but there were no differences in peak bilirubin.  
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Dowley et al (2009) found hyperbilirubinaemia was the most significant risk factor in 12 
preterm infants with ANSD out of 30 infants with hearing loss, followed by sepsis and 
exposure to gentamicin [15]. Infants with ANSD were more likely to have received neonatal 
care and been more unwell. These groups included term and preterm infants, and 
comparisons were made between the ANSD and non-ANSD groups per variable. A 
multivariable analysis would have been useful in establishing whether elevated bilirubin 
levels were independently predictive of ANSD or whether this was related to other risk 
factors involved in neonatal treatment that could affect binding affinity. In a study that also 
grouped and compared the most unwell infants with and without hearing loss (level of illness 
was based upon life support variables, days of antibiotics and number of blood transfusions), 
elevated peak bilirubin levels were significantly different between groups [31]. Although the 
significance of hyperbilirubineamia was ascribed to an outlier with liver disease, these infants 
were more likely to have received longer durations of diuretics and received these 
concomitantly with aminoglycosides or vancomycin. As the groups were matched for level of 
illness, and hyperbilirubinaemia could only be attributed to one infant as a precursor for 
hearing impairment, these variables could be playing an influential role. 
The combinations of risk factors in conjunction with hyperbilirubinaemia have been 
associated with hearing loss. In 15 children with SNHL born at less than 33 weeks gestation, 
high bilirubin levels were more likely to cause hearing loss when in combination with acidosis 
or aminoglycoside treatment [4]. In a further study, acidosis and raised bilirubin levels were 
also found to be influential in the cause of hearing loss in jaundiced infants with low birth 
weight (<1500g in comparison to a control group >1500g) [69]. The duration of jaundice was 
longer in those who had impaired hearing, in whom there were a greater number of episodes 
of acidosis. Aminoglycosides, many other drugs and acidosis are known to displace or impair 
binding between bilirubin and albumin, emphasising the importance of considering a 
congruence of risk factors on hearing loss. 
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As audiological changes have been detected below the exchange level, attempts have been 
made to reduce neurotoxicity as a consequence of unconjugated hyperbilirubinaemia. Lower 
treatment thresholds have been trialled in preterm infants to reduce hearing impairment in 
infants born below 32 weeks gestational age [63], or with very low birthweight [70]. The 
aggressive treatment of elevated bilirubin produced inconclusive results in both studies in 
terms of the effect on hearing impairment and longer term neurodevelopmental outcome. 
A lack of improvement in outcome may be suggestive of hyperbilirubinaemia being less toxic 
to the auditory system than previously estimated, or that these populations had other risk 
factors for hearing impairment. 
The relationship between hyperbilirubinaemia and hearing impairment in preterm infants is 
complex and to some extent, explains the inconclusive results from previous research. Whilst 
early exchange transfusion may prevent the direct impact of jaundice on hearing impairment, 
the accepted level at which exchange occurs differs across neonatal units. Late exchange 
transfusions may not reverse damage that has already occurred. The indirect effects of 
hyperbilirubinaemia most likely involve the interaction with other aspects of serious 
neonatal illness. 
1.2.6 Infection 
Infection is a common occurrence within the neonatal population due to an immature 
immune system. There are two main congenital causes of hearing loss, rubella and 
cytomegalovirus (CMV). Meningitis is the most common postnatal infection that causes 
hearing loss. Korver et al (2011) identified 185 children with permanent hearing loss to 
investigate the causes of impairment. The prevalence of CMV was 8.6% of which the majority 
had a profound impairment, meningitis in 3.2% and rubella in 1.1%, although there was no 
control group for comparison [18].  
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Cytomegalovirus (CMV) can be congenital or postnatally acquired. Congenital CMV infections 
can have a devastating effect in the developing fetus with primary infections being more 
severe than a reactivated infection. CMV is also known to cause late onset progressive 
hearing loss which can be unilateral or bilateral [71], by altering white matter in the central 
nervous system which affects the functioning of the cochlea [9]. The mechanism by which 
this occurs remains unknown. 
Infants with congenital CMV can be symptomatic or asymptomatic; symptoms can include 
low birth weight, jaundice, seizures, microcephaly, pneumonia and a rash. Dahle et al (2000) 
conducted a longitudinal study of 860 newborn infants with congenital CMV [72]. Hearing 
loss was evident in 180 of which 7% had been asymptomatic and 40% symptomatic, 
indicative of a greater risk of hearing loss following a symptomatic presentation. However, 
some of the signs of CMV have been independently associated with hearing loss in infants. 
Perinatal risks were compared in a study of 504 infants with asymptomatic congenital CMV; 
of which only gestational age and lower birth weight were associated with hearing loss [73]. 
Boppana et al (2005) investigated the differences in viral load of congenital CMV in children 
with SNHL [74]. This was a cohort study of 76 infants with congenital CMV, 12 were found to 
have SNHL, of which 8 children had clinical symptoms of the virus, and 4 without. Children 
were identified and enrolled following positive saliva samples taken during the first week of 
life, urine samples were collected within the first month and follow-up hearing tests were 
completed at the age of one year or older. Of those who were asymptomatic for CMV but 
had hearing loss, there were higher viral loads of CMV detected in urine samples than those 
who had normal hearing. In addition, infants that were premature (<37 weeks), or had a low 
weight for gestational age, were more likely to have SNHL than normal hearing but only 
prematurity reached significance. Although numbers in this study are small, the risk of CMV 
and low birth weight correspond with the findings from Fowler’s (2003) study [73]. Screening 
for viral load might identify those at the greatest risk for hearing impairment.  
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Up to 90% of congenitally infected infants will display no symptoms of the virus at birth [75]; 
asymptomatic infants are not routinely tested for CMV in the UK as screening is deemed 
unjustifiable. Passing the initial hearing screen means that these children will not be 
monitored in subsequent assessments, and as a late onset progressive hearing loss this 
further increases the potential impact of hearing loss. The role of CMV in childhood hearing 
loss is likely to be underestimated for several reasons; the variation in the age of onset and 
the progression of the hearing impairment, and the methodology of studies which will often 
adopt retrospective data collection from medical notes, all of which could mask the true 
numbers of infection within samples of children with a hearing deficit.  
Bacterial meningitis tends to cause a bilateral hearing impairment although unilateral may 
occur. Neonatal meningitis can be caused by infections including Group B Strep (GBS), gram 
negative infections, listeria and fungi. Meningitis is thought to impair the functioning of the 
peripheral spiral ganglion cells and dendrites [76]. In a study of 41 ex-NICU infants, from a 
sample of 777, bacterial sepsis and/or meningitis was found to be a significant independent 
risk factor for hearing loss [55]. Infants were eligible for the study based upon exposure to at 
least one risk factor for hearing loss, and multivariate comparisons were used in this study. 
This finding was supported by a smaller study of 416 preterm infants, whereby meningitis 
was more prevalent in the hearing loss group than the normal hearing controls [49]. Number 
of days of ventilation, IVH and exchange transfusion were also associated with hearing loss. 
However, it is not clear whether a multivariate analysis was used to consider confounding 
risk factors, questioning whether meningitis would be an independent predictor of SNHL 
given the impact of other variables which were also significantly greater than the control 
group.  
Congenital rubella is an infection that can cause multiple abnormalities inclusive of 
sensorineural hearing loss [77]. The earlier in pregnancy it occurs the more likely the infant 
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is to be affected due to an increased susceptibility to the teratogenic effects of infection. The 
virus replicates within the inner ear causing a progressive loss which is likely to be bilateral 
and ultimately profound. Postnatal rubella is unlikely to have the same impact. Rubella is 
now much more uncommon due to the uptake of the rubella vaccine, although remains 
prevalent in countries without a vaccination programme for rubella. 
Neonatal necrotising enterocolitis (NEC) has also been implicated as a cause of hearing 
impairment. NEC is a disorder of the gastrointestinal tract which can result in inflammation 
leading to a perforation of the gut, associated infection and surgical treatment for the 
perforation [78]. Extremely premature and low birthweight babies are at the greatest risk for 
developing NEC. Jiang et al (2014) compared infants born between 30-36 weeks gestation 
that had been diagnosed with NEC to a healthy preterm group and a healthy term group of 
infants [79]. Brainstem auditory evoked responses (BAER) were used to test hearing; to 
reduce confounding effects, infants with other major perinatal complications aside from NEC, 
that could affect the auditory brainstem pathway were excluded. In comparison to the 
healthy controls, the preterm infants that had previously been diagnosed with NEC, showed 
signs of a central rather than peripheral auditory brainstem abnormality. Specifically a 
delayed neural conduction was considered to reflect impaired myelination or synapse 
dysfunction. Gastrointestinal surgery was also a predictor of hearing loss in a study of infants 
born with a lower gestational age (less than 28 weeks) [12], although this is likely to be 
indicative of the level of illness requiring surgery. NEC is associated with a range of 
physiological factors including circulatory difficulties, acidosis and the use of ototoxic 
medication. NEC is unlikely to be a direct cause of SNHL but rather greatly increases the risk 
with the treatment involved. 
Neonatal sepsis is estimated to affect up to 20% of preterm infants [80]. Late onset sepsis in 
very low birthweight babies (<1000g) can occur in up to 50% [81]. Manifestation of neonatal 
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sepsis is often unspecific and can progress rapidly; therefore treatment is often commenced 
when infection is suspected. Aminoglycoside antibiotics are widely used in the treatment of 
gram negative sepsis and are frequently the first line of treatment for suspected infection as 
well. Neonatal sepsis was found to be an independent predictor of hearing loss in the 
presence of other risk factors for hearing loss in 777 infants [55]. Similarly, infection increased 
the risk of poor neurodevelopmental outcome, inclusive of hearing loss in extremely low 
birthweight infants (<1000g) in comparison to those who had not had sepsis [82]. Current 
clinical practice is to provide pre-emptive treatment for presumed sepsis following preterm 
birth until confirmed otherwise. This however, causes several difficulties with studies on 
neonatal sepsis. Methodological differences in the determination of neonatal sepsis are 
apparent, including using early and late onset sepsis, the use of positive blood cultures, raised 
inflammatory markers, and the number of days of antibiotics which may include treatment 
for suspected sepsis, therefore hearing loss may be more likely related to the treatment 
rather than the unconfirmed infection. 
Infection in infants can have lasting adverse neurodevelopmental outcomes, and has been 
consistently associated with hearing loss in multiple types of infection. It is less clear as to 
whether the sepsis or the subsequent physiological or medicinal risk factors are the cause. 
1.2.7 Noise 
Exposure to noise within the neonatal intensive care unit is continual and potentially 
damaging to the immature audiological system of infants. The sudden and unpredictable 
sounds of ventilators, monitor alarms, conversations and babies crying can all exceed 
recommended noise levels for NICU [83]. Immediate effects can include startling, agitation, 
fluctuations in heart rate and oxygen levels, and sleep disturbance [84]. Longer term effects 
have associated noise with hearing loss. In animal models, noise primarily affects the outer 
hair cells which are unable to regenerate [85]. High frequency noise caused small areas of 
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loss from the outer hair cells to begin with, which progressed to damaging the organ of Corti 
and myelinated nerve fibres as noise exposure continued. Low frequency noise affected a 
broad area of outer hair cells, with prolonged noise exposure resulting in similar damage to 
that of prolonged high frequency noise.  
Noise intensity, particularly from respiratory support is thought to exceed levels of ambient 
noise within the ear, although advances in technology seek to reduce this. Rastogi et al (2012) 
compared mechanical ventilation and bubble CPAP in 344 premature infants with a birth 
weight <1500g [86]. CPAP produces a greater amount of noise than mechanical ventilation 
which was expected to identify a notable difference between the groups. Infants requiring 
any respiratory support were more likely to have hearing loss than an infant who had not 
needed either. However, there was no difference in risk between those treated with 
mechanical ventilation in comparison to those treated with CPAP when the hearing loss 
group were seen 2 years after treatment. Therefore, the increased noise exposure 
encountered as a result of prolonged CPAP did not increase the risk of hearing loss. 
Interestingly, in multivariate analysis, only ventilation, apnoea and NEC were independently 
associated with a failed hearing screen, each of which could indicate the necessity of a 
prolonged period of respiratory support. An alternative explanation is that noise is likely to 
exacerbate the concurrent complications of apnoea and NEC, including physiological 
instability and risks associated with ototoxic medication. 
In a review of ototoxicity and noise, it was suggested that noise potentiates the effects of 
aminoglycoside ototoxicity by increasing the stimulation of hair cells, and opening the 
channels by which aminoglycosides enter the cells [87]. Threshold shifts are evident even 
when insults from noise and aminoglycosides are not simultaneous [88]. Furthermore, there 
are additional ototoxins that can increase damage to the cochlea by aminoglycosides, such 
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as loop diuretics. Whilst this process is not well understood, safe doses of each medication 
in the presence of noise, could result in interactions that increase the risk of hearing loss. 
The synergistic interaction between environmental and pharmacological effects requires 
further investigation. Studies are limited by experimental technique, specifically a lack of 
randomisation, and controlled environments. Noise has been implicated as a risk factor for 
hearing loss but there is currently little substantial evidence to support this. 
1.2.8 Medication 
A range of medications have long been associated with preterm hearing loss. These include 
aminoglycoside antibiotics, indometacin, dexamethasone, and loop diuretics. Some of the 
effects of ototoxicity may be through potentiation of drug induced ototoxicity by 
undercurrent physiological events that lead to high drug levels. Examples of this are 
displacement from albumin binding, liver dysfunction and renal impairment. 
Aminoglycosides are widely used as a first line antibiotic for suspected or proven bacterial 
infection. The ototoxic side effects of this group of medication are well known, hence the 
strict monitoring of peak blood level concentrations. Aminoglycoside induced renal 
impairment is usually reversible, however audiological impairment is often permanent. 
Aminoglycosides are cleared slowly from the inner ear, and can affect hearing after the 
cessation of ototoxic medication. Ototoxic medication was the most commonly presented 
risk factor in a study of 4478 infants with high risk for hearing loss who had been cared for in 
NICU [89], although gentamicin in particular has been associated with causing permanent 
SNHL. Aminoglycosides accumulate within the basal hair cells of the inner ear causing 
irreversible damage. The basal outer hair cells are affected initially resulting in a high 
frequency loss [90], which subsequently progresses to the lower frequencies as the apical 
cells also become affected, all of which are unable to regenerate [91].  
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Gentamicin 
Despite the known ototoxic properties of gentamicin, this has been debated by a number of 
studies with mixed findings. A recent study of 1582 infants born at less than 32 weeks 
gestation (from which there were 25 with hearing loss and 50 matched controls) observed 
no difference in cumulative doses or trough serum levels of gentamicin between infants with 
and without hearing loss that were matched for sex, gestational age and very low birthweight 
[92]. Vella-Brincat et al (2011) also found gentamicin alone did not increase the risk of hearing 
loss, and suggested gentamicin was in fact protective against hearing loss. This study 
compared 2347 term and preterm infants following a NICU admission >48 hours, separating 
babies into groups dependent on which antibiotics (gentamicin and vancomycin) or 
combinations of which they had received. A significantly lower number of children failed their 
OAE screen in the gentamicin group in comparison to the no antibiotic control group (OR 
0.66, 95% CI 0.45-0.97) [93]. It was therefore suggested that gentamicin may protect against 
hearing loss. Nevertheless, both studies claiming the low risk of gentamicin were limited by 
a small number of children with confirmed SNHL which weakens the impact of the results. In 
particular, Vella-Brincat et al (2011) found only 30 children had confirmed hearing loss at 
follow up, half of which had received no antibiotics and almost 20% of those referred for 
further testing had been lost to follow up [93].  
Vancomycin 
The ototoxic effects of vancomycin are unclear, although ototoxicity is thought to be a 
consequence of high serum concentration levels or from prolonged or repeated courses. 
Vella-Brincat et al (2011) as discussed above, implicated vancomycin as a risk to hearing in 
infants following NICU [93]. However these results were not repeated in a study of 625 
infants (45 with hearing loss) admitted to NICU with at least one risk factor for hearing 
impairment [94]. There was no increased risk of hearing loss in infants exposed to peak or 
29 
  
trough levels above the recommended levels, or exposed to prolonged durations of 
vancomycin. A limitation of this study was the use of failed neonatal hearing screening, 
repeating the assessment would enable delayed onset hearing loss to be included. 
Nevertheless, the case studies of the children that exceeded therapeutic concentration levels 
or had longer durations of treatment with vancomycin, also had additional risk factors for 
hearing loss. Whilst there is limited evidence that vancomycin is an independent risk for 
hearing loss, exposure to concomitant risks may exacerbate the threat, which will be 
discussed.  
Furosemide 
Furosemide is a loop diuretic frequently used in neonatal care for fluid balance regulation, 
including treatment of oedema, to increase urine output and during blood transfusion. 
Furosemide is thought to change the composition of the endolymph within the inner ear 
causing decreases in endocochlear potential [95]. Nevertheless, the association between 
furosemide and hearing loss has yielded contrasting results. In a study of 1360 preterm 
infants (born <32 weeks of gestation or with a birthweight of <1500g), furosemide was found 
to be an independent risk factor for hearing loss (OR 4.6 95% CI 4.8-25.3) [96]. The analysis 
for this study was multivariate and included a range of neonatal risk factors including 
diagnoses such as BPD, and ototoxic medication such as aminoglycosides. Whilst the 
confidence intervals were wide for the analysis of furosemide this is representative of the 
low prevalence rate of infants in the study that were found to have hearing loss (19 babies). 
These results were not found in a retrospective review by Rais-Bahrami et al (2004) whereby 
an association between furosemide and hearing loss was not found [97]. This study did not 
compare the potential additive effect of other ototoxic medications. 
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Combinations of ototoxic medication 
Interactions between ototoxic medications have also been associated with hearing loss. In 
the study by Vella-Brincat et al (2011) the group of infants who received gentamicin plus 
vancomycin had the highest risk of hearing loss after follow up assessments [93]. A total of 
30% of the gentamicin plus vancomycin group were hearing impaired in comparison to the 
groups of infants that received gentamicin alone, vancomycin alone, or the control group 
that received no antibiotics, suggestive of an increased ototoxicity in the presence of both 
antibiotics.  
Robertson et al (2006) found a relationship between the use of individual aminoglycosides 
and hearing loss when treatment coincided with the use of loop diuretics, in a population of 
term or near term infants [71]. An overlap between vancomycin and diuretics was also more 
likely in the hearing loss group. Aminoglycosides in the presence of renal dysfunction 
increase the amount of medication accumulating in the inner ear. Borradori et al (1997) 
found infants with hearing impairment born at less than 35 weeks were more likely to have 
had longer durations and higher doses of furosemide along with aminoglycosides [98]. 
Cumulative doses of aminoglycosides and furosemide were also both higher for cases than 
controls, and although the paper speculated as to the interaction between aminoglycosides 
and diuretics and the potential effect of both, this study was not able to analyse this. Both 
studies were limited by a lack of multivariate analysis in which independent risk factors could 
be ascertained in the presence of other markers of illness.  
De Hoog et al (2003) also considered the importance of cumulative ototoxic medication on 
hearing [94]. This study included 625 NICU infants with at least one risk factor for hearing 
loss. A total of 45 infants failed their hearing screen and the remaining 580 comprised the 
control group. This study looked at individual peak and trough concentration levels, duration 
of therapy, total exposure (mg/kg) of vancomycin, tobramycin and furosemide, with the 
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addition of combinations of these three medications. Findings revealed no association 
between hearing screen failure with any of the variables in multivariate analysis. As the 
effects of ototoxic medications can continue beyond the end of treatment, the total number 
of children with a permanent hearing loss could have been higher at follow up assessments, 
and therefore results could be underestimated. A further limitation was not testing the high 
frequencies (>4kHz), since hearing loss as a consequence of ototoxic medication is likely to 
present initially in the higher ranges. 
Aminoglycosides not only present an ototoxic risk but also a nephrotoxic risk, which can 
increase the circulating volume of aminoglycosides and also the need for diuretics. In 
laboratory studies, accumulation of aminoglycosides within the inner ear enabled an 
increased permeability of loop diuretics to penetrate the inner ear cells in a higher 
concentration than when aminoglycosides have not been given [90]. Furosemide 
administration when serum creatinine levels are raised may also lead to an accumulation of 
ototoxic drug which has been associated with SNHL [4]. The elimination of ototoxic 
medication is dependent on adequate renal function which is often impaired in very preterm 
infants, and for which loop diuretics are prescribed. This highlights the complex interaction 
not only between ototoxic medications but also the physiological condition of the baby at 
the time. 
The use of diuretics alongside neuromuscular blockers (NMBs) such as pancuronium bromide 
was also found to be associated with hearing loss [97]. This relationship was also found by 
Robertson et al (2006) [71]. As NMBs can cause oedema which is then treated with diuretics, 
the relationship between the two is complex and difficult to separate.  
Interestingly, and in contrast to previous research, ototoxic medication has been linked 
specifically with ANSD. Xionis et al (2007) found exposure to furosemide, vancomycin and 
aminoglycosides was associated with ANSD in comparison to a matched normal hearing 
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control group [14]. There were longer durations of aminoglycoside exposure in the ANSD 
group in comparison to the children with SNHL and the control group. Furthermore, 
furosemide was independently associated with ANSD and SNHL in a multivariate analysis in 
which aminoglycoside antibiotics and vancomycin were entered together with 
dexamethasone. Amikacin similarly to furosemide, has also been associated with ANSD, in 
which increased latencies in waves I-III were present in newborn infants [93]. Higher serum 
levels that remained within the therapeutic range were positively correlated with an 
increased brainstem conduction time. In previous studies, ototoxic medication has tended to 
be associated with cochlear hair cell loss, rather than abnormal or absent brainstem 
responses. 
Indometacin 
The association between the administration of indometacin and hearing loss may be indirect. 
Indometacin is used to treat PDA or prophylactically to prevent IVH, but can decrease renal 
function which might enable the accumulation of circulating ototoxic medication. 
Indometacin was given to infants with hearing loss more frequently than infants with normal 
hearing matched for gestational age and birthweight, although this did not reach significance 
and exposure rates were low [98]. A randomised controlled trial of 547 extremely low birth 
weight infants compared the neurodevelopmental outcome following treatment with 
prophylactic indometacin aimed to reduce the risk of both PDA and IVH [99]. Indometacin 
was administered at 24 hour intervals within the first 3 days of life and outcome was 
compared to a placebo group of 569 babies. Infants had no greater risk of hearing loss than 
the control group who received placebo. Indometacin is used less frequently due to the 
increased risk of developing NEC, and multivariable analyses have mostly supported a lack of 
correlation between hearing loss and indometacin. 
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Dexamethasone 
Intravenous dexamethasone may be used to help wean infants who require prolonged 
mechanical ventilation to prevent complications such as BPD [100]. A rapid improvement in 
lung function is triggered by the anti-inflammatory effects of systemic steroids. However, 
exposure to dexamethasone has also been implicated as a cause of hearing loss. In a 
comparison between infants with ANSD, SNHL and normal hearing controls, exposure to 
dexamethasone was found to be associated with hearing loss in both of the impaired hearing 
groups [14]. Although the infants with ANSD had a higher exposure frequency, it was not a 
predictor of this type of hearing loss over SNHL. Furthermore, the association between 
dexamethasone and hearing loss was not independent of a diagnosis of BPD, indicating the 
complexities in establishing independent risk factors. Due to a correlation with long term 
adverse neurological complications dexamethasone is used far less frequently [101]. 
The ototoxic effects of individual medications remain debated in literature, differences in 
results are likely to stem from a variation in study methodology and sample population. Risks 
are likely to correlate with the concurrent exposure of ototoxic medication including 
aminoglycosides, loop diuretics, and vancomycin, with physiological risk factors such as 
raised creatinine levels. Further risk factors involve a genetic predisposition to deafness 
which will be explored in the next section. 
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1.3 Genetic causes of hearing loss 
The aetiological contribution of genetics to hearing impairment is thought to be around 50% 
[3], although this is likely to differ between developed and developing countries. Patterns of 
inheritance can be from one parent carrying a dominant gene (autosomal dominant), from 
parents who both carry a recessive gene (autosomal recessive), through the maternal line 
(mitochondrial inheritance), or can affect predominantly males only (X linked, which can be 
a dominant or recessive inheritance). Hereditary hearing loss is estimated to be 18% 
autosomal dominant, 80% autosomal recessive and the remaining 2% X linked and 
mitochondrial inheritance [102]. 
Autosomal inheritance 
Autosomal inheritance is determined by the nuclear genome, in which 22 pairs of linear 
chromosomes are located within the nucleus of each cell. Each chromosome is made up of 
deoxyribose nucleic acid (DNA) wound around proteins called histones. DNA contains the 
genetic information as a code made up of chemical bases: adenine (A), guanine (G), cytosine 
(C) and thymine (T). The order of the bases influences the traits or conditions that are 
expressed in an individual. Each base has a sugar molecule and a phosphate molecule 
backbone, and these 3 components make up a nucleotide. Nucleotides join to form a strand 
of DNA, with the bases matching to form pairs, A with T, and C with G which forms the double 
stranded helix. When cells divide, the DNA strands will be replicated, and the functioning of 
a cell is dependent on an exact replica of the previous cell being copied.   
An individual has two copies of each gene, one copy inherited from each parent. A dominant 
mutation in a gene from either parent will result in a 50% chance of their child inheriting that 
mutation. Whereas, there is a 25% chance of a child inheriting and exhibiting a recessive gene 
mutation as two copies are required, one from each parent.  
35 
  
X linked inheritance 
X linked inheritance is determined by the X chromosome, which is larger and contains a 
greater number of genes than the Y chromosome. A female carrier of an X linked condition 
has a 50% chance of passing this on to her daughters who would be healthy carriers as they 
have an unaffected gene on the other X chromosome. 50% of sons would be affected as they 
only have one X chromosome. Affected males would not pass it on to their sons but all 
daughters would be carriers. 
Mitochondrial inheritance 
The mitochondrial genome differs from the nuclear genome in a number of ways. Firstly, 
mitochondrial DNA is located within the mitochondria, outside of the nucleus of a eukaryote 
cell, and a cell will contain several thousand copies of mitochondrial DNA molecules in 
comparison to the 46 in a diploid nuclear cell. The mitochondrial genome is much smaller; it 
is comprised of approximately 16 000 DNA base pairs in comparison to over 3 billion base 
pairs in the nuclear genome. DNA within the mitochondria is responsible for providing 
instructions for the production of cellular energy in the form of adenosine triphosphate 
(ATP), and for the synthesis of proteins needed by and used within mitochondria in this 
process. Mitochondrial DNA has a circular shaped chromosome similar to bacteria, rather 
than the linear chromosomes within the nucleus. Mitochondrial DNA also has an increased 
susceptibility to mutagenesis. Patterns of inheritance also differ from the inheritance of 
nuclear chromosomes, whereby mitochondrial DNA can only be passed on from the mother. 
Paternal mitochondrial DNA located in the tail of the sperm detaches and is discarded 
following fertilisation, resulting in maternal uniparental transmission. Hearing loss as a result 
of mutations in mitochondrial chromosomes would be inherited by all children, but only 
female offspring would pass this on to their children. Nuclear DNA is inherited equally from 
both parents. 
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The genetic causes of childhood hearing impairment can be split into syndromic and non 
syndromic hearing loss. Approximately 70% of genetic hearing loss will be non syndromic, 
with the remaining 30% accounting for syndromic hearing losses [103]. 
1.3.1 Syndromic hearing loss 
A syndrome is characterised by a group of symptoms that occur together and include 
features in other body systems. Syndromes can be classified by the pattern of inheritance, 
autosomal dominant, autosomal recessive, X linked, chromosomal and some syndromes 
have an unknown inheritance (table 1-1). Therefore, investigations into the aetiology of 
hearing impairment may involve clinical tests additional to audiology screening such as 
ophthalmic tests, cardiac or renal investigation.  
Typically the most common types of autosomal dominant, and autosomal recessive hearing 
loss, are Waardenburg syndrome and Usher syndrome respectively [104], but this may differ 
between populations. In a population based European study of children with permanent 
childhood hearing loss, from moderate to profound, hearing impairment was attributed to 
hereditary causes in 38% of all children [18]. From the children with a genetic aetiology, 
syndromes comprised 15% whilst the remainder were classified as non syndromic or non 
specified with a positive family history. The most frequent syndromic cause of hearing loss in 
this population was Pendred syndrome (4%).  
Hearing loss is a recognised clinical feature of around 400 syndromes, the most common 
syndromic causes of hearing loss are presented in table 1-1 along with type of hearing loss 
and clinical features. 
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Table 1-1: Common syndromic causes of hearing impairment 
Syndrome 
 
Type of hearing loss Clinical features  
Autosomal 
dominant 
Branchiootorenal 
syndrome (BOR) 
Conductive, 
sensorineural, mixed  
Preauricular pits or tags, malformation of inner, middle or outer ear, 
hypoplastic/dysplastic kidneys, branchial fistulae 
CHARGE syndrome Conductive/sensorineural Coloboma, heart defects, choanal atresia, restricted growth, genital 
anomalies, ear abnormalities, learning difficulties 
Stickler syndrome Progressive, conductive/ 
sensorineural 
Myopia, joint anomalies, micrognathia, cleft palate 
Townes Brocks Sensorineural/conductive, 
can be progressive 
Anomalies of the hand, foot and ear, imperforate anus  
Treacher Collins Mixed Downslanting palpebral fissures, malar and zygomatic hypoplasia, 
macrostomia, small, malformed external ear  
Waardenburg 
syndrome (types I-IV) 
Non progressive, 
unilateral or bilateral, 
sensorineural 
Hypopigmentation of hair/eyes/skin, 
I - dystopia canthorum, joining eyebrows 
II - without dystopia 
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III - limb deformities 
IV - some of above with intestinal obstruction 
Autosomal 
recessive 
Jervell and Lange-
Nielsen syndrome 
Profound bilateral 
sensorineural 
Prolongation of QT interval, with syncope and sudden death 
Pendred syndrome Severe to profound, 
bilateral, progressive 
sensorineural 
Enlarged vestibular aqueducts and goitre 
Usher syndrome Mild to profound, 
sensorineural 
Retinitis pigmentosa 
Zellweger syndrome Profound, bilateral 
sensorineural 
Low birth weight, jaundice, hypotonia, ear eye and nose anomalies, 
short digits, developmental delay 
X-Linked  Alport syndrome Progressive sensorineural 
(varying severity) 
Hematuria, impaired renal function, ear and eye anomalies 
Mohr-Tranebjaerg 
syndrome 
Progressive sensorineural Progressive movement disorder (dystonia), visual deficits, behavioural 
problems 
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Chromosomal Down syndrome Usually conductive, can 
be bilateral sensorineural 
Hypotonia, facial anomalies, palmar crease, cardiac anomalies, delayed 
development 
Turner syndrome Conductive/sensorineural Short stature, webbed neck, eye anomalies, low set ears 
Unknown 
inheritance 
Goldenhar syndrome Bilateral sensorineural Facial hypoplasia, ear anomalies, cardiac defects, macrosomia, cleft 
palate/lip, coloboma 
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1.3.2 Non syndromic hearing loss 
Genetic predisposition to hearing loss is investigated when there is no other cause identified 
or there is a family history of deafness. Heredity plays a major role in congenital hearing 
impairment, however mutations in genes have also been identified as influential in 
progressive hearing loss [105]. Non syndromic hearing loss is categorised by inheritance, with 
approximately two thirds being autosomal recessive, one third being autosomal dominant, 
and more rarely 1% are X linked and there is approximately the same proportion for 
mitochondrial inheritance [105].  
Autosomal dominant non syndromic hearing loss is caused by mutations in over 60 loci with 
around 30 of those genes identified to date [106]. Mutations can affect the production of 
proteins which encode all sorts of components of the hearing pathway: potassium channels 
[107], tectorial membranes [108] and gap junctions [109], and structural molecules, which 
reduces the transmission of signals between the inner ear and the auditory pathway. 
Non syndromic hearing loss is more likely to be inherited in an autosomal recessive pattern 
(80% of cases). This means that the majority of children with genetic hearing loss are born to 
parents with normal hearing. Connexin 26 is a protein encoded by the GJB2 gene which is the 
most frequent autosomal recessive cause of sensorineural deafness [110]. Both parents need 
to be carriers of the gene mutation to pass it on to their offspring. Connexin 26 related 
hearing loss is usually a congenital, non progressive hearing impairment, ranging from mild 
to profound and tends to be symmetrical [111]. Connexin 26 is a component of intercellular 
gap junction channels in the cochlea [112]. The mutation disrupts potassium ion recirculation 
pathways resulting in a loss of endolymphatic potential and consequently hearing loss [113]. 
In a Norwegian study of children referred for cochlear implant, 21.5% of children had GJB2 
mutations which was the most frequently found genetic cause of non-syndromic hearing loss 
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[21]. This prevalence was higher still in a study of neonates referred with hearing impairment, 
whereby GJB2 accounted for 37.9% of cases [19].  
Mitochondrial mutations are much rarer than both autosomal dominant and autosomal 
recessive inheritance. Nevertheless, mutations in the mitochondrial DNA may interact with 
environmental factors which results in deafness. Mitochondrial 12S ribosomal RNA has been 
associated with mutations that idiosyncratically exacerbate aminoglycoside induced hearing 
loss [114], and is of particular relevance to a preterm population. The frequency of 
aminoglycoside administration in neonatal care was discussed in section 1.2.8. Mutations 
within the 12S rRNA increase structural similarity to bacterial rRNA which is the primary 
target of aminoglycoside antibiotics. One of the most common mutations within this gene is 
m.1555A>G. At position 1555 a point mutation of guanine in place of adenine occurs. The 
mutation is thought to enable the aminoglycosides to bind more readily to mitochondrial 
ribosomes, decreasing the rate of protein synthesis to below the required rate for a 
functional cell, subsequently causing damage to cochlear hair cells [115]. Degeneration of 
the hair cells which are dense with mitochondria, can lead to irreversible cell hair death [116].  
Individuals carrying m.1555A>G therefore have a predetermined susceptibility to the 
ototoxic effects of aminoglycosides. Bilateral, profound and progressive hearing loss is a 
consequence of receiving aminoglycosides even when blood levels are maintained within 
clinical recommendations. In this population, the penetrance of deafness has been reported 
to be 100% following exposure to even a single dose of aminoglycosides [117]. Importantly, 
in this study there was reported deafness in some family members prior to the introduction 
of aminoglycosides in clinical practice, suggestive of a risk of impairment in the absence of 
aminoglycosides. However, the median age of onset of hearing loss was much lower in those 
that had received aminoglycosides, than those that had not been exposed (5 and 20 years 
respectively), although the time taken to deafness following ototoxic exposure had not been 
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ascertained. Interestingly, age of onset and aminoglycoside exposure were self-reported, 
confirmation from medical records would enable greater reliability. In a study of four Arab-
Israeli families with maternally-inherited aminoglycoside induced deafness within the 
families, the only mutation common to all of them was m.1555A>G [118]. Similarly, case 
studies of three children with leukaemia who initially presented with normal hearing, 
experienced audiological deterioration over the course of their treatment [119]. Each child 
received multiple courses of aminoglycosides for neutropenia and all were retrospectively 
found to carry m.1555A>G. Measures have since been taken to screen for m.1555A>G prior 
to the treatment of aminoglycosides in paediatric oncology. 
Following the reporting of an absolute penetrance, a number of studies have investigated 
the interaction between the mutation and aminoglycosides in both family and population 
studies, few of which were found to have the same results. Al-Malky et al (2014) investigated 
the penetrance of m.1555A>G in 59 children with cystic fibrosis [120]. This was a selected 
sample based on the likelihood of children having been exposed to aminoglycoside 
antibiotics or likely to have future exposure to these antibiotics as part of their treatment. 
The mutation was found in 2 children who had both previously received repeated courses of 
aminoglycosides; one child had a severe high frequency hearing loss, and the other had 
normal hearing. The penetrance in this study was below the previously reported 100%. This 
study raised important questions regarding non-penetrance and the possible recruitment 
bias of previous research with regard to the use of familial studies, or solely hearing impaired 
samples. Mixed penetrance across studies could also possibly be explained by the type of 
aminoglycoside an individual was exposed to, or by the number of doses or courses of 
ototoxic medication. Streptomycin was more commonly associated with deafness in 
individuals with the mutation than kanamycin [116]. Both of these antibiotics are less 
frequently used in the UK, yet the mutation is prevalent across the UK. A population cohort 
 43 
  
study of 9371 European children unselected for hearing ability, revealed a prevalence of the 
mutation to be 0.19% with no known aminoglycoside use [121].  
Aminoglycoside antibiotics are widely used in many countries owing to their effectiveness 
and low cost. In a Chinese study of 2417 deaf-mute students with severe to profound hearing 
loss, 126 were found to have m.1555A>G giving a prevalence rate of 5.21% [122]. A history 
of aminoglycosides was reported in 52 of those with the mutation (41.27%); one control was 
a carrier of the mutation and had normal hearing. However, no aminoglycoside exposure was 
reported for the control and exposure was self-reported in the impaired group. Based upon 
the higher prevalence of the mutation in the deaf population in Guo et al’s (2010) study, 
combined with the widespread use of aminoglycosides in China, it is important to consider 
the implications for a neonatal population where hearing loss is more likely than term born 
infants, and aminoglycoside exposure is frequent. Preterm infants are more likely to have 
concomitant disease and therefore a predetermined susceptibility could be overlooked when 
retrospectively considering the cause of hearing loss. Children are not routinely screened for 
this mutation unless there is a clinical reason, and so aminoglycoside-induced hearing loss 
would be expected to be higher than the general population if there is a 100% penetrance of 
deafness.  
Prevalence rates for m.1555A>G in neonatal populations vary between 0 and 0.69% with 
differences in population sample, for example gestational age and birth weight (Appendix 3). 
In a cohort of 703 infants from neonatal intensive care, m.1555A>G had a prevalence of 
0.28% however there was no related hearing loss despite these infants having had a 
minimum of 9 days gentamicin exposure [123]. This indicates a lower frequency of 
aminoglycoside induced hearing loss than expected and further emphasises a penetrance 
below 100%. In a recent European study, 3 out 10 preterm infants with m.1555A>G who had 
received gentamicin failed their newborn hearing screen [124]. Aminoglycosides combined 
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with the mutation were a significant predictor for failing the hearing screen (95% CI 1.07-
1.49). However, data from both studies are slightly misleading as hearing outcome is primary 
data based solely upon the newborn hearing screen. Follow up studies would confirm hearing 
loss, and specify the type of hearing impairment. As this is usually a progressive hearing 
impairment with a possibility of a late onset presentation, numbers could increase over the 
two years following birth, and thus the sole use of neonatal hearing screening potentially 
underestimates the full impact of aminoglycoside induced deafness in susceptible 
individuals. Johnson et al (2010) in a study of 436 NICU graduates (with a birthweight 
<2500g), found 4 infants with m.1555A>G mutations [125]. All 4 had received gentamicin but 
only one demonstrated abnormal hearing. Each of the infants with normal hearing had 
received 2 days of gentamicin, in comparison to 4 days of exposure in the child with hearing 
loss, concluding that there could be a threshold effect for aminoglycoside induced hearing 
loss in carriers of the mutation. Additionally, studies with an inclusion criteria of individuals 
with only severe to profound deafness [126], are likely to miss many affected children with 
early stages of a progressive hearing loss, therefore further underestimating the impact of 
the mutation. 
The interference of mitochondrial function is indisputably critical to hearing loss. However 
the risk of aminoglycosides to individuals with the m.1555A>G mutation, is somewhat 
unclear. Inconsistency has been observed within a single family of carriers of the mutation in 
terms of deafness presenting in individuals with and without aminoglycoside exposure [117] 
and within patient groups [120]. Aminoglycosides also present a risk to hearing loss 
independently, but susceptibility appears to be increased in the presence of both m.1555A>G 
and ototoxic antibiotics. Aminoglycoside induced hearing loss in carriers of m.1555A>G has 
not only been found to lower the age of onset [117], but also increase the severity of 
impairment [127]. It is not clear what causes individual inconsistency within a family of 
carriers, whether deafness is due to the type of aminoglycoside used, dependent on the dose 
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administered or whether there are additional confounding factors. The prevalence and 
penetrance of m.1555A>G remains undetermined in previous literature owing to mixed 
populations and methodology including ascertainment bias. Due to the high rates of 
aminoglycoside use in the care of preterm infants, the differences in prevalence of 
m.1555A>G across this population in varying studies and the reported high penetrance of 
deafness following aminoglycoside administration, further investigation is warranted in this 
population.  
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1.4 Multifactorial pathways 
The aetiology of hearing loss in preterm infants remains unclear. Whilst some variables might 
independently cause hearing impairment, there are more likely to be multifactorial 
relationships with indirect variables influencing the ototoxicity of more direct causative 
factors resulting in an increased risk of hearing loss (Figure 1-2). 
 
Figure 1-2: Relationships between risk factors for hearing loss occurring independently or 
interactively in infants. 
 
  
It is plausible that hearing loss is a consequence of a congruence of risk factors which previous 
studies have so far failed to adequately address. Several studies have suggested this. For 
example in the study of Vohr et al (2000) from the NICHD Neonatal Network database, 59% 
of infants had one or more risk factors for hearing loss, and two or more risk factors were 
found in 26% of NICU admissions [89].  However, hearing loss was not formally assessed in 
this study and the prevalence rates determined by this study provides only an indicator as to 
the number of children that could be at risk. Nevertheless, coexisting risk factors have been 
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demonstrated to increase the probability of hearing loss. Two risk factors or above have been 
found to increase the chances of SNHL in comparison to infants that have a single risk factor 
[128]. Furthermore, almost double the prevalence of children with hearing loss had five or 
more risks present in comparison to infants with 3 or 4 risks [129]. However, a greater 
prevalence of risk factors does not determine the relative importance of different factors. 
Salamy et al (1989) grouped infants based on the number of days of intensive care, 
ventilation, antibiotics and total number of blood transfusions and made comparisons within 
illness groups when investigating the aetiology of hearing loss. However, these variables are 
inextricably associated with other aspects of neonatal illness which could cause hearing loss, 
such as sepsis and BPD. Attempts to match groups based on risk factors ideally require these 
variables to be independent. 
The increased risk of adverse outcome has also been expressed in terms of neonatal 
morbidities. Adverse neonatal outcome include delay in cognitive ability, 
neurodevelopmental functioning, and difficulties with sensory ability including vision and 
hearing impairment. In comparison to cognitive and motor impairments, difficulties with 
vision or hearing are less common across gestational age [1]. Although the rate of hearing 
loss is lower than other more prevalent impairment domains, it has a direct impact on 
language development and communication ability. Previous studies have investigated the 
risk of poor developmental outcome in respect of diagnoses received during neonatal care. 
Schmidt et al (2003) compared the rates of BPD, brain injury and ROP on poor 
neurodevelopmental outcome in extremely low birthweight infants (<1000g) following the 
Trial of Indometacin Prophylaxis in Preterms (TIPP) trial [130]. At 18 months, each morbidity 
was independently associated with an increased risk of neurosensory impairment, including 
severe hearing loss. These findings were replicated in a follow up of infants from the Caffeine 
for Apnoea of Prematurity (CAP) trial [131]. The risk of poor outcome at 5 years, increased 
incrementally with each additional morbidity (OR 2.4, 95% CI 2.0-2.9). The prevalence of 
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hearing loss was higher in children who had 2 or more morbidities in comparison to those 
without any morbidities (9% and 1% respectively). Further studies investigated BPD, brain 
injury and ROP with the addition of infection [82] or cholestasis following total parenteral 
nutrition [132]. Infection added to the prediction of poor neurodevelopmental outcome, but 
cholestasis was not significant. Although the total number of morbidities is suggestive of a 
more complex relationship, this is not specific to hearing loss but rather overall 
neurodevelopmental outcome.  
Although the total number of risk factors or morbidities is suggestive of a more complex 
relationship, a timeline of coexisting risk factors rather than the prevalence of risk may be of 
greater benefit.  Marlow et al (2000) compared a range of neonatal variables between 45 
very preterm infants (<33 weeks), 15 of which had impaired hearing [4]. Infants with hearing 
loss required longer durations of respiratory support and treatment for poor circulation and 
oedema. However, they hypothesised that the coincidence of risk factors might provide a 
better understanding of the development of SNHL in preterm infants. The administration of 
furosemide when creatinine levels were raised, or in the presence of netilmicin was 
associated with hearing loss as was the administration of netilmicin when bilirubin was 
elevated. Furthermore, acidosis occurring when bilirubin levels were raised also increased 
the risk of hearing loss. These combinations highlight the potentiation of ototoxicity between 
medication and physiological instability, and there may be a further differential susceptibility 
depending on infant age or the duration of exposure. Netilmicin, bilirubin and creatinine 
levels were not significantly different between groups when comparing each risk factor 
individually. Coexisting risk factors for preterm hearing loss highlight the importance of 
timing in neonatal treatment.  
The relative risk of different neonatal factors and their interactions are still not clearly 
understood. Studies are difficult to compare owing to a wide span of literature with differing 
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populations, definitions, criteria, outcome, and based on the time of the study and the 
subsequent type of care provided. This is further complicated by an often small sample size. 
There are a multitude of simultaneous factors which have separate effects and will influence 
other factors in complex ways; these relationships are still largely unknown. Time will play a 
role and there are problems with comparing babies when maturity will vary with gestational 
age, birthweight and additionally birthweight for gestation along with duration of treatment 
and exposure to risk factors. 
1.5 Summary and aims 
The aetiology of hearing loss in preterm infants is complex and likely to be influenced by a 
number of neonatal risks. It is well established that the babies born at the earliest gestational 
ages, with the lowest birth weights, have an increased prevalence of hearing loss. Hearing 
loss is derived from two aetiologies: SNHL as a result of damage to the outer hair cells of the 
cochlea, and ANSD as a consequence of inner hair cell or auditory nerve dysfunction. The 
aetiology of SNHL or ANSD is likely to be multifactorial; so far few studies have found 
discernible differences between the two. For this reason the current study will consider them 
as one population of preterm infants with hearing loss. 
Despite many attempts to understand acquired hearing loss in a preterm population, eliciting 
the relationship between hearing impairment and clinical and therapeutic factors remains 
unclear. To some extent this is primarily due to the complexity of the interactions, and partly 
due to methodological heterogeneity in previous studies.  
The pathological significance of m.1555A>G to deafness and the relationship between the 
mutation and aminoglycoside antibiotics has also yet to be established. Whilst this has not 
been thoroughly evaluated, m.1555A>G and an exposure to aminoglycosides could play a 
central role in the causative pathway of hearing loss in preterm infants. 
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The aim of this study is to evaluate the causative factors of hearing loss in children born 
prematurely over a geographic area. To achieve this the study will identify preterm infants 
with hearing loss and control infants with normal hearing, and compare risk factors and 
confounding factors between the groups. The specific objectives of this study are  
1. To establish the role of the mitochondrial mutation, m.1555A>G in deafness in 
preterm babies. 
2. To consider the frequency and penetrance of the genetic variant m.1555A>G 
between the two groups of infants. 
3. Within the context of genetic status, to identify individual neonatal risk factors 
involved in hearing loss. 
4. To identify combined risk factors in order to improve prediction by looking at 
occurrence rates and overlapping risks. 
1.5.1 Hypotheses 
The following hypotheses will be tested in this study. 
1. The mutation, m.1555A>G, will make a significant contribution to deafness in 
preterm infants following neonatal intensive care even when levels of 
aminoglycosides have remained within the therapeutic range. 
2. The frequency of the mutation will be higher in the group of infants with hearing loss. 
3. Hearing loss in infants born prematurely is related to individual neonatal risk factors.  
4. Exposure to multiple coexisting risk factors in the neonatal period will be associated 
with hearing loss.  
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2 Chapter 2: Method 
2.1 Study design  
This was a case control study, with multiple controls recruited per case. 
2.2 Population 
This study recruited children with confirmed hearing loss who were born at less than 31 
weeks and 6 days gestational age. Children were born between 1st January 2009 and 31st 
December 2013 and were treated at a neonatal intensive care unit within the Greater London 
area. Initially all children with hearing loss of any severity were recruited to the study. 
Exclusions were subsequently made if there was a known genetic or “syndromic” cause of 
hearing loss or a neurological abnormality that could cause deafness. For purposes of clarity, 
children were excluded after genetic screening as a diagnosis of a syndrome or neurological 
abnormality did not predetermine a negative result for m.1555A>G. Methodology was 
informed by variations of inclusion and exclusion criteria in previous studies which led to 
limitations in interpreting data (as discussed in Chapter 1), therefore this study aimed to 
include as many children with hearing loss as possible.   
For each child with hearing loss, up to five children with normal hearing were recruited. 
Control children were matched for sex, number of completed gestational weeks (plus or 
minus one week), calendar year in which they were born to minimise changes in neonatal 
treatment during the study period, and neonatal intensive care unit where they received the 
first two weeks of treatment after birth. Exclusion criterion for control children were missing 
pharmacological data, on the premise that other control participants with complete medical 
records could potentially be identified. 
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2.3 Identification of participants 
Children with hearing loss were primarily identified by the national Newborn Hearing 
Screening Programme (NHSP) database. Initially the children born between 2009 and 2012 
were identified, and a second cohort was identified for children born in 2013. The delay in 
identifying the 2013 babies meant that recruitment could start whilst enabling the babies 
born late in the year (who may have received many weeks of neonatal care) to have their 
hearing screen prior to discharge. The two birth cohorts aimed to reduce the number of 
children potentially missed from late 2013. Children were additionally identified through 
hearing assessment records, neonatal follow up services, and referral to the genetic deafness 
clinics. The study was advertised on the Action on Hearing Loss and Bliss websites, enabling 
parents to enquire about the study directly. As this study used multiple methods of 
ascertainment to identify eligible participants, new cases were screened for duplication 
following identification and prior to invitation letters being sent.  
Children with normal hearing were partially identified through NICU admission books, where 
these were available, using matching criteria. This was supplemented by data from the 
National Neonatal Research Database (NNRD), through the Neonatal Data Assessment Unit 
(NDAU) who identified the remaining eligible control children. The NNRD is an ‘opt out’ 
database that contains demographic and clinical information about infants who have been 
admitted to any neonatal unit within the UK. No specific identifiers are held on this database, 
which is updated following cleaned quarterly downloads from the national ‘real-time’ 
database (BadgerNet Neonatal; managed by Clevermed Ltd). Having identified children using 
their unique NNRD badger identification numbers, NHS numbers were obtained 
subsequently through the original BadgerNet database. All children who met eligibility 
requirements were invited to participate to allow for potential recruitment failure. 
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2.4 Procedure 
Children identified by NHSP with a failed newborn hearing screen had their hearing 
impairment confirmed by their Consultant Audiovestibular Physician/Paediatrician prior to 
being invited to participate in the study. Following confirmation of a permanent hearing loss, 
letters of invitation were sent to parents of all children by their Consultant (Appendix 4). In 
cases where it was not possible to identify a Consultant Audiovestibular Physician, the child’s 
General Practitioner (GP) was approached and asked to send a letter of invitation instead. 
Parents of control children were invited by letter from the Neonatal Consultant acting as the 
local investigator for the study from the unit in which they received their first two weeks of 
neonatal intensive care. Invitations included a parent information leaflet providing details 
regarding the study, and parents were asked to return a reply sheet to the researcher if they 
would like to be contacted to participate (Appendix 5).  
Parents of all children who responded, were contacted by phone or email, dependent on 
their stated preference, and a home visit was arranged. Parents who did not respond were 
contacted by telephone to ensure that they had received the study information. For children 
with an unconfirmed hearing loss, the diagnosis and severity of impairment was discussed 
with the parent/guardian, and the name of the Consultant Audiovestibular Physician leading 
their care was established for data collection purposes. Written consent was taken for all 
participants from a parent or legal guardian (Appendix 6). Consent was obtained to take a 
saliva sample for genetic screening for m.1555A>G where this had not already been done, to 
access medical notes to retrieve a clinical history from the neonatal period, and to obtain 
recent audiology data. Parents were given a £10 gift card to thank them for their time. 
2.5 Hearing assessments 
Hearing screening for all children was completed prior to discharge from neonatal units. The 
recommended initial screen for preterm babies is usually AOAE, followed by Automated ABR 
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in both ears, unless the baby has been previously diagnosed with meningitis or bilateral 
atresia. In these cases the baby will be referred for specialist ABR testing. Results of newborn 
hearing screening are recorded as either a pass (a clear response in both ears) or refer for 
outpatient follow up if there was no clear response in one or both ears. Follow up screening 
was carried out by an experienced audiological physician/paediatrician. A standardised 
audiological proforma for the study was completed by the audiology physician (Appendix 7). 
Hearing impairment was confirmed as being sensorineural hearing loss or auditory 
neuropathy spectrum disorder, and was either unilateral or bilateral. The definition for 
severity of hearing loss for this study was mild (21-40 dB HL), moderate (41-70 dB HL), severe 
(71-95 dB HL), or profound (>95 dB HL). The use of hearing aids or cochlear implant was 
recorded, along with any testing completed prior to the study exploring the aetiology of 
deafness. All data were entered onto the study database, which was built in the REDCap 
(Research Electronic Data Capture) environment (https://www.project-redcap.org). 
2.6 Neonatal data collection 
Data were collected from neonatal units following written parental consent. Data were 
abstracted from medical notes as a hard copy using a standardised proforma (Appendix 8), 
which was entered onto the electronic database (REDCap). To preserve anonymity, a unique 
study ID number was allocated to each child and used on both the proforma and 
computerised data entry, as well as the date of birth.  
Variables for which data were collected were in accordance with previous research and were 
as follows; sex (male/female), date of birth, gestational age at birth (completed weeks and 
days), multiple birth, birth weight, intrauterine growth restriction (less than the 10th centile 
for gestational age), Apgar score (at 5 minutes), CRIB II scores [44, 133], all hospitals where 
treatment was received including transfer dates, acquired brain injury ( IVH grades I-II, IVH 
with ventricular distension, intraparenchymal lesion, and periventricular leukomalacia) [53], 
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pneumothorax, pulmonary haemorrhage, PDA (no treatment needed, medical treatment, 
surgical intervention), NEC (medical treatment, surgical drain, laparotomy), BPD (oxygen at 
28 days and in air at 36 weeks corrected GA, <30% oxygen at 36 weeks, >30% oxygen at 36 
weeks) [44], septicaemia (positive blood culture), meningitis (positive cerebrospinal fluid), 
highest bilirubin level, highest creatinine level. The number of days were recorded as for each 
of the following; ventilation, CPAP, oxygen, long line in situ, level 1 care, level 2 care and level 
3 care [134]. 
Data was collated in the form of a daily timeline for each variable/risk factor to calculate co-
occurring risks, for the first 14 days and then weekly until the infant had either been 
discharged home or transferred to a paediatric ward. Variables were as follows; medication 
recorded if administered; amikacin, netilmicin, gentamicin, vancomycin, furosemide, 
indometacin, ibuprofen, inotropes (dopamine, dobutamine, adrenaline, norepinephrine), 
dexamethasone, hydrocortisone and methylprednisolone. Blood levels recorded; highest 
levels (for amikacin, netilmicin, gentamicin and vancomycin), highest serum bilirubin, highest 
creatinine, highest lactate, lowest pH level. Further variables documented; exchange blood 
transfusion, blood transfusion, highest mode of respiratory support (HFO, conventional 
ventilation, CPAP, oxygen), and the administration of total parenteral nutrition (TPN). 
Many children received neonatal care at more than one hospital and therefore had multiple 
volumes of clinical notes. For those where the medical notes could not be accessed, 
information was derived from the daily and stay summaries on the BadgerNet system where 
available. 
2.7 Genetic screening 
Buccal swabs were taken from all children who had not been tested previously, to screen for 
the m.1555A>G mutation, using an Oragene OG-575 sample kit. Samples were labelled with 
the child’s unique study ID number and date of birth. Children with hearing loss that had 
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been tested clinically were not re-tested if their results were accessible from their medical 
notes.  
Samples were analysed at the North Thames Regional Genetics Laboratory, Great Ormond 
Street Hospital. DNA was extracted from saliva using standard procedures and analysed by 
polymerase chain reaction (PCR) by laboratory personnel.  
A primer mix and megamix (containing proprietary buffer, Mg and dNTPs and Taq 
polymerase) were added to the DNA sample for thermal cycling. The sample was heated to 
95 oC for 5 minutes. Cycles of heating to 95 oC for 30 seconds and cooling to 56 oC for 1 minute 
for primer annealing and polymerase extension were repeated 33 times for amplification of 
the target sequence of DNA. After the 33 cycles the temperature was held at 72 oC for 5 
minutes. The expected fragment size was 657 base pairs. 
The DNA was cut at the target sequence (GTCTC(N)1↓) by the restriction enzyme Alw26l 
(figure 2-1) at 37oC for a duration of 4 hours. The mutation causes a loss of the Alw26l site 
and therefore DNA sequences containing the mutation remained uncut and with a length of 
657 base pairs.   
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Figure 2-1: Target site for enzyme restriction digestion in wild type and mutant DNA 
sequences 
 
 
Wild type sequences were cut into two fragments of 405 base pairs and 252 base pairs. The 
digested DNA together with 10µl of dye were loaded on 3% agarose gel, separating the DNA 
by size and subject to electrophoresis. Any uncut fragments were then checked by bi-
directional Sanger sequencing. A second sample was taken from children with the mutation 
for re-testing.  
Families found to have the m.1555A>G mutation were offered a genetic clinic appointment 
at Great Ormond Street Hospital with the study Chief Investigator, Professor Maria Bitner-
Glindzicz. 
2.8 Statistical analysis 
Data were double entered into a REDCap (Research Electronic Data Capture) database with 
a double coding error rate of less than 2%. REDCap is a secure website for developing an 
online database which enables audit trails for tracking data changes, and the export of data 
to statistical software packages. Only anonymised data was entered onto this database. The 
birth rate in London is approximately 120 000 babies per year (600 000 for 5 years of the 
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birth cohort for the study). Approximately 1% will have a birth weight under 1500g which 
gives a probable population of 3000 – 6000 infants born at less than 32 weeks gestation over 
the 5 year period. The prevalence of hearing loss is approximately 1-2% [4] which results in 
a possible 30-120 children with hearing impairment in this population. In a group of 3000 – 
6000 preterm infants (less than 32 weeks of gestation) 4-10 children would be expected to 
carry m.1555A>G based upon a mutation frequency of 1 in 526 [121]. In the event, 93 eligible 
children were identified with hearing loss from all sources. It is possible that no child would 
be identified with m.1555A>G from such a small number, but if the thesis that neonatal 
acquired hearing loss resulted from aminoglycoside administration in the face of the 
mutation, we would expect that this group would be greatly enriched by children with 
m.1555A>G. 
2.8.1 Baseline characteristics of case and control groups 
Up to 5 matched normal hearing control children were recruited per case to increase power. 
To achieve a statistical power of 0.8, with a medium effect size and a p value of 0.05, the 
sample size required was 156 [135]. The expected sample size of cases was 30-60 children 
with hearing impairment, leaving an expected matched control group of normal hearing 
children as 3-5 children per case. A larger sample size was expected to narrow confidence 
intervals. All analyses were adjusted for matching criteria (sex and gestational age, as well as 
birthweight for gestational age to reduce additional confounding). Birthweight by gestational 
age was derived using a standard deviation score using UK standards 
(http://www.healthforallchildren.com/shop-base/shop/software/lmsgrowth/). Neonatal 
clinical characteristics were described using frequency and percentages for categorical data, 
and median and interquartile range for continuous variables. Differences between cases and 
controls were examined using chi square, independent t tests and non-parametric Mann 
Whitney U tests for binomial and continuous variables in Stata (version 13). The distribution 
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of the primary variables were plotted as histograms revealing a non-normal distribution in 
the majority of the variables, and therefore non-parametric testing was used where possible. 
All analyses were reported as the more conservative 2 tailed level of probability for each 
variable.  
2.8.2 Risk factors as independent predictors of hearing loss 
Neonatal data and clinical diagnoses were analysed individually using logistic regression for 
univariate analysis. Continuous variables were re-coded for the analysis of combined risk 
factors as follows, creatinine was considered a risk at greater than 90mmol/l, blood pH level 
less than 7.2, total bilirubin greater than 200micromol/l, and lactate greater than 2.0mmol/l 
[4]. Additional variables were added for aminoglycosides (amikacin, gentamicin and 
vancomycin) firstly as ‘any aminoglycoside’ denoting any drug given at any point during 
hospitalisation as a binary variable, and as a second variable to investigate the total number 
of individual drugs that had been given. Steroids (methylprednisolone, hydrocortisone and 
dexamethasone) were categorised in three ways: firstly the number given per day (and per 
week from week 3 onwards), secondly if any steroid had been given in the first 72 hours after 
birth, and thirdly, whether any steroid was received at any point during care.  
2.8.3 Combinations of risk factors as independent predictors of hearing loss 
Associations between simultaneously occurring combinations of clinical risk factors as 
predictors for hearing impairment were evaluated using multivariate regression. Models 
included baseline risk factors, diagnoses, treatments and physiological risk factors, and 
subsequently, with the exclusion of clinical diagnoses. Individual models for specific 
diagnoses (PDA, BPD, NEC/sepsis and IVH), and their associated treatments alongside 
potential effect modifiers in the form of physiological factors, were also run using 
multivariate regression analyses. Variables included in all models were predominantly 
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categorical. Sample size for multivariate regression models was based upon the largest 
regression model which included 22 predictors. To run this model the minimum sample size 
required was 50 + (8k) [135]; therefore 50 + (8x22) = 226. Data was available for 237 children 
meeting the minimum required sample size parameter. 
Exposure to risk factors for hearing loss across the neonatal period, included 8 risks which 
had all reached significance in univariate analyses. A mean number of risk factors were 
derived for each day for the first 14 days and per week, using categorical variables.  
The risk of ototoxic medication, including gentamicin, vancomycin and furosemide, was 
measured in two ways. Firstly as a binary variable, whereby infants had received any of the 
three medications in the first 14 days, or per week in the subsequent weeks. Logistic 
regression was used to compare each group per day, and then as an overall effect. Secondly, 
the total number of cumulative days of each medication (the total possible over the first 14 
days was 42), as a continuous variable. Comparisons between the groups were made per day 
and as an overall effect using multivariate logistic regression. Comparisons were made 
between groups per week using logistic regression, and then as an overall comparison.  
Multivariate regression analyses were again used to investigate the relationship between 
ototoxic medication, ‘haemodynamic instability’, clinical diagnoses and deafness in this 
population. The variables for ototoxic medication have been described above. Comorbid 
conditions diagnosed at any point during neonatal care included PDA, IVH/PVL, BPD and NEC 
and/or sepsis. Haemodynamic instability included variables indicating poor renal function or 
evidence of poor perfusion and need for circulatory support, namely: creatinine >90mmol/l, 
lactate >2.0mmol/l or the administration of inotropes. Similarly to ototoxic medication, a 
binary variable was created to ascertain whether any of the markers had been present per 
day. A cumulative total of the three variables was also created per day. Ototoxic medication 
and haemodynamic instability were analysed individually by day, and as an overall 
 61 
  
comparison between cases and controls. The fit of all regression models was based upon the 
likelihood ratio chi-square significance value. 
2.9 Ethical approval 
The study received ethical approval by Central and East London Local Clinical Research 
Network (ref: 12/LO/0005). Approval was also granted by the Ethics and Confidentiality 
Committee of the National Information Governance Board to lift Section 251 of the NHS Act 
2006 and the Health Service Regulations 2002. Approval enabled access to patient 
identifiable information without prior parental consent for the purpose of identifying eligible 
children.  
Research and Development approval was sought by the student, and granted at 25 trusts 
covering 33 collaborating sites (Appendix 9), including both hospitals and community trusts. 
Substantial amendments were made to the parent information leaflet with updated contact 
information (dated 10.05.13), to the parent letter and protocol to enable GPs to be contacted 
(dated 20.03.14) and finally to the reply sheet and protocol to contact parents if no response 
was received from them (dated 09.12.14). Minor amendments were made to the consent 
form following approval for changes to the parent information leaflet (dated 20.05.13), to 
the protocol for the same reason (dated 28.05.13), and again to the protocol to update 
information regarding NNRD (dated 24.07.14). A research passport was obtained for the 
study which was required to gain a letter of access or honorary contract for each trust. It took 
approximately 9 months to receive the majority of the approvals and corresponding 
paperwork. The study was registered with the International Standard Randomised Controlled 
Trial Number (ISRCTN39982239) and was part of the National Institute for Health Research 
(NIHR) study portfolio. Action on Hearing Loss together with the Rosetrees Trust provided 
full funding for the study (ref: RNID G47). 
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3 Chapter 3: Influence of m.1555A>G on hearing loss in 
preterm infants 
3.1 Introduction 
Aminoglycoside antibiotics are widely used in the first line treatment of suspected sepsis in 
infants born prematurely. In line with NICE guidelines, 89% of the 160 neonatal units in 
England use gentamicin [136]. Susceptibility to the ototoxic side effects of aminoglycosides 
is increased in carriers of the maternally inherited m.1555A>G genetic variant, even when 
blood levels of aminoglycosides are within the normal clinical recommended range. 
Owing to the frequency of gentamicin use in neonatal care, aminoglycoside induced hearing 
loss would be expected to be higher than the general population if penetrance is as high as 
previously reported (as discussed in Chapter 1). Methodology and population samples have 
varied between previous studies and the true risk of deafness caused by aminoglycosides in 
the presence of m.1555A>G remains unknown. 
This study aimed to compare the difference in m.1555A>G prevalence between children with 
hearing impairment and those with normal hearing who were born prematurely. Children 
were expected to be more likely to have the mutation in the group with hearing loss, and to 
have received aminoglycoside antibiotics.  
Before considering the frequency and penetrance of the mutation, it is firstly important to 
consider the number of children with hearing loss, recruitment, and demographic differences 
between the recruited and non-recruited groups of children identified with impaired hearing, 
before making comparisons between genetic influences on hearing loss. 
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3.2 Results 
3.2.1 Participants 
Between 2009 and 2013, there were 91 children identified with hearing loss by the Newborn 
Hearing Screening Programme, which was supplemented with parent and clinician referrals 
to give a total of 108 children. This is consistent with the predicted estimate of 30-120 
preterm infants with hearing impairment over a 5 year period (see section 2.8). Sixty two 
children with hearing loss were recruited to the study, 5 of whom were subsequently 
excluded. The pattern of identification and recruitment is displayed in figure 3-1. 
Figure 3-1: Flow diagram displaying the identification and recruitment of children with 
hearing loss born below 32 weeks of gestation 
  
 
A total of 93 children were eligible from the 108. There were 5 children invited as matched 
controls that had not been identified as cases but parents reported impaired hearing. On 
confirmation of hearing loss (by Consultant Audiological Physician) they were recruited as 
cases. There were 3 children who had failed their hearing screen prior to discharge but at 
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follow up had normal hearing and were therefore not eligible for the study. This is consistent 
with an early study of newborn hearing screening which demonstrated a false positive rate 
of 1-2% [137]. Although the number of children in this study that went on to have normal 
hearing is slightly higher than the initial rate of false positives, 2 of the 3 children were seen 
in audiology clinics for multiple follow up appointments before they were discharged from 
the service. All 34 families from whom there was no response, were unable to be contacted 
in writing or by telephone.  
Children excluded after recruitment were as follows. Two children were later found to have 
a conductive hearing loss and no confirmed permanent hearing impairment. One child 
received their neonatal care at a neonatal intensive care unit outside of Greater London. A 
further child received care at a hospital from which approval to access medical notes could 
not be obtained. As access to medical records to determine aminoglycoside exposure was a 
prerequisite to eligibility it was not possible to include them. Using data provided by NDAU, 
the distribution of sex, birth year and gestational age were compared between the recruited 
and non-recruited group of children with hearing loss (table 3-1).  
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Table 3-1: Comparison of core data in responders and non-responders for children with 
hearing loss 
 Recruited (%) 
(n=57) 
Not recruited (%) 
(n=36) 
Total 
(n=93) 
Sex Male 
Female 
38 (76) 
19 (44) 
12 (24) 
24 (56) 
50 
43 
Birth year 2009 
2010 
2011 
2012 
2013 
16 (73) 
13 (59) 
9 (60) 
8 (62) 
11 (52) 
6 (27) 
9 (41) 
6 (40) 
5 (38) 
10 (48) 
22 
22 
15 
13 
21 
Gestational age 
(weeks) 
23-25 
26-28 
29-31 
Unknown (<32) 
16 (62) 
19 (54) 
22 (81) 
0 
10 (38) 
16 (46) 
5 (19) 
5 (100) 
26 
35 
27 
5 
 
 
The proportion of males recruited to the study was higher than females, and the proportion 
of children identified with hearing loss was lower in 2011 and 2012 but relatively consistent 
across the other 3 years. More than half of the children identified at each gestational age 
were recruited, and there were 5 children from the non-recruited group with missing 
gestational age, but identified by the Newborn Hearing Screening Programme as having been 
born at less than 32 weeks of gestation.  
3.2.2 Prevalence and penetrance of m.1555A>G 
Genetic screening for m.1555A>G was carried out on 241 children (62 cases and 179 
controls). One sample testing for a normal hearing control child failed (the laboratory was 
unable to process a result), and a repeat sample could not be obtained. The results for all 
children, including those that were later excluded, are displayed in table 3-2. 
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Table 3-2: Distribution of m.1555A>G for children with and without hearing loss 
 
 
Number of children tested m.1555A>G positive 
Cases* 
 
62 0 
Controls 
 
179 1 
*Total number of children tested before exclusion criteria applied 
 
The prevalence of the mutation in this study is 1 in 241 which is 0.41% (95% CI 0.07-2.30). 
There were no children with hearing loss that tested positive for the mutation. Furthermore, 
the child with the genetic variant was recruited from the control group and had normal 
hearing.  
The penetrance of permanent hearing loss following aminoglycoside exposure in this study 
cannot be established, as only one child was carrying the mutation. However, as hearing 
screening was normal despite aminoglycoside administration, penetrance is not as high as 
the previously reported 100%. 
3.2.3 Case study 
One child was found to be a carrier of m.1555A>G; for confidentiality purposes this child will 
be referred to as Child A. Child A was a male infant, born at 29+4 weeks gestational age with 
a birth weight of 956g (below the 10th centile for gestational age), Child A received one course 
of amikacin (3 doses at 4mg/kg over 3 days) on admission to the neonatal unit and one course 
of gentamicin (dose and duration unknown as he was transferred to a local neonatal unit 
from which it was not possible to access medical records) in the third week after birth for 
suspected NEC. Blood cultures were negative throughout. No other ototoxic medication was 
received. During the first course of aminoglycosides creatinine level was >89mmol/l and 
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lactate was >3.5mmol/l for the duration of the course. Before being discharged from the 
neonatal unit, Child A had a newborn hearing screen which was passed.  
Subsequently, genetic screening was completed for Child A’s mother who also had 
m.1555A>G, and for an older female sibling (Child B). Child B was also preterm, born at 33+5 
weeks gestation (not eligible for recruitment to the study) and also received gentamicin and 
vancomycin (dose and duration unknown for both antibiotics) during the neonatal admission 
for suspected sepsis. Child B also passed her newborn hearing screen prior to discharge from 
the neonatal unit. Known blood concentration levels for aminoglycosides in Child A and B 
were reported to be within the normal clinical range. Both children were offered a hearing 
assessment following confirmation of m.1555A>G, which indicated normal hearing for both 
children, at the age of 2 years for Child A (audiogram displayed in figure 3-1), and 5 years for 
Child B.   
At a Principal Investigator follow up assessment 6 months later, a unilateral high frequency 
hearing loss was noted for Child A, at age 3 years (audiogram displayed in figure 3-2). OAE’s 
were present bilaterally, indicative of functional outer hair cells. Child B continues to have 
normal hearing. This finding does not materially affect the conclusions of this study. 
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Figure 3-2: Audiogram for Child A at follow up audiology assessment, aged 2 years and 9 months 
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Figure 3-3: Audiogram for Child A at follow up audiology assessment, aged 3 years and 3 months 
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3.3 Discussion of results 
The aim of the study was to determine the contribution of m.1555A>G to deafness in a 
preterm population. It was expected that this genetic variant would play a significant role in 
the loss of hearing in a premature population that is likely to have received aminoglycoside 
antibiotics. In the event, one child was found with the mutation, who had received amikacin 
and gentamicin during the neonatal admission but who had normal hearing throughout the 
study period. Hearing impairment was noted after the data collection period during continual 
follow up assessments. Although only detecting the mutation in one control child was an 
unexpected finding, his has been found by previous research (which will be discussed in 
relation to the penetrance of the mutation). Whilst there is a possibility that the mutation 
was present in children that were not recruited, there were no substantial clinical differences 
between the recruited and non-recruited children (table 3-1) therefore, it is unlikely that 
there will be a higher proportion of the mutation in the untested non-recruited children with 
hearing loss.  
The overall prevalence of m.1555A>G in this study was 0.41% (95% CI 0.07-2.30), which fits 
within the trends that previous studies with neonatal populations have found (Appendix 3). 
Prevalence rates in studies in China, Germany and the US range between 0.12 and 0.69% 
[123-125, 138]. The US studies had the highest prevalence rates; Johnson et al (2010) from a 
population of 436 premature, low birth weight (<2500g) infants found 3 infants to be carriers 
of the mutation (0.69%) [125]. Ealy et al (2011) enrolled 703 infants who had previously been 
admitted to NICU, and found a prevalence rate of the mutation in this population to be 0.28% 
[123]. Gopel et al (2014) found 12 infants with m.1555A>G from 7056 (0.17%) recruited from 
neonatal intensive care units in Germany [124]. In a Chinese study of newborn infants, Wang 
et al (2011) recruited 14 913 infants and found the mutation in 18, giving a prevalence rate 
of 0.12% [138]. In contrast, a large Brazilian study of newborn infants found no mutations in 
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a sample size of 8974 infants that comprised almost 2000 more than the largest US or 
European neonatal studies [139]. There is therefore global variation in the prevalence of the 
mutation. In older children, a population study of European children (unselected for hearing 
status) demonstrated a prevalence of 0.19% (95% CI 0.10-0.28) [121]. The 95% confidence 
intervals in the current study overlap with those from the European study, indicating no 
significant difference between the populations which are therefore comparable. Although 
the range of prevalence varies according to geographical region, the current study follows 
the trend found in US and other European studies.  
The penetrance of deafness in carriers of m.1555A>G following a single dose of 
aminoglycosides has previously been reported to be 100% [117]. The current study found 
one child (and their sibling, both with normal hearing throughout the study period as 
discussed in section 3.2.3) with m.1555A>G making penetrance impossible to establish with 
this dataset, although it would certainly appear to be lower than 100%. If hearing loss had 
been evident during the study period, this child would have been recruited as a case. 
Subsequently, this would have resulted in a 1 in 57 frequency which is not significantly 
different to the expected mutation frequency of 4 (p>0.05), and in retrospect does not alter 
the overall study conclusions. Even when taking into account the late onset hearing loss in 
this child, the sibling had normal hearing and therefore penetrance remains below 100%. The 
London Operational Delivery Network discharged home 1475 infants <32 weeks in 2014 
(unpublished source: NHS England).  Admission rates at these gestational ages have been 
stable leading to an estimated discharge population of 7375 infants over the five year study 
period (full yearly data are not readily available for the whole period).  We would anticipate, 
therefore, 14-15 children discharged home at <32 weeks with m.1555A>G (based on a 
prevalence of the mutation of 1 in 525 in the UK). Of the babies recruited to this study 93% 
received gentamicin, amikacin, or vancomycin (table 4-3).  Given 100% penetrance, we would 
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have anticipated 14-15 infants with the mutation among those with hearing loss or 8-9 within 
our study cohort, or 6 patients if based on gentamicin administration alone (73%: table 4-3).  
Since this study began, other studies have also found children to have normal hearing despite 
having the mutation and receiving gentamicin, again indicating 100% penetrance is an 
overestimate. Ealy et al (2011) identified 2 children born prematurely who both received 
gentamicin for 9-13 days, carried the m.1555A>G mutation and had normal newborn hearing 
screens [123]. Gopel et al (2014) identified 12 preterm infants with m.1555A>G, 10 of whom 
had received gentamicin, 9 of 12 children passed their initial newborn hearing screen [124]. 
All 3 babies who failed their hearing test had been exposed to gentamicin. Follow up hearing 
assessments to confirm hearing loss have not yet been reported for either study, and 
therefore their hearing status is unconfirmed. Given that the child in the current study had a 
late onset hearing loss, confirming hearing loss in previous neonatal studies is pivotal. 
Furthermore, 2 of the 3 infants from Gopel et al’s study that failed their hearing screen had 
low birth weights, 2 of the 3 infants were also the smaller infant of a twin pair (the siblings 
having a normal hearing screen despite gentamicin exposure), which raises the possibility of 
additional risk factors along the pathway to hearing loss in those with m.1555A>G. Johnson 
et al (2010) also found carriers of m.1555A>G had normal hearing after having been exposed 
to 2 days of gentamicin (2 out of 3 infants) [125]. The infant with impaired hearing had 
received a longer course of aminoglycosides (4 days) but was also noted to have an extremely 
low birthweight. Furthermore, the child in the current study was also born below the 10th 
centile which coincides with previous findings. 
A low penetrance suggests other unidentified genetic or environmental factors are involved 
in the progression of hearing impairment [140]. Low birth weight as mentioned, appears to 
be a common occurrence when looking at the children with hearing loss across these studies. 
However, there are other neonatal factors that could increase susceptibility to 
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aminoglycosides in these individuals. The mutation enables aminoglycosides to bind more 
readily to mitochondrial ribosomes; protein synthesis is decreased and therefore cellular 
energy also declines to below the required rate. Moreover, the infiltration of 
aminoglycosides to the inner ear hairs cells can be potentiated by additional medications 
such as furosemide which would increase the availability of aminoglycosides binding to 
mitochondrial ribosomes (discussed in section 1.2.8). Whilst there were no further ototoxic 
medications given to the child in this study, there were raised physiological markers that 
reduce the clearance of aminoglycosides. This has also previously been discussed in relation 
to preterm hearing loss, but not specifically in the presence of m.1555A>G. Cumulative doses 
and blood levels of aminoglycosides have previously not been associated with hearing loss in 
the presence of the mutation [120], therefore the influence of additional factors must be 
explored. Studies often do not report the cause of aminoglycoside exposure in children. 
Proven sepsis from blood cultures would indicate increased physiological stress that again 
can impede elimination of aminoglycosides. In the current study both child A and B were 
treated for suspected sepsis only, none was proven, however child A was unwell following 
birth as indicated by the administration of respiratory support, antibiotics and elevated 
creatinine and lactate levels. The presence or absence of sepsis (and associated physiological 
stress) in the presence of m.1555A>G following aminoglycosides might explain why, in some 
families, individuals may or may not be affected.  
A further point for consideration is the age of onset of hearing loss in previous research. In 
the absence of aminoglycosides, a prospective study in Finland looked at the audiological 
screening of 19 children from one family aged 2-13 with m.1555A>G [141]. Thirteen out of 
these 19 children passed their newborn hearing screen, the remaining 6 did not receive a 
newborn hearing test. Of these 19 children, 10 (8 of which were male) later developed a 
hearing impairment ranging from high frequencies to severe progressive losses, with an 
average age of diagnosis 3.7 years. Non-exposure to ototoxic medication was self-reported 
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and it is therefore possible that this could be incorrect. Nevertheless, this study demonstrates 
the risk to hearing from the mutation even without aminoglycosides. In one of the early 
studies looking at aminoglycoside induced hearing loss, 763 deaf mutes were retrospectively 
investigated for exposure to aminoglycosides and familial inheritance [142]. Inheritance was 
exclusively through the maternal line. Over half of participants with aminoglycoside exposure 
in the presence of a family history of deafness, had an age of onset of hearing loss before 3 
years. The group with the positive family history of deafness also received shorter durations 
of treatment, indicating a higher susceptibility to aminoglycosides existed in this group in 
comparison to the group without a family history. Not only have shorter durations been 
observed, but the use of aminoglycosides may hasten the appearance of hearing loss. In a 
study of 70 families with severe SNHL, 19 were found to carry the m.1555A>G mutation [117]. 
The age of onset of deafness for patients with m.1555A>G in the presence of aminoglycoside 
exposure was much lower (median age of 5 years) in comparison to those not treated with 
aminoglycoside antibiotics (median age 20 years). Again, exposure to aminoglycosides were 
self-reported as was the onset and progression of hearing impairment. With a probable 
median time to deafness of 3-5 years in the aforementioned studies in the presence of 
aminoglycosides, caution should be taken interpreting normal hearing in studies with a 
neonatal population in those with m.1555A>G; as they could still be at a higher risk of 
developing hearing loss than those who have the genetic change but have not been exposed.  
Since data collection was completed for this study, the control child with m.1555A>G 
developed a mild high frequency loss of hearing. This was noted around the age of 3 years 
and is therefore consistent with the findings of previous research.  
3.3.1 Summary 
The contribution of m.1555A>G was predicted to play a significant role in the development 
of deafness in a preterm population who are likely to have received aminoglycoside 
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antibiotics. However, no children from 57 with hearing loss were observed to carry the 
mutation, and only one child amongst 179 controls carried the mutation. Therefore, the 
overall prevalence of the m.1555A>G mutation was 1 in 241, but this is unlikely to be 
significantly different from population estimates from previous studies. It would appear that 
the m.1555A>G mutation contributes little, if at all, to the excess of hearing loss observed in 
survivors of very preterm birth. 
The penetrance of aminoglycoside induced hearing loss in the presence of m.1555A>G is 
unlikely to be 100%, given the widespread use of aminoglycosides in a neonatal population 
(see chapter 3.3). Owing to the unexpectedly low number of children observed to carry the 
mutation, in contrast to the anticipated finding of there being at least 6 children (see section 
2.8), this interaction is unlikely to be responsible for the increased prevalence of deafness 
among very preterm children. Hence, the following chapter will evaluate the potential role 
of other risk factors in the causation of hearing loss in this population.
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4 Chapter 4: Neonatal influences on hearing loss 
4.1 Introduction 
Previous studies have evaluated risk factors either from neonatal illnesses or treatments, as 
independent or combinations of factors, with few consistent conclusions. The clinical course 
and treatment exposures of very preterm infants are frequently complex and often spread 
across a number of weeks of hospitalisation.  
The aim of the study was to investigate independent and coincident risk factors for hearing 
loss. Analysis was therefore developed to assess baseline characteristics, diagnoses, 
intensive care measures and potential ototoxic medications, before evaluating the 
coincidence of risk factors assessed on a timeline that specified daily occurrences for 14 days 
and weekly thereafter until discharge. 
This section will address the two hypotheses: 
1. Hearing loss in infants born prematurely are related to individual neonatal risk 
factors.  
2. Exposure to multiple coexisting risk factors in the neonatal period will be associated 
with hearing loss.  
4.2 Results 
4.2.1 Characteristics of children with hearing loss 
Fifty-seven children with a confirmed hearing loss were included in the study. This gives an 
estimated prevalence of 13 children with hearing loss per 1000, in infants born at less than 
32 weeks gestation. Data were collected regarding their hearing diagnosis, severity, 
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detection of impairment and treatment. The audiological characteristics in terms of hearing 
loss and severity of the sample is summarised in table 4-1. 
Table 4-1: Audiological characteristics of hearing impairment in 57 children born at less than 
32 weeks of gestation 
 Data available (n) n  (%) 
SNHL 57 57 (100) 
   Unilateral 57 8  (14) 
   Bilateral 57 49 (86) 
ANSD    
   Confirmed 54 15 (27.8) 
   Suspected 54 6  (11.1) 
   Not recorded 54 7  (13) 
Severity of hearing loss    
   Mild                (21-40dB) 57 2  (3.5) 
   Moderate      (41-70dB) 57 29  (50.9) 
   Severe            (71-95dB) 57 12  (21.1) 
   Profound       (>95dB) 57 14  (24.6) 
Newborn hearing screen     
   Passed 55 6  (10.9) 
   Referred 55 49  (89.1) 
Hearing aids 56 47  (83.9) 
Cochlear implant/referral 57 15  (26.3) 
Intellectual disability 53 29  (54.7) 
Additional disability 51 33  (64.7) 
Abbreviations; SNHL, Sensorineural hearing loss; ANSD, Auditory neuropathy spectrum 
disorder  
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All children were reported by their consultant audiological physician as having SNHL, but for 
15 children there was evidence that this might be ANSD. A further 11% were suspected as 
having ANSD but this was unconfirmed, and a further 13% had reportedly not been tested 
with ABR; ANSD could not therefore be confirmed. Of the 57 cases, 49 had a bilateral 
impairment. The majority of children had a moderate to profound loss and had received 
treatment in the form of hearing aids. The distribution of severity by gestational week is 
displayed in figure 4-2. At the point of data collection, 26% of children had been referred for, 
or had undergone a cochlear implant. Almost 90% of children were identified at the Newborn 
Hearing screen prior to neonatal discharge and were referred for follow up audiology 
assessments. Aside from hearing impairment, 33 children had an additional disability. 
Investigations into the aetiology of hearing impairment had been undertaken prior to the 
study as follows: CMV testing (78.7%), GJB2 testing (54.8%), m.1555A>G prior to this study 
(47.4%), MRI of inner ear (76.6%) and ophthalmic review (71.4%). 
As all children were reported to have SNHL, for the purposes of these analyses, in order to 
differentiate between the SNHL and ANSD, children that did not show signs of ANSD will be 
referred to as having Cochlear Hearing Loss (CHL). 
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Figure 4-1: The distribution of the severity of hearing impairment by week of gestation 
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The severity of hearing impairment was not significantly different across gestational weeks 
within the study range (p>0.05). Of the 57 children, 3% had a mild loss (21-40dB), 51% had a 
moderate loss (41-70dB), 21% had a severe loss (71-95dB) and 25% had a profound 
impairment (>95dB).  
4.2.2 Neonatal clinical differences between CHL and ANSD 
Based on my review of the literature, discussed in chapter 1, differences in clinical condition 
and diagnosis between infants with CHL or specifically ANSD have been reported. CHL and 
ANSD have been associated with different patterns of clinical risk. As already identified in 
section 4.2.1, ANSD was difficult to determine in some children. Therefore, the distribution 
of clinical factors in those at a high risk of ANSD (confirmed or suspected) were compared to 
those of children with CHL in a univariate analysis (table 4-2). There were few differences in 
the distribution of clinical risk factors between the two. Children with cochlear losses were 
more likely to have a low birthweight for gestation but were less frequently found to be from 
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a multiple pregnancy or to have any evidence of serious neonatal brain injury, specifically 
PVL. The frequency of other risk factors did not vary significantly between the two conditions. 
Given the small numbers of individuals in each group and the use of multiple comparisons, it 
seems unlikely that there are any important clinical risk differences between the two groups, 
which for the purposes of further investigation, have subsequently been treated as one.
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Table 4-2: Distribution of neonatal risk factors in 57 children with CHL and ANSD born at less than 32 weeks gestational age 
Risk factor CHL (n=36) ANSD (n=21)   
 n/median (%/range) n/median (%/range) OR (95% CI) Significance 
Male sex  25 (69.4%) 13 (61.9%) 1.40 (0.45-4.33)  
Gestation (week+days) 28+1 (25+6-29+6) 27+5 (25+6-30)   
Birthweight (g) 894 (751-1135) 1000 (800-1400)   
Birthweight (sd) -0.51 (-1.71-0.21) 0.12 (-0.6-0.82)  * 
IUGR 12 (36.4%) 2 (9.5%) 0.21 (0.04-1.05)  
Multiple pregnancy 3 (8.3%) 9 (42.9%) 8.25 (1.90-35.7) ** 
Apgar (5 mins) 7 (6-9) 8 (7-9)   
CRIB-II 9 (7-11) 8.5 (4.5-11)   
       
Diagnoses       
IVH  17 (47.2%) 8 (61.9%) 0.97 (0.57-1.64)  
     IVH I-II 8 (22.2%) 4 (19.1%)   
     IVH with ventricular distension 5 (13.8%) 1 (4.8%)   
     Intraparenchymal lesion 3 (8.3%) 3 (14.3%)   
Periventricular leukomalacia 1 (2.8%) 5 (23.8%) 10.9 (1.18-101.4) * 
Pneumothorax 5 (13.9%) 4 (19.1%) 1.45 (0.35-6.17)  
Pulmonary haemorrhage 4 (11.1%) 2 (9.5%) 0.84 (0.14-5.04)  
PDA  25 (69.4%) 14 (66.7%) 0.98 (0.57-1.67)  
     No treatment 12 (33.3%) 7 (33.3%)   
     Medical treatment 9 (25%) 4 (19.1%)   
     Surgical treatment 4 (11.1%) 3 (14.3%)   
NEC 17 (47.2%) 10 (48.6%) 0.92 (0.56-1.52)  
     Medical treatment 10 (27.8%) 7 (33.3%)   
     Surgical drain 0  0    
     Surgical treatment 7 (19.4%) 3 (14.3%)   
BPD 29 (80.6%) 16 (80%) 0.88 (0.56-1.38)  
     Mild 2 (5.6%) 3 (15%)   
     Moderate 6 (16.7%) 3 (15%)   
     Severe 21 (58.3%) 10 (50%)   
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Septicaemia 21 (58.3%) 11 (52.4%) 0.79 (0.27-2.32)  
Meningitis 2 (5.6%) 0  N/A  
       
Treatment       
Ventilation (/d) 12 (2-33) 17 (5-52)   
CPAP (/d) 36 (15-61) 37.5 (10-68.5)   
Oxygen (/d) 22 (5-63) 22 (8.5-38)   
Long line (/d) 17 (11-44) 20 (12-40)   
ITU (/d) 22.5 (7-43) 29 (12.5-60)   
HDU (/d) 37.5 (20-55) 31 (18-52)   
SCBU (/d) 35 (23-44) 26.5 (18.5-41.5)   
Aminoglycoside (any)  36 (100%) 21 (100%) N/A  
  Amikacin 17 (47.2%) 7 (33.3%) 0.56 (0.18-1.71)  
  Gentamicin 30 (83.3%) 19 (90.5%) 1.90 (0.35-10.40)  
  Vancomycin 23 (63.9%) 18 (85.7%) 3.39 (0.84-13.73)  
Steroid® 15 (41.7%) 7 (33.3%) 0.70 (0.23-2.15)  
Furosemide 29 (80.6%) 14 (66.7%) 0.48 (0.14-1.65)  
Inotropes¤ 22 (61.1%) 11 (52.4%) 0.70 (0.24-2.08)  
Indometacin 3 (8.3%) 2 (9.5%) 1.16 (0.18-7.56)  
Ibuprofen 8 (22.2%) 3 (14.3%) 0.58 (0.14-2.49)  
Maximum creatinine  111 (86-128) 104.5 (93.5-125)   
Maximum serum bilirubin 203 (172-247) 185 (157-215)   
pH 29 (80.6%) 14 (66.7%) 0.48 (0.14-1.65)  
Creatinine 22 (61.1%) 17 (81.0%) 2.70 (0.75-9.72)  
Total bilirubin 18 (50.0%) 10 (47.6%) 0.91 (0.31-2.67)  
Categorical variables; Mann Whitney U test, continuous variables; Odds ratio (95% confidence interval) 
medications given at any point during treatment 
¤ includes use of dopamine, dobutamine, adrenaline and nor-adrenaline infusions 
® includes use of methylprednisolone, hydrocortisone and dexamethasone  
pH <7.2, creatinine >90mmol/l, total serum bilirubin > 200micromol/l – at any point during treatment 
* P<0.05; **p<0.01
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4.2.3 Distribution of risk factors 
Neonatal data was obtained for 237 children (57 cases with impaired hearing and 180 
controls with normal hearing). As the majority of variables were not normally distributed; 
non parametric testing was used (table 4-3). Logistic regression was used to identify 
univariate risk factors. Risk factors for hearing loss include baseline data (sex, gestational age, 
multiple birth, birthweight, birthweight for gestation, SGA, Apgar and CRIB-II scores), 
diagnoses occurring during neonatal care (septicaemia, meningitis, IVH, PDA, NEC, 
pneumothorax, pulmonary haemorrhage, BPD), treatment variables (ventilation, CPAP, 
oxygen, long line, ITU, HDU and SCBU) and drug treatments received at any point during the 
neonatal stay (antibiotics, steroid, diuretics, inotrope, indometacin, ibuprofen). Markers of 
haemodynamic impairment were included as indicators of circulatory risk (elevated 
creatinine, acidosis and bilirubin levels). Raised bilirubin was included as it may compete for 
binding sites on albumin, as does low pH, thereby increasing the availability of other risk 
factors.
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Table 4-3: Distribution and univariate analysis of neonatal risk factors in hearing impaired and normal hearing children born at less than 32 weeks of gestation 
 Hearing loss Normal hearing    
 n/median (%/IQR) n/median (%/IQR) OR (95% CI) Significance 
Male sex  38 (67.7%) 130 (72.2%) 1.30 (0.69-2.47)  
Gestation (week+days) 28 (25+6-30) 28+2 (26+2-30)   
Multiple pregnancy 12 (21.1%) 54 (30%) 0.62 (0.31-1.27)  
Birthweight (g) 900 (795-1150) 1090 (855-1333)  * 
Birthweight (sd) -0.26   (-1.18-0.49) -0.1 (-0.63-0.43)   
SGA 14 (24.6%) 23 (12.8%) 2.22 (1.05-4.68) * 
Apgar (5 mins) 8 (7-9) 9 (7-9)  * 
CRIB-II 9 (7-11) 8 (5-10)   
       
Diagnoses       
   Septicaemia 32 (56.1%) 61 (34.5%) 2.43 (1.32-4.47) ** 
   Meningitis 2 (3.5%) 4 (2.3%) 1.56 (0.28-8.77)  
   IVH 30 (42.1%) 51 (28.3%) 1.45 (1.05-2.00) * 
       IVH I-II 12 (21.1%) 34 (19.3%)   
       IVH with ventricular distension 6 (10.5%) 9 (5.1%)   
       Intraparenchymal lesion 6 (10.5%) 8 (4.5%)   
   Periventricular leukomalacia 6 (10.5%) 5 (2.8%) 4.02 (1.18-13.73) * 
   PDA 39 (68.4%) 60 (34.1%) 1.55 (1.18-2.05) ** 
       No treatment 19 (33.3%) 23 (13.1%)   
       Medical treatment 13 (22.8%) 20 (11.4%)   
       Surgical treatment 7 (12.3%) 17 (9.7%)   
   NEC 27 (47.4%) 52 (29.7%) 1.51 (1.12-2.04) ** 
       Medical treatment 17 (29.8%) 39 (22.3%)   
       Surgical drain 0  1 (0.6%)   
       Laparotomy 10 (17.6%) 12 (6.9%)   
   Pneumothorax 9 (15.8%) 8 (4.6%) 3.94 (1.44-10.76) ** 
   Pulmonary haemorrhage 6 (10.5%) 7 (4.0%) 2.84 (0.91-8.83)  
   BPD 45 (80.4%) 126 (71.2%) 1.66 (1.26-2.19) ** 
       Mild 5 (8.9%) 48 (27.9%)   
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       Moderate 9 (16.1%) 35 (19.8%)   
       Severe 31 (55.4%) 43 (24.3%)   
Treatment       
   Ventilation (/d) 12 (4-41) 2 (1-11)  ** 
   CPAP (/d) 36 (11-63) 16 (2-32)  ** 
   Oxygen (/d) 22 (6-49) 16 (2-32)  ** 
   Long line (/d) 18 (12-40) 11 (2-23)  ** 
   ITU (/d) 27.5 (8-52) 11.5 (4-33)  ** 
   HDU (/d) 36 (18-55) 22 (9-39)  ** 
   SCBU (/d) 31 (20-44) 30 (23-39)   
   Aminoglycoside (any)  57 (100%) 164 (91.1%) N/A  
       Amikacin 24 (42.1%) 67 (37.2%) 1.23 (0.67-2.25)  
       Gentamicin 49 (86%)  127 (70.6%) 2.56 (1.13-5.76) * 
       Vancomycin 41 (71.9%) 76 (42.2%) 3.51 (1.83-6.71) ** 
   No. of aminoglycosides  
       1  
       2  
       3 
 
13 
31 
13 
 
(22.8%) 
(54.4%) 
(22.8%) 
 
80 
62 
22 
 
(44.4%) 
(34.4%) 
(12.2%) 
N/A  
   Steroid® 22 (38.6%) 16 (8.9%) 6.44 (3.07-13.5) ** 
   Furosemide 43 (75.4%) 83 (47.1%) 3.59 (1.84-7.02) ** 
   Inotropes¤ 33 (57.9%) 45 (25%) 4.13 (2.21-7.70) ** 
   Indometacin 5 (8.8%) 7 (3.9%) 2.37 (0.72-7.80)  
   Ibuprofen 11 (19.3%) 30 (16.7%) 1.20 (0.56-2.57)  
   Maximum serum bilirubin 203 (171.5-246.5) 185 (158-214)  ** 
   Maximum creatinine 105 (87.5-125) 90 (77-102)  ** 
   pH <7.2 43 (75.4%) 101 (56.1%) 2.40 (1.23-4.70) ** 
   Lactate >2.0 57 (100%) 172 (95.6%) N/A  
   Creatinine >90 39 (68.4%) 91 (50.6%) 2.12 (1.13-3.98) * 
   Bilirubin >200 28 (49.1%) 70 (38.9%) 1.52 (0.83-2.76)  
Categorical variables; Mann Whitney U test, continuous variables; Odds ratio (95% confidence interval)                    medications given at any point during treatment 
¤ includes use of dopamine, dobutamine, adrenaline and nor-adrenaline infusions                                                           ® includes use of methylprednisolone, hydrocortisone and dexamethasone  
pH <7.2, creatinine >90mmol/l, total serum bilirubin > 200micromol/l – at any point during treatment         *p<0.05; **p<0.01
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From baseline data, sex and gestational age were similarly distributed between groups. 
Children who developed hearing loss were more likely to have a lower birthweight, a smaller 
weight for gestation and have a lower Apgar score at birth. Children with hearing impairment 
were more likely to have been diagnosed with sepsis, IVH of all grades, PVL, PDA, NEC, 
pneumothorax and BPD. Only meningitis and pulmonary haemorrhage were not significantly 
different between groups. Index children received increased periods of respiratory support 
(ventilation, CPAP and days of oxygen therapy), and longer durations of both intensive and 
high dependency care. Gentamicin, vancomycin, steroid, diuretics, and inotrope were all 
received more frequently in the case group. Haemodynamic impairment was also more 
frequent in the hearing loss group. Renal function as indicated by levels of creatinine were 
higher, peak bilirubin was also elevated and acidosis was more likely. 
4.2.4 Diagnoses and treatment risk factors for hearing loss 
The combination of neonatal risk factors for hearing loss were analysed using multivariate 
logistic regression (figure 4-2). Factors include baseline risks (sex, gestational age, 
birthweight for gestation), medications received at any point during the neonatal stay 
inotrope, diuretics, antibiotics, steroid, indometacin, and ibuprofen), presence of 
physiological risk factors (elevated creatinine, acidosis and bilirubin levels), and diagnoses 
(IVH, pneumothorax, pulmonary haemorrhage, PDA, NEC, BPD, septicaemia, and meningitis). 
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Figure 4-2: Multivariate logistic regression analysis: odds ratio (95% CI) for independent risk factors for hearing impairment in children born at less than 32 
weeks of gestation 
 Hearing loss (n=57) Normal hearing (n=180)     
Risk factor n/median (%/IQR) n/median (%/IQR) 
 
OR 95% CI  
0 .0 1 0 .1 1 1 0 1 0 0
O d d s  R a tio  (9 5 % C I)
 
Sex (male) 38 (67.7) 130  (72.2) 1.17 0.50-2.78  
Gestation (/w) 28 (25+6-30) 28+2  (26+2-30) 1.43 1.07-1.92 * 
BW (/sd) -0.26 (-1.18-0.49) -0.1 (-0.63-0.43) 1.98 0.55-1.17  
Inotropes 33 (57.9) 45 (25) 1.72 0.60-4.93  
Furosemide 43 (75.4) 83  (47.1) 1.28 0.41-4.02  
Amikacin 24 (42.1) 67  (37.2) 0.84 0.32-2.19  
Gentamicin 49 (86)  127  (70.6) 1.95 0.62-6.15  
Vancomicin 41 (71.9) 76  (42.2) 2.28 0.89-5.81  
Steroid® 22 (38.6) 16  (8.9) 4.00 1.25-12.79 * 
Indometacin 5 (8.8) 7  (3.9) 0.80 0.14-4.57  
Ibuprofen 11 (19.3) 30  (16.7) 0.15 0.03-0.64 * 
Creatinine 39 (68.4) 91  (50.6) 1.22 0.52-2.86  
pH 43 (75.4) 101  (56.1) 0.95 0.39-2.33  
Bilirubin 28 (49.1) 70  (38.9) 1.53 0.67-3.51  
IVH/PVL 30 (53.0)  56  (32.0) 1.37 0.99-1.90  
Pneumothorax 9 (15.8) 8  (4.6) 2.55 0.63-10.27  
Pulm. Haem 6 (10.5) 7  (4.0) 2.49 0.54-11.59  
PDA 39 (68.4) 60  (34.1) 1.72 0.92-3.22  
NEC 27 (47.4) 52  (29.7) 1.13 0.73-1.73  
BPD 45 (80.4) 126  (71.2) 1.14 0.69-1.88  
Septicaemia 32 (56.1) 61  (34.5) 1.68 0.67-4.21  
Meningitis 2 (3.5) 4  (2.3) 3.21 0.32-31.75  
 
 includes use of dopamine, dobutamine, adrenaline and norepinephrine infusions 
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® includes use of methylprednisolone, hydrocortisone and dexamethasone  
 creatinine >90mmol/l, pH <7.2, total bilirubin >200micromol/l – at any point during treatment 
* P<0.05; **p<0.01
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Gestational age was significantly associated with hearing loss, increasing risk at lower 
gestational ages. Of the postnatal clinical factors only two associations remained: the use of 
steroids was associated with an increased risk of hearing loss, whilst ibuprofen remained 
protective of hearing impairment. None of the diagnostic groups were independently 
associated with hearing loss but the relationship was not consistent among the contributing 
items. For example, within the brain injury subset, PVL was independently associated with 
hearing loss (p=0.05), whereas IVH was not. The relationship with hearing loss was more 
complex within the items making up the PDA subset, and will be investigated further below. 
Variables that were not significantly distributed in the univariate analysis were removed and 
the multivariate analysis repeated with no real change in the overall picture. 
 
Due to potential interactions between conditions and treatments, treatment variables were 
analysed following the exclusion of diagnoses during neonatal care (figure 4-3). Factors in 
this analysis were: baseline risks (sex, gestational age, birthweight for gestation, CRIB-II and 
Apgar scores), medications received at any point during the neonatal stay (inotrope 
(including dopamine, dobutamine, adrenaline and norepinephrine), diuretics, antibiotics, 
steroid (including hydrocortisone, methylprednisolone and dexamethasone), indometacin, 
ibuprofen), and the presence of physiological risk factors (elevated creatinine, acidosis and 
bilirubin levels). 
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Figure 4-3: Multivariate logistic regression analysis: odds ratio (95% confidence interval) for independent risk factors for hearing impairment in children born 
at less than 32 weeks of gestation 
 Hearing loss           
(n=57) 
Normal hearing 
(n=180) 
    
Risk factor n/median (%/IQR) n/median (%/IQR) 
 
OR 95% CI   
      
0 .1 1 1 0 1 0 0
O d d s  R a tio  (9 5 % C I)
 
Sex (male) 38       (67.7) 130  (72.2) 1.21 0.45-3.26  
Gestation (/w) 28       (25+6-30) 28+2  (26+2-30) 1.98 1.04-3.80 * 
BW (/sd) -0.26   (-1.18-0.49) -0.1  (-0.63-0.43) 1.21 0.69-2.15  
Apgar (5 min) 8          (7-9) 9  (7-9) 0.89 0.70-1.12  
CRIB-II 9  (7-11) 8  (5-10) 1.29 0.91-1.84  
Inotropes 33  (57.9) 45  (25) 5.23 1.54-19.83 ** 
Furosemide 43  (75.4) 83  (47.1) 1.90 0.54-6.76  
Amikacin 24  (42.1) 67  (37.2) 0.95 0.33-2.75  
Gentamicin 49   (86) 127  (70.6) 1.57 0.46-5.39  
Vancomycin 41  (71.9) 76  (42.2) 2.96 1.08-8.13 * 
Steroid® 22  (38.6) 16  (8.9) 6.06 1.73-21.22 ** 
Indometacin 5  (8.8) 7  (3.9) 0.47 0.07-3.17  
Ibuprofen 11  (19.3) 30  (16.7) 0.19 0.05-0.76 * 
Creatinine 39  (68.4) 91  (50.6) 1.20 0.47-3.01  
pH 43  (75.4) 101  (56.1) 1.05 0.37-3.01  
Bilirubin 28  (49.1) 70  (38.9) 2.24 0.88-5.72  
Abbreviations; BW, birthweight for gestation 
 includes use of dopamine, dobutamine, adrenaline and norepinephrine infusions                                                  ® includes use of methylprednisolone, hydrocortisone and dexamethasone  
 creatinine >90mmol/l, pH <7.2, total bilirubin >200micromol/l – at any point during treatment               * P<0.05; **p<0.01;  
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In contrast to the global regression analysis, new independent associations were found. Of 
the baseline risk factors, only week of gestation was still associated with hearing loss. None 
of the physiological risk factors independently increased the risk of hearing loss. However, 
the use of three medications (inotrope, vancomycin and steroid) were associated with 
hearing loss and the use of ibuprofen appeared to reduce the risk. Specifically, previously 
identified risk factors such as furosemide, gentamicin and indometacin within this dataset 
appeared to have little independent effect. The strongest associations were with the use of 
inotrope and steroid medications. The association with inotropic medication may relate to 
the drugs used or to the presence of low blood pressure for which they are prescribed. The 
use of steroid is more complex, as it can be prescribed to treat hypotension resistant to 
inotropic medication, alongside its use to support extubation in children with airway 
problems or with severe BPD. The protective effect of ibuprofen was unanticipated, and 
interestingly in this population indometacin use also decreased the risk of hearing loss, 
although this did not reach significance.  
 
Several of the courses of treatment in table 4-3 are associated with specific diagnoses, 
therefore exploratory analyses were conducted grouping these related risk factors. Further 
targeted analyses to investigate associations with hearing loss in these situations were 
undertaken and are presented below. Firstly, diagnoses will be considered independently. 
 
4.2.4.1 Morbidities as factors for hearing loss  
Previous research has used the measurement of comorbidities as a predictor of 
neurodevelopmental impairment, but none were specific to hearing loss in isolation. Table 
4-3 shows diagnoses including brain injury, NEC/sepsis and BPD are more frequent in children 
with hearing loss in comparison to children with normal hearing, the association between 
hearing loss and the presence of these morbidities was therefore analysed (figure 4-4). 
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Figure 4-4: Comorbid diagnoses as risk factors for hearing loss in children born at less than 
32 weeks of gestation 
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Children with impaired hearing were less likely to have had no diagnoses (7%) compared to 
children with normal hearing (21%). The diagnosis of any morbidity increased the risk of 
hearing loss (OR 1.64, 95% CI 1.20-2.26), but the likelihood of hearing loss was more strongly 
associated with two (OR 3.80, 95% CI 1.21-11.88) or three morbidities (OR 4.90, 95% CI 1.51-
15.92). In a comparison of the 3 diagnoses in the presence of the others, only acquired brain 
injury was significant (OR 1.46, 95% CI 1.14-1.89). 
 
Each of these diagnoses are associated with very different courses of treatment, therefore 
analyses were conducted grouping these related risk factors to investigate associations with 
hearing loss. This included risk factors relating to acquired brain injury (IVH/PVL), BPD, 
NEC/sepsis, and PDA. 
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4.2.4.2 PDA and associated treatments as risk factors for hearing loss 
 
A PDA was more frequent in the case group and reached statistical significance in 
independent analyses. Treatment methods for PDA (ibuprofen, indometacin and 
furosemide) were analysed separately along with baseline risks (sex, gestation and 
birthweight for gestation), and physiological factors (raised creatinine and bilirubin) as 
potential effect modifiers to ascertain whether the likelihood of hearing loss is related to the 
PDA or the treatment received (figure 4-5). 
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Figure 4-5: Multivariate logistic regression analysis: odds ratio (95% confidence interval) for independent risk factors for hearing impairment associated with 
PDA in children born at less than 32 weeks of gestation 
 Hearing loss         
(n=57) 
Normal hearing 
(n=180) 
    
Risk factor n/median  
(%/IQR) 
n/median  
(%/IQR) 
OR 95% CI   
    
0 .1 1 1 0 1 0 0
O d d s  R a tio  (9 5 % C I)
 
Sex (male) 38  (67.7) 130  (72.2) 1.21 0.58-2.51  
Gestation (/w) 28  (25+6-30) 28+2  (26+2-30) 1.09 0.88-1.35  
BW (/sd) -0.26  (-1.18-0.49) -0.1  (-0.63-0.43) 0.73 0.53-1.01 * 
PDA 39  (68.4) 60  (34.1) 2.15 1.25-3.71 ** 
Ibuprofen 11  (19.3) 30  (16.7) 0.21 0.06-0.72 ** 
Indometacin 5  (8.8) 7  (3.9) 0.77 0.18-3.35  
Furosemide 43  (75.4) 83  (47.1) 3.07 1.26-7.46 * 
Creatinine 39  (68.4) 91  (50.6) 1.74 0.86-3.52  
Bilirubin 28  (49.1) 70  (38.9) 1.87 0.93-3.79  
Abbreviations; BW, birthweight for gestation; PDA; patent ductus arteriosus 
 creatinine >90mmol/l, total bilirubin >200micromol/l – at any point during treatment 
* P<0.05; **p<0.01
 95 
  
The diagnosis of PDA independently confers a greater risk for hearing loss than for infants 
without a diagnosis of PDA. Low birthweight for gestational age and receiving furosemide 
were also independently associated with hearing loss. Furosemide may also be prescribed 
during blood transfusions; 72% of infants (86% of cases and 68% of controls) received at least 
one transfusion. It is not possible to determine whether hearing loss associated with 
furosemide occurs with PDA or with blood transfusion. However, infants with a diagnosis of 
PDA (including untreated, medically and surgically treated PDA) were analysed separately, 
whereby only furosemide was independently associated with hearing loss (p=0.04). 
Treatment of PDA with ibuprofen remained protective of hearing loss. 
 
4.2.4.3 BPD and associated treatments as risk factors for hearing loss 
 
Bronchopulmonary dysplasia (BPD) defined as the receipt of supplemental oxygen at 36 
weeks postmenstrual age, is a somewhat artificial concept as the lung disease suffered by 
very preterm infants is a continuum. However, BPD has been used as a diagnosis for some 
considerable time and co-occurs with many other risk factors. These were also analysed in a 
separate regression model (figure 4-6). Factors included baseline variables (sex, gestational 
week and birthweight for gestation), treatment risk factors (days of ventilation and oxygen, 
receiving steroid (including hydrocortisone, methylprednisolone and dexamethasone, from 
week 3 onwards) or furosemide), and physiological risk factors (elevated creatinine and 
bilirubin). Steroid is administered to aid the weaning of respiratory support but also as an 
alternative to inotropes in treating hypotension in the first few days after birth. For this 
reason, only steroid given from week 3 onwards were included in this model.
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Figure 4-6: Multivariate logistic regression analysis: odds ratio (95% confidence interval) for independent risk factors for hearing impairment associated with 
BPD in children born at less than 32 weeks of gestation 
 Hearing loss        
(n=57) 
Normal hearing 
(n=180) 
    
Risk factor n/median  n/median  OR 95% CI   
 (%/IQR) (%/IQR)    
0 .1 1 1 0 1 0 0
O d d s  r a t io  ( 9 5 %  C I )
 
Sex (male) 38       (67.7) 130   (72.2) 1.50 0.71-3.18  
Gestation (/w) 28       (25+6-30) 28+2   (26+2-30) 1.30 1.01-1.66 * 
BW (/sd) -0.26  (-1.18-0.49) -0.1   (-0.63-0.43) 0.86 0.61-1.21  
BPD 45       (80.4) 126   (71.2) 1.29 0.80-2.06  
Ventilation (/w) 1.71    (0.57-5.86) 0.29  (0.14-1.57) 1.05 0.93-1.17  
Oxygen (/w) 3.14    (0.86-7.00) 2.29  (0.29-4.57) 1.07 0.96-1.18  
Steroid® 18       (31.6) 13     (7.2) 3.05 1.11-8.41 * 
Furosemide 43       (75.4) 83     (47.1) 2.35 0.88-6.23  
Creatinine >90 39       (68.4) 91     (50.6) 1.62 0.78-3.35  
Bilirubin >200 28       (49.1) 70     (38.9) 1.70 0.82-3.56  
Abbreviations; BW, birthweight for gestation; BPD; bronchopulmonary dysplasia 
® includes use of methylprednisolone, hydrocortisone and dexamethasone  
 creatinine >90mmol/l, total bilirubin >200micromol/l – at any point during treatment 
* P<0.05; **p<0.01
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Although BPD was associated with hearing loss in univariate analysis, it was not an 
independent predictor in the presence of other related risk factors. The administration of 
steroid remained independently associated with an increased risk of hearing impairment. All 
three types of steroid were more frequently given to infants with hearing loss, with 
dexamethasone and hydrocortisone being used more frequently than methylprednisolone. 
Hydrocortisone was the most commonly prescribed in 28% of cases and 6% of controls; 21% 
of cases received a course of dexamethasone compared to 4% of controls, only 1 child with 
hearing loss received methylprednisolone. Of note in this model, in contrast to the PDA 
model, furosemide was not associated with hearing loss. Apgar scores, the total number of 
days of CPAP and a low pH level were included in an additional analysis and were not 
significant.  
 
4.2.4.4 Sepsis and/or NEC and associated treatments as risk factors for hearing loss 
 
Neonatal sepsis was associated with hearing impairment in univariate analyses. The types 
and frequency of sepsis between the two groups are listed in table (Appendix 10). NEC was 
also associated with hearing loss in univariate analyses but has an overlapping risk with 
sepsis. These were therefore combined as an either/or variable and analysed along with 
other known risk factors for hearing loss including baseline variables (sex, gestational week 
and birthweight), treatment factors (amikacin, gentamicin, vancomycin), and physiological 
risk factors (elevated creatinine and bilirubin) associated with neonatal sepsis (figure 4-7).
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Figure 4-7: Multivariate logistic regression analysis: odds ratio (95% confidence interval) for independent risk factors for hearing impairment associated with 
NEC and/or sepsis in children born at less than 32 weeks of gestation 
 Hearing loss         
(n=57) 
Normal hearing  
(n=180) 
    
Risk factor n/median  
(%/IQR) 
n/median  
(%/IQR) 
OR 95% CI   
    
0 .1 1 1 0 1 0 0
O d d s  R a tio  (9 5 % C I)
 
Sex (male) 38  (67.7) 130  (72.2) 1.21 0.59-2.52  
Gestation (/w) 28  (25+6-30) 28+2  (26+2-30) 1.00 0.84-1.19  
BW (/sd) -0.26   (-1.18-0.49) -0.1  (-0.63-0.43) 0.77 0.55-1.07  
NEC/Sepsis 37  (64.9) 85  (47.2) 0.99 0.89-1.11  
Amikacin 24  (42.1) 67  (37.2) 1.08 0.50-2.30  
Gentamicin 49  (86) 127  (70.6) 2.16 0.84-5.54  
Vancomycin 41  (71.9) 76  (42.2) 3.58 1.62-7.94 ** 
Creatinine 39  (68.4) 91  (50.6) 2.03 1.02-4.03 * 
Bilirubin 28  (49.1) 70  (38.9) 2.04 1.02-4.10 * 
Abbreviations; BW, birthweight for gestation; NEC, necrotising enterocolitis 
 creatinine >90mmol/l, total bilirubin >200micromol/l – at any point during treatment 
* P<0.05; **p<0.01 
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In this group of babies, none of the baseline risks were associated with hearing loss and the 
frequency of septicaemia and/or NEC was not significantly different between the hearing loss 
and normal hearing groups when controlling for other variables. The use of vancomycin was 
significantly associated with hearing loss. However, vancomycin is used in the treatment of 
infection, suspected sepsis and prophylactically by way of continuous infusion to prevent 
long line sepsis. An elevated creatinine level and high bilirubin were also independently 
associated with the outcome of hearing loss, both of which had been associated with hearing 
loss in previous research, and neither of which had been predictive in the initial regression 
model including baseline variables, diagnoses and treatments (figure 4-2). Meningitis has 
previously been implicated as causative of hearing loss and so was added to the above model. 
Meningitis was not associated with hearing loss in the univariate analysis and did not change 
the overall model (p>0.05), with vancomycin, raised creatinine and bilirubin remaining 
associated with the outcome. In summary, the use of vancomycin and two physiological 
markers increased the risk of hearing loss amongst babies with sepsis; which will be explored 
further. 
 
4.2.4.5 IVH/PVL and associated treatments as risk factors for hearing loss 
 
IVH and PVL has been associated with hearing loss as described above, and was significantly 
more common (inclusive of all grades of IVH) in infants with hearing loss than normal hearing 
controls. Risk was therefore explored within this group of babies (figure 4-8), with relevant 
associated variables, including the early use of steroid (<72 hours from birth, including 
hydrocortisone, methylprednisolone and dexamethasone) and inotrope (including 
dopamine, dobutamine, adrenaline and norepinephrine). 
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Figure 4-8: Multivariate logistic regression analysis: odds ratio (95% confidence interval) for independent risk factors for hearing impairment associated with 
IVH/PVL in children born at less than 32 weeks of gestation 
 
 Hearing loss        
(n=57) 
Normal hearing 
(n=180) 
    
Risk factor n/median  n/median  OR 95% CI   
 (%/IQR) (%/IQR)    
0 .1 1 1 0 1 0 0
O d d s  R a t io  (9 5 %  C I)
 
 
Sex (male) 
 
38        (67.7) 
 
130   (72.2) 
 
1.32 
 
0.65-2.68 
 
Gestation (/w) 28        (25+6-30) 28+2  (26+2-30) 1.17 0.97-1.40  
BW (/sd) -0.26   (-1.18-0.49) -0.1  (-0.63-0.43) 0.73 0.54-1.00 * 
IVH/PVL 30        (53.0)  56     (32.0) 1.55 1.15-2.08 ** 
Inotrope 33        (57.9) 45     (25) 4.90 2.17-11.06 ** 
Steroid® 22        (38.6) 16     (8.9) 0.73 0.16-3.24  
      
      
      
Abbreviations; BW, birthweight for gestation; IVH, intraventricular haemorrhage; PVL, periventricular leukomalacia  
 includes use of dopamine, dobutamine, adrenaline and norepinephrine infusions 
® includes use of methylprednisolone, hydrocortisone and dexamethasone in the first 72 hours of life 
* P<0.05; **p<0.01 
 101 
  
Within the subset of babies who had identified brain injury, birthweight was inversely related 
to the risk of hearing loss. In contrast, the presence of brain injury and use of inotropic 
medication were independently positively associated with hearing loss. Among the 
constituent injuries PVL conferred the major risk. The strongest association was with the use 
of inotropic drugs, but it is unclear whether it is the underlying poor perfusion, the 
medication, or the elevation in perfusion pressure by the drug that leads to the increase risk 
of impaired hearing.  
4.2.5 Coincidence and timing of neonatal risk factors for hearing loss 
The relationship between hearing loss and neonatal illness is complex. Previous research has 
suggested that an accumulated, or coincident risk may be more important than single 
identifiable risk factors [4]. Infants may experience an increased sensitivity to ototoxic agents 
in the initial period after birth when multiple risk factors may coincide, or as the newborn 
adapts to life outside the womb. To address this, a timeline of clinical risk factors across the 
neonatal period was compared between children with and without impaired hearing. 
Coinciding risk factors within a 24 hour period were explored across the first 14 days after 
birth for children with hearing loss and normal hearing children (figure 4-9). Mean number 
of risk factors for children with and without hearing loss with confidence intervals were also 
compared (figure 4-10). In this analysis we identified key independent factors and three 
physiological risk factors. As previous studies have identified aminoglycosides as part of the 
co-incident risk, gentamicin was included in the analysis. Thus, risk factors included 
treatments; gentamicin, vancomycin, steroid, inotrope, furosemide, and physiological risk 
factors; creatinine >90mmol/l, total serum bilirubin >200microm/l and pH<7.2. Diagnoses 
were removed from this analysis as they are not independent from treatment variables. 
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Figure 4-9: Daily number of risks in non-hearing and hearing children born at less than 32 
weeks of gestation, over the first 14 days after birth 
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Figure 4-10: Mean number of risk factors (with 95% CI) for children with and without hearing 
loss born at less than 32 weeks gestation over the first 14 days after birth 
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Children with hearing loss were exposed to a greater number of risk factors for the first 14 
days after birth, reaching significance every day. Cumulative number of risks were higher for 
children with impaired hearing (mean 15.7, range 1-41) in comparison to children with 
normal hearing (mean 7.8, range 0-43; OR 1.10, 95% CI 1.06-1.15). Exposure to 9-18 risks was 
incurred by 42.1% of hearing impaired children compared to 23.3% of normal hearing 
children, and greater than 19 risks by 28.1% of children with hearing loss compared to 8.3% 
of control children. Greater exposure to risk factors continued until week 23 where there was 
a higher incidence of mean risk factors every week until discharge for infants who were later 
found to have an audiological impairment.  
4.2.6 Ototoxic medication as a risk factor for hearing loss  
The impact of ototoxic medication including gentamicin, vancomycin and furosemide, on 
neonatal acquired hearing loss has been long debated in the literature. Gentamicin use is 
widespread in neonatal care but was given significantly more frequently to children with 
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hearing loss than control children. In the first 14 days, 73.7% of index cases and 62.2% of 
control children received at least one dose of gentamicin. Children with hearing loss received 
a higher number of doses (mean 3.2 days of exposure/child (range 0-12)) compared to 
normal hearing children (mean 2.1 days of exposure (range 0-10; OR 1.19 (95% CI 1.06-
1.33))). Subsequent weeks of exposure to gentamicin was also more frequently received by 
children with hearing loss (mean 1.2; range 0-7) in comparison to children with normal 
hearing (mean 0.7; range 0-7). The highest gentamicin levels recorded were similar in cases 
(median 1.8, IQR 1, 2.9) in comparison to control children (median 1.5, IQR 1, 2.6; p>0.05). 
 
Vancomycin exposure was significantly more frequent and for longer durations in children 
with hearing loss. A course of vancomycin (>4 days) was given in 24.6% of the hearing loss 
group in the first 14 days compared to 11.7% of control infants (OR 1.17, 95% CI 1.05-1.30), 
but courses were of similar duration (6.6 days and 7.0 days, respectively). Subsequently, 
courses of vancomycin of greater than 14 days were more frequent in the hearing loss group 
(45.6%) compared to controls (21.7%; p<0.01). Additionally, children that later developed 
hearing loss were more likely to have received a course of vancomycin in the first two weeks 
and subsequently (19.3%), compared to controls (7.8%; p=0.01). Peak concentration levels 
of vancomycin did not significantly differ between groups (p>0.05). 
 
Finally, furosemide use was also significantly more frequent during the first 14 days in 
children with hearing loss. Of the children with impaired hearing, 38.6% (mean 1.2; range 0-
11) received furosemide in comparison to 20% of hearing controls (mean 0.4; range 0-5 (OR 
1.41, 95% CI 1.14-1.75)). Similarly, weeks of exposure to furosemide were greater in the 
hearing impaired children (mean 2.9; range 0-10) in comparison to normal hearing children 
(mean 1.3; range 0-10 (OR 1.33, 95% CI 1.17-1.50)). 
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During the first 14 days of treatment, the number of days of exposure to gentamicin (OR 1.23, 
95% CI 1.09-1.39), vancomycin (OR 1.15, 95% CI 1.03-1.29) and furosemide (OR 1.39, 95% CI 
1.11-1.74) were all independently associated with hearing loss in the presence of the others. 
 
Exposure to ototoxic medication (including gentamicin, vancomycin and furosemide) were 
compared between index cases and controls, for the first 14 days after birth are reported in 
figure 4-11. 
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Figure 4-11: Comparison of profiles of the use of individual ototoxic medications in children with and without hearing loss born at less than 32 weeks of 
gestation 
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The profile of ototoxic medication use differed between the two groups, mainly in terms of 
the use of vancomycin and furosemide (figure 4-12). Only 5.3% of children with hearing loss 
did not receive any ototoxic medications compared to 27.8% of control children. Over the 
first 14 days, the mean number of days of treatment using individual ototoxic medications 
was 6.7 for the hearing impaired (maximum 19), compared to 3.6 for the hearing controls 
(maximum 15). The median number of doses received by cases was 6 (IQR 3-10), in 
comparison to control children (3; IQR 0-6). Gentamicin and furosemide were given to a 
higher percentage of infants with hearing loss every day for all 14 days, and vancomycin from 
day 2 onwards. 
The association between days of ototoxic medication administered in the first 14 days and 
hearing loss increased with each additional day that either gentamicin, vancomycin or 
furosemide were given (OR 1.21, 95% CI 1.12-1.31). However, children who received ototoxic 
medication between 1-7 days out of the first 14 had an increased probability of hearing loss 
(OR 5.61, 95% CI 1.65-19.12), than children who had not received ototoxic medication. 
Furthermore, the odds were highest if 8 or more dose days had been given in the first 14 
days in comparison to children that had not received any ototoxic medication (OR 12.18, 95% 
CI 3.30-44.99). 
Cumulative episodes of ototoxic medication (including gentamicin, vancomycin and 
furosemide) from week 3-12 were also higher for children with hearing loss (maximum 20; 
IQR 2-10) compared to normal hearing children (maximum 16 aside from one child who 
received 21 episodes; IQR 0-5.5). Ototoxic medication was measured as having received each 
individual medication at any point that week. Children with hearing loss received more 
vancomycin and furosemide every week until week 12, and more gentamicin in all but 2 
weeks. Hearing loss was significantly more likely with each increasing week of gentamicin, 
vancomycin and furosemide in this time frame (OR 1.18, 95% CI 1.10-1.26).  
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4.2.7 Time related risk of ototoxic medication and coincidental risk factors 
The relationship between ototoxic medication and hearing loss has been investigated as a 
cumulative risk (section 4.2.6). However, the condition of the baby at the time of exposure 
to medications, specifically in terms of clinical diagnoses and the physiological clearance of 
medication might influence this further. Ototoxic medication in this section therefore 
included gentamicin, vancomycin and furosemide received in the first 14 days of life. 
Comorbid clinical diagnoses included PDA, IVH/PVL, NEC/sepsis and BPD. A priori measures 
of physiological instability, included lactate >2.0mmol/l, use of inotrope, and creatinine 
>90mmol/l which were used as measures of potential haemodynamic instability in the first 
14 days of life (figure 4-12). 
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Figure 4-12: Multivariate logistic regression analysis: odds ratio (95% confidence interval) for independent risk factors for hearing impairment associated 
with ototoxic medication, comorbid diagnoses, and haemodynamic instability in preterm children 
 Hearing loss         
(n=57) 
Normal hearing 
(n=180) 
   
0 . 1 1 1 0 1 0 0
O d d s  R a t io  ( 9 5 % C I)
 
Risk factor n/median  
(%/IQR) 
n/median  
(%/IQR) 
OR 95% CI  
    
        
Sex (male) 38  (67.7) 130  (72.2) 1.11 0.53-2.33  
Gestation (/w) 28  (25+6-30) 28+2  (26+2-30) 1.40 1.12-1.76 ** 
BW (/sd) -0.26  (-1.18-0.49) -0.1  (-0.63-0.43) 0.87 0.63-1.20  
Morbidities 3  (2-4) 2  (1-3) 1.89 1.26-2.81 ** 
Ototoxic medication 6  (3-10) 3  (0-6) 1.15 1.05-1.26 ** 
Haemodynamic 
instability® 
8  (4-14) 4  (1-7) 1.07 1.02-1.13 ** 
Abbreviations; BW, birthweight for gestation 
includes PDA, IVH/PVL, NEC/sepsis and BPD 
 includes use of gentamicin, vancomycin and furosemide in the first 14 days of life 
® includes creatinine >90mmol/l, lactate >2.0mmol/l and the administration of inotropes in the first 14 days of life 
* P<0.05; **p<0.01 
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Infants born at the lowest gestational age were at the greatest risk of hearing loss. 
Cumulative days of ototoxic medication remained associated with hearing loss independent 
of comorbid diagnoses and haemodynamic instability. Children at the greatest risk of hearing 
impairment were more likely to have been diagnosed with comorbid conditions during the 
neonatal period. Children with hearing loss were more frequently diagnosed with all four 
conditions (PDA, IVH, BPD and NEC and/or sepsis) than normal hearing children (28.1% and 
13.9% respectively (OR 7.89, 95% CI 2.08-29.94)). Only 5.3% of index cases had none of these 
diagnoses during their neonatal care in comparison to 20.6% of normal hearing children. 
Cumulative days of haemodynamic instability was also independently associated with the 
outcome. The total number of times each individual marker of haemodynamic instability was 
observed in the first 14 days, was again significantly higher in children who were later found 
to have impaired hearing (creatinine OR 1.26, 95% CI 1.13-1.42, lactate OR 1.24, 95% CI 1.11-
1.39, and inotrope OR 1.21, 95% CI 1.09-1.34). The total number of days of ototoxic 
medication in the presence of haemodynamic instability on the same day was added to the 
analysis in place of the individual variables. Low gestational age, comorbid diagnoses and the 
combination of ototoxic medication and haemodynamic instability were independently 
associated with hearing impairment. 
 
4.3 Discussion of results 
The aim of the study was to investigate the individual and combined influence of risk factors 
for hearing loss in the neonatal period, in infants born at less than 32 weeks of gestation. 
Acquired hearing loss is a common complication of prematurity in long term developmental 
studies. Among this population, a consistent challenge in previous research has been the 
overlap of risk factors; this study aimed to establish some of the relationships between them. 
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Based on previous findings this study expected to find firstly, individual clinical risks for 
hearing impairment, and secondly multiple coinciding risk factors.  
In the current study, there were 57 children with hearing loss born below 32 weeks of 
gestation; the estimated preterm birth rate over the 5 year study period was 7375, giving a 
prevalence of 0.77%. In comparison to previous studies with a gestational age below 32 
weeks, this is slightly lower [22, 28], however studies have shown wide variance in prevalence 
rates. This could be due to the method of identifying children with a hearing impairment 
which was based upon the newborn hearing screening programme, so some children with 
later onset hearing loss may not have been identified.  
4.3.1 Neonatal differences between types of hearing loss 
The prevalence of cochlear hearing loss was 73% of all children with a hearing impairment, 
giving an incidence of 5.7 per 1000. The prevalence of ANSD in this study was 27% but a 
further 10% of hearing loss was potentially attributable to ANSD. The estimated incidence of 
ANSD from the population of preterm births is between 2-2.8/1000 which is slightly higher 
than Dowley et al (2009), who reported an incidence of 0.67 per 1000 infants for SNHL and 
0.27/1000 for ANSD in the UK [15]. This may be explained by population differences, the 
current study looked exclusively at preterm hearing impairment and included all severities of 
hearing loss, in comparison to a newborn study of severe to profound impairment. However, 
the higher incidence of cochlear hearing impairment compared to ANSD follows the trends 
shown in previous studies [14, 15]. 
Literature has suggested CHL and ANSD in preterm infants may have differences in aetiology, 
however comparisons between clinical factors in this study found few differences. 
Birthweight was lower for CHL indicating the smallest babies are at greatest risk for CHL, 
contradicting the findings from previous research whereby infants with ANSD were found to 
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have lower birthweights [14]. Infants from a multiple pregnancy were also more likely to have 
a diagnosis of ANSD. IVH occurred more frequently in the ANSD group, but was not 
significantly different which is consistent with previous research [14], although PVL was 
significantly higher in the ANSD group in this study. PVL is characterised by damage to the 
cerebral white matter which could be associated with the central audiological impairment of 
ANSD.  
In this study, there were no substantially distinguishing factors between CHL and ANSD in 
terms of any diagnoses or exposure to treatment factors. Literature might have expected 
raised peak bilirubin levels, which is a known neural toxin, to be associated with ANSD [13, 
15], which was not supported. Aminoglycosides and furosemide have also been associated 
with increasing the risk of ANSD in preterm infants [14], however findings in this study also 
did not support this. Some of the differences in results could be accounted for by differences 
in sample population, or the uncertainty surrounding the diagnosis of hearing impairment in 
this study.  
4.3.2 Independent clinical risks for hearing loss 
Neonatal risk factors for hearing loss revealed almost all diagnoses and treatments to be 
more frequent for infants with hearing loss than normal hearing controls. The most frequent 
risks for hearing loss in the literature were supported by the findings in this study. Children 
with hearing loss were more likely to have been diagnosed with NEC, PDA, IVH, sepsis and 
BPD. Duration of intensive care treatment and days of respiratory support were longer for 
the index group. Each medication was more likely to have been received by the hearing loss 
group, most notably the use of aminoglycosides, steroid, furosemide and inotrope, and they 
had a greater presence of physiological risk factors, reflecting a higher level of illness for 
infants who were later found to have impaired hearing. 
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Level of illness was further demonstrated by investigating co-morbidity frequencies. Previous 
research has used morbidity counts to express the increased risk of adverse 
neurodevelopmental outcome inclusive of hearing impairment, but none to date, had 
considered hearing loss as an independent outcome. The overall risk of hearing loss increased 
incrementally with each additional morbidity (OR 1.64, 95% CI 1.20-1.26) although the 
greatest risk of hearing loss was found in infants with two or three morbidities which again 
coincides with the results from previous studies [82, 131]. Both studies included ROP which 
the current study did not include but the findings were similar regardless. Bassler et al (2009) 
found the inclusion of blood culture proven infection or NEC to improve the prediction of 
adverse outcome [82], which this study also included however when comparisons were made 
between each morbidity in combination, only brain injury was significantly associated with 
hearing impairment, which will be discussed further below. Whilst the use of morbidity 
counts provide an indicator of infants at the greatest risk for impairment, little further is 
gained in terms of understanding the underlying processes that are associated with each 
morbidity which this study aimed to unravel.  
Reported individual risks for hearing loss in previous studies have been difficult to elucidate 
as preterm infants are likely to have encountered a number of risk factors, as demonstrated 
by the morbidity frequencies. Specifically, distinguishing between a diagnosis and 
subsequent related treatments has proved challenging. However, in this study there were 
interesting findings, related to the management of several clinical conditions.  
Diagnoses and medications as risk factors for preterm hearing loss 
The youngest and smallest babies are known to be at an increased risk of poorer 
developmental outcomes. The babies with the smallest gestational age were at the greatest 
risk for developing hearing loss when adjusting for all diagnoses and treatment (figure 4-2). 
The use of steroid was independently associated with hearing impairment in the presence of 
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diagnoses for which it can be prescribed. The relationship between ibuprofen and hearing 
loss was also significant but in the opposite direction.  
The administration of individual medications used regularly in neonatal care was investigated 
independently of diagnoses (figure 4-3), the smallest gestational age, again, was a risk for 
hearing impairment. Steroid, as mentioned above, and also the use of vancomycin and 
inotrope were independently associated with hearing loss. Each of which were included in 
further sub-analyses alongside clinical conditions for which they might be associated, which 
will be discussed below. 
PDA and associated risk factors for preterm hearing loss 
Low birthweight for gestational age was associated with hearing loss in babies when 
investigating PDA and treatments associated with the management of this diagnosis. Babies 
with the lowest birthweights are known to be at a higher risk of poor outcome. Infants that 
are born small for dates are more physiologically immature than their appropriate weight for 
age comparisons. Low birthweight also confers a greater risk of other preterm conditions. 
PDA is also more common in the youngest and smallest babies, and is one of the known 
morbidities likely to influence later outcome. A PDA increased the risk of hearing loss in this 
study. PDA can cause oxygenation perfusion to fall which may interrupt normal cochlear 
function; the cochlea is dependent on an adequate oxygen supply. Studies of infants born 
very preterm (less than 32 weeks [96], and less than 28 weeks gestation [12]) found similar 
results, in which there was an association between PDA ligation and hearing impairment. 
One difficulty in excluding babies for which medical management of a PDA has been 
successful, is that they are likely to have been exposed to similar oxygenation issues and 
medications as a baby that then requires surgery, in these studies it could be the surgery and 
associated complications that are being measured, rather than the PDA. The current study 
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included untreated and medically treated infants and found the same association, indicating 
the PDA rather than the additive risk of surgery are linked to hearing loss.  
Furosemide is a long loop diuretic often used in the management of a PDA. In the current 
study, furosemide increased the risk of hearing loss. Loop diuretics are thought to change the 
composition of the endolymph within the inner ear resulting in decreases in endocochlear 
potential [95]. Previous studies have been inconclusive in determining the independent risk 
of furosemide; Eras et al (2014) found furosemide to increase the risk of hearing loss in 
multivariate analyses [96] but Rais-Bahrami et al (2004) had contrasting findings [97]. 
Furosemide has been found to potentiate the ototoxic side effects of other medications, 
namely aminoglycosides which will be discussed in terms of cumulative exposure to ototoxic 
medication (section 4.3.3). Importantly, furosemide administration when creatinine levels 
are raised has also been demonstrated to increase the risk of hearing loss [4]; results in this 
study found that furosemide was independently associated with the development of hearing 
impairment in the face of elevated creatinine, but creatinine was not independently 
increasing the risk of hearing loss.  
Most surprisingly, was the protective nature of ibuprofen, and although indometacin did not 
reach significance the correlation was in the same protective direction. Indometacin has been 
associated with increased cerebral vasoconstriction whilst ibuprofen is not thought to affect 
cerebral oxygenation, and therefore is used preferentially in comparison to indometacin. 
However, both medications have been associated with decreases in renal function which 
could be associated with hearing loss when occurring alongside the administration of 
ototoxic medication. Previous studies have not found a protective relationship between 
ibuprofen or indometacin with hearing impairment but neither have they been associated as 
being a cause of hearing loss [99]. The unusual findings in this study could be representative 
of the inclusion of children with untreated and medically treated PDA in the analyses.  
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BPD and associated risk factors for preterm hearing loss 
BPD is a further comorbid diagnosis that increases the chances of poor outcome. BPD is most 
common in the youngest babies, and as expected, gestational age correlated with an 
increased risk of hearing loss. Also in this study, whilst BPD occurred more frequently in 
children with hearing loss than in normal hearing children, it did not independently increase 
the risk. BPD involves the long term dependence on respiratory support and prolonged 
oxygen therapy, and whilst the duration of each was longer for the children with hearing loss 
these risk factors were also not associated with developing impaired hearing. This contrasts 
with previous research that have correlated hearing loss with BPD [12], mechanical 
ventilation [28, 49, 50], and the number of days of respiratory support [32]. The need for 
prolonged respiratory support is often a result of severe birth asyphyxia; Hille et al (2007) 
and Eras et al (2014) found birth asphyxia to be independently associated with hearing 
impairment, as well as prolonged respiratory support [28, 96]. Disrupted oxygen supply to 
the cochlear is likely to be the cause, however condition following birth (as indicated by a 
low Apgar score) in this study was also not an indicator of later hearing impairment.  
Exposure to increased and prolonged noise levels has also been implicated in the 
development of hearing loss [85], particularly in infants that require long periods of 
ventilation [86]. Noise was not monitored in this study, but as measures of time spent 
ventilated, and respiratory support required at 36 weeks of age were not associated with 
hearing impairment, it could be inferred that exposure to noise associated with respiratory 
support in this study is unlikely to be having a direct impact, but this would not rule out a 
potentiation of drug induced ototoxicity as previously purported [87].  
The administration of steroid in neonatal care is used to wean respiratory support, or in early 
care, to improve circulation. Previous research has been inconclusive in the association 
between steroid and hearing loss, however in the current study steroid was not only more 
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frequently given to the children with hearing impairment but was consistently associated 
with hearing loss when accounting for both BPD and respiratory support, contrasting with 
previous studies [14]. Dexamethasone in particular is used to reduce dependency on 
mechanical ventilation. However, since being associated with the development of cerebral 
palsy, it is used less frequently in clinical practice. Nevertheless, dexamethasone was given 
to 5 times as many cases as controls who also received a greater number of days of 
respiratory support. Steroid was also independently associated with impaired hearing when 
controlling for all types of medication in this study. It is unclear as to how steroid affects the 
ear, but with a known risk of cerebral palsy, it is likely to be a result of neurological damage. 
Furosemide is frequently used in the management of BPD, but was not associated with 
hearing loss in the presence of BPD. This contrasts with the significant association with 
hearing loss in the presence of PDA. The use of furosemide has already been discussed, and 
the ototoxicity of this was considered further alongside antibiotics which will be discussed in 
section 4.3.3. 
Infection and associated risk factors for preterm hearing loss 
Hearing loss is a known complication of many infections such as CMV and meningitis, and up 
to 20% of preterm infants are thought to be affected by neonatal sepsis [80]; the prevalence 
of septicaemia was much higher in this study with over 50% of children with hearing loss 
having had at least one episode of neonatal infection. The association between infection and 
hearing loss has been demonstrated previously [55]. Meningitis in particular, was an 
independent predictor of preterm hearing loss in previous studies [49], however these 
findings were not supported by this study. Meningitis is a rare condition but is a known cause 
of hearing loss, the small numbers in both groups of participants may account for these 
results. Sepsis and NEC have a poor effect on outcome and were both associated with hearing 
impairment in univariate analyses which corresponds with previous research [30]. Infants 
 118 
 
following a diagnosis of NEC have shown a delay in neural conduction likely to result from 
impaired myelination or synapse dysfunction [79]. However, it has not been discernible as to 
whether the cause of hearing loss is due to the sepsis itself, the medication used to treat 
infection, or the two in combination.  
In this study, in the presence of a range of antibiotics previously associated with hearing loss, 
and markers of physiological instability commonly associated with ill health in premature 
infants, sepsis was not independently associated with hearing loss. However, vancomycin 
increased the risk of impaired hearing. Exposure to vancomycin occurred frequently in this 
study with 54% of all children receiving at least one dose during their neonatal care. The 
ototoxicity of vancomycin has previously been attributed to prolonged exposure; children in 
this study were more likely to have received vancomycin earlier than normal hearing children 
(in the first 14 days after birth), and had received longer courses of treatment. The effect of 
vancomycin is complicated further by the varied uses for which it is administered, which will 
be discussed further as part of the cumulative effect of ototoxic medication (section 4.3.3).   
The impact of gentamicin on hearing loss in preterm infants has provided mixed results in 
previous studies. However, gentamicin in therapeutically controlled doses did not increase 
the risk of hearing loss in recent research [92], which is consistent with this study. Gentamicin 
and amikacin were the most frequently administered antibiotics in this sample and neither 
were independently associated with hearing loss in multivariate analysis in the presence of 
infection. Clinical measures have been taken to reduce the risk of harmful blood levels of 
these medications, and whilst the babies with hearing loss had longer durations and a greater 
overall exposure than normal hearing children, neither of these medications showed any 
increased relationship to preterm hearing loss.  
Elevated creatinine and bilirubin were however associated with hearing loss. Both of which 
have been related with preterm hearing impairment previously [4]. Interestingly, both of 
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these markers of physiological instability were not associated with hearing loss when 
investigating risks associated with a diagnosis of a PDA or BPD, only infection in the presence 
of aminoglycosides showed a relationship. Bilirubin ototoxicity increases the risk of neuronal 
damage [62], in particular unconjugated bilirubin that has been displaced from albumin and 
can cross the blood brain barrier. In low birthweight infants, longer durations of raised 
bilirubin have been previously associated with hearing loss [31, 69], which increases the time 
period of potential exposure to concomitant antecedents, decreasing bilirubin binding 
capacity and increasing circulating unconjugated bilirubin. Relationships between bilirubin 
and acidosis [69], and ototoxic medication [4] have been proposed, resulting in competition 
for albumin binding sites. Despite using peak bilirubin (>200micromol/l) as a measure of 
hyperbilirubinaemia rather than duration in this study, the relationship with hearing loss 
persisted. Peak bilirubin was higher in children with hearing loss than normal hearing 
children, it is likely that this is related to the number of concomitant risk factors they were 
exposed to, such as acidosis and ototoxic medication as found in previous studies. A lack of 
association between bilirubin and hearing loss in previous studies could be due to the 
inclusion of term infants that are less likely to be exposed to the same number of risk factors 
as a very preterm baby [65]. 
Elevated creatinine levels were also associated with an increased risk of hearing loss in this 
study. Previous research has related this to a synergistic interaction with exposure to 
additional risk factors such as furosemide [4]. Creatinine levels are indicative of decreased 
renal function for which diuretics may be prescribed. In this study, there is evidence of a 
relationship between bilirubin and creatinine with preterm hearing impairment, however it 
is likely that they are effect modifiers rather than predictors of hearing loss. This will be 
discussed further amongst the cumulative risk of ototoxic medication and markers of 
haemodynamic instability (section 4.3.3). 
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Acquired brain injury and associated risk factors for preterm hearing loss 
The relationship between brain injury and hearing loss is complex. In the presence of other 
diagnoses (pneumothorax, pulmonary haemorrhage, PDA, NEC, BPD, septicaemia, and 
meningitis) and their associated treatments (figure 4-2), brain injury including IVH and PVL 
did not predict a later hearing impairment. However, when investigating individual 
morbidities, alongside neonatal infection and BPD, brain injury was the only independent 
predictor. The same association was found when investigating the effect of brain injury in the 
presence of associated treatments (figure 4-8). Acquired brain injury is most common in the 
youngest and smallest infants. In this study, babies that were born with a low birthweight for 
gestational age conferred the greatest risk of impaired hearing. All grades of IVH were 
included in analyses; grade I-II IVH is the most commonly diagnosed neurological 
complication of prematurity and was the most frequently incurred by both groups of infants 
in this study. A correlation between low grades of neurological injury and hearing loss is 
consistent with previous research which specifically considered children with mild 
haemorrhages [52]. Martinez-Cruz et al (2008) also found cerebral haemorrhage to be a risk 
factor for hearing loss, along with serum bilirubin levels and exchange transfusion [49]. It was 
postulated that the relationship between brain injury and hearing impairment could be 
influenced by the location of the bleed or the physiological process of reabsorption of the 
bleed resulting in an increase in bilirubin. Bilirubin has been associated with neurotoxicity 
causing damage to the auditory pathway. Bilirubin was not associated with hearing loss in 
the presence of IVH, but as already discussed maximum bilirubin was higher in children with 
impaired hearing. Studies that had not reached significance were underpowered in terms of 
both the number of children that had a hearing impairment, and with the number that had 
also been diagnosed with an IVH [31, 55]. 
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The complex aetiology of IVH and the effects on audiological outcome are further 
compromised by the use of treatment for hypotension. Faranoff et al (2006) in a study of 
extremely low birthweight infants found hearing loss was almost 10% greater in the treated 
group for low blood pressure, as was severe IVH (grade III-IV) [57]. Early low blood pressure 
and treatment in the first 3 days for hypotension is more likely to result in an IVH, and poorer 
neurodevelopmental outcome inclusive of hearing loss. The use of inotropes are 
administered to increase circulating volume and low blood pressure. Inotropes were also 
independently associated with preterm hearing loss in the presence of IVH in this study which 
coincides with previous research [57]. However, the use of steroid in the first 3 days, which 
is typically when an IVH is most likely to occur was not associated with hearing loss. Similarly 
to inotrope, steroid is also likely to be administered early to correct poor circulation; both 
medications can cause bleeds as a result of rapid increases of cerebral blood volume, but 
steroid did not present the same risk to hearing as the use of inotropes. Whilst brain injury, 
small for dates babies, and inotropes increase the risk of hearing loss, it remains unclear as 
to whether the bleed, location of the bleed, medication, changes in cerebral blood volume 
or interactions with the subsequent acidosis underlie the relationship. 
This study has built upon previous research and used an alternative method of analysis which 
aimed to establish whether a diagnosis or the clinical treatment of such, could be 
differentiated. This methodology is somewhat novel and therefore challenging to make 
direct comparisons to previous findings. Nevertheless, this showed some interesting findings 
which were then investigated as cumulative risks. 
4.3.3 Combined clinical risk factors for hearing loss 
A timeline of risk factors (including medications; gentamicin, vancomycin, steroid, inotrope, 
furosemide, and physiological risk factors; creatinine >90mmol/l, total serum bilirubin 
>200microm/l and pH<7.2) showed infants with hearing impairment experienced a greater 
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number of risk factors throughout their care (figure 4-9). It was hypothesised that exposure 
to multiple coexisting risk factors in the neonatal period would be associated with hearing 
loss, and this was supported. The infants at the greatest risk for hearing loss encountered a 
greater incidence of risk factors from birth throughout their neonatal care until discharge. 
Whilst other studies have looked at the number of risk factors [128, 129], morbidity counts 
as predictors of neurodevelopmental outcome including hearing loss [82, 130-132], or used 
multivariate analyses to identify independent risk in the presence of other factors [14, 71], 
few have looked at the coincidence of variables across a timeline of care. This was 
investigated further in terms of ototoxic medication, concomitant diagnoses and the risk of 
physiological risk factors as discussed below. 
4.3.3.1 Ototoxic medication  
Ototoxic medication such as gentamicin, amikacin and vancomycin are known to be harmful 
to the inner ear, hence strict adherence to blood level monitoring in neonatal practice. In this 
study, children with impaired hearing were more likely to receive 2 or 3 types of antibiotic 
(amikacin, gentamicin and vancomycin), in comparison to normal hearing children (77% and 
47% respectively). Furthermore, furosemide has been associated as potentiating the effect 
of ototoxic antibiotics. Yet, the impact of ototoxic medication on hearing loss in preterm 
infants has been controversial in previous studies.  
Exposure to gentamicin, vancomycin and/or furosemide in cumulative doses was associated 
with hearing loss in the current study. Within the first 14 days of life children were almost 6 
times more likely to be in the group of children with impaired hearing if they had received 
up to 7 doses of any of the ototoxic medications within that time frame.  
The risk of increased exposure to these medications coincides with the results of previous 
studies [31, 93]. Total number of days of treatment and cumulative doses were higher in the 
case group than the normal hearing group, in a sample of preterm infants (<34 weeks 
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gestation) [98]. Similarly, but in term or near term infants, the use of vancomycin was higher, 
and cumulative doses and duration of diuretics was greater for children with hearing loss 
[71]. Concomitant administration of aminoglycosides and furosemide was also found to 
increase the risk of hearing loss.  
Methodological variation is likely to explain the differences between the findings in the 
current study and studies that have failed to find an association between hearing impairment 
and drug induced ototoxicity. Combinations of tobramycin, vancomycin and furosemide 
were not related to hearing loss in a sample of 45 infants who failed their hearing screen [94]. 
There are several reasons for which these results might underestimate the ototoxicity of 
these medications. Firstly, conclusions were based upon hearing screening results whereas, 
the current study recruited children with hearing loss up to the age of 7 with a confirmed 
hearing loss. Secondly, reliance on the newborn hearing screen is likely to include children 
that do not have hearing loss at follow up. In the absence of confirmed hearing impairment, 
the safe use of gentamicin is a conservative finding. Furthermore, high frequency losses were 
not tested. Impaired hearing as a result of ototoxic medication commonly start with a high 
frequency loss and can cause delayed onset impairment due to slow clearance from the inner 
ear which progresses to the lower frequencies. Finally, tobramycin is used less frequently in 
the UK, and therefore gentamicin which is a commonly used antibiotic in neonatal care which 
also has ototoxic properties, was included in the analysis instead; the ototoxicity levels of 
tobramycin are understood to be lower than that of gentamicin which could play a role in 
the differing results [143]. 
A further study, with a similar population of preterm infants (<32 weeks gestation or <1500g) 
to the current study, also found contrasting results [92]. Cumulative doses and total number 
of days of aminoglycosides posed no additional risk to hearing function. The frequency of 
exposure to gentamicin (case group 86% in the current study, 76% in Fuchs et al’s study, 
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control groups 71% and 70% respectively) and vancomycin (case group 72% in the current 
study, 64% in Fuchs et al’s study, control groups 42% and 50% respectively) were comparable 
between the studies, but furosemide administration was substantially lower than the current 
study (double the number of cases and controls received furosemide), as was the frequency 
of BPD for which furosemide will often be prescribed as part of the treatment course. 
Published literature has indicated a cumulative effect of ototoxic medication leads to an 
accrual within the inner ear that potentiates hearing loss. Furthermore, in laboratory studies, 
an interaction between an accumulation of aminoglycosides within the inner ear and loop 
diuretics increase the damage to cochlear hair cells [90]. As discussed in chapter 1, 
aminoglycosides not only present an ototoxic risk but also a nephrotoxic risk, which can 
increase the circulating volume of aminoglycosides and also the need for diuretics. Therefore, 
infants with the greatest exposure are the most at risk of hearing loss. 
The critical period for preterm infants is typically the first two weeks of intensive care 
following birth. Therefore, it was thought that this time frame would pose a greater risk, 
however the risk of ototoxic medication did not appear to be time critical. Infants received a 
cumulatively higher amount of ototoxic medication and were at as much risk of hearing loss 
in subsequent weeks of care as they were in the first two weeks of life. This extended on 
previous research that has found an association between ototoxic medication and hearing 
loss but has not looked at the influence of time. 
Gentamicin is frequently used as a first line antibiotic in neonatal care, and while it has been 
deemed innocuous to the functioning of the inner ear, possibly as a direct consequence of 
stricter monitoring of both prescribed doses and serum blood levels during treatment, the 
results in this study suggest otherwise. The coincidence of gentamicin with other ototoxic 
medications, namely vancomycin and furosemide have been cumulatively associated with 
hearing loss in infants born at less than 32 weeks gestation. The clinical uses of vancomycin 
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vary between babies; it is prescribed as a second line antibiotic for proven sepsis, suspected 
sepsis or prophylactically to prevent long line sepsis. Long line duration was longer for 
children with hearing loss (mean 31 days, range 0-155) in comparison to children with normal 
hearing (mean 17 days, range 0-133). This could be indicative of the increased prevalence of 
gastrointestinal disturbances such as NEC in children with impaired hearing, for which long 
line nutrition may be required. 
4.3.3.2 Ototoxic medication and coincidental risk factors for hearing loss 
Multifactorial relationships are likely to increase the relative risk of hearing loss in preterm 
infants. Published literature suggested exposure to a coincidence of risk factors exacerbates 
the risk of hearing loss [4]. Combinations of furosemide in the presence of elevated creatinine 
levels, furosemide and netilmicin, netilmicin when bilirubin levels were raised, and acidosis 
in the presence of hyperbilirubinaemia posed a risk to hearing. The potentiation of ototoxic 
medication by physiological instability partially informed the analysis for the current study. 
Cumulative ototoxic medication, clinical diagnoses and haemodynamic instability were all 
independently predictive of hearing loss (figure 4-12). Furthermore, the combination of 
ototoxic medication and haemodynamic instability occurring on the same day was also 
associated with an increased chance of hearing impairment which coincides with previous 
findings [4]. Ototoxicity may be more severe in those with haemodynamic instability 
compared to those with exposure to ototoxic medication alone or haemodynamic instability 
alone, but the study was not powered to detect this. Small numbers of infants with no 
exposure to ototoxic medication or haemodynamic instability in the first 14 days following 
birth meant that analyses could not determine whether exposure to both in combination 
increased the risk of hearing loss more than to exposure to either of these alone.  
This study provides an indication of the exposure to multiple risk factors which were greatest 
during the first two weeks of life (section 4.2.5). The complexity of the interactions between 
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these risk factors are commonly recognised in previous studies mainly in terms of ototoxic 
medication [71, 92, 93, 98]. Ototoxic medication, namely antibiotics used to treat sepsis, 
administered at safe doses is dependent on adequate renal function which is often impaired 
in very preterm infants. Creatinine levels are a marker of inadequate elimination, and for 
which loop diuretics are often prescribed. Diuretics are often also used to treat BPD and 
occasionally PDA. Inotrope is administered for poor perfusion (often associated with a 
diagnosis of PDA and IVH) which is more common in preterm infants, but is also associated 
with acidosis and raised lactate levels. Inotrope has been independently associated with 
hearing loss in the current study and acidosis is known to compete for albumin binding sites 
along with ototoxic medication. Few studies have considered a time based aspect to analyses 
and the overlap of a multitude of risk factors. The current study has provided an insight into 
the risks for hearing loss encountered by preterm infants in the critical period after birth.  
Overall, the hypothesis was supported in terms of the most unwell children being at the 
greatest risk for hearing loss.  
4.3.4 Summary 
In this study of preterm infants, a number of risk factors for hearing loss were elicited. Infants 
with the lowest gestational ages, the smallest birthweights and born in poorer condition are 
at the greatest risk of hearing impairment. Infection, acquired brain injury, PDA, NEC, BPD 
and pneumothorax were all more frequent in the hearing loss group. Duration of respiratory 
support, oxygen therapy and intensive care treatment were also more common in children 
with impaired hearing, as was exposure to almost all medications. Children with hearing loss 
were therefore expected to have been exposed to a higher number of individual risk factors 
than children with normal hearing, across a timeline of neonatal care. The findings in this 
study support that expectation.  
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Individual risks for preterm hearing impairment include low gestational age, low birth weight, 
acquired brain injury, a diagnosis of PDA, the use of steroid, inotrope, vancomycin, and 
furosemide, and raised creatinine and bilirubin independently increased the risk of hearing 
loss. The rate of comorbid diagnoses tended to be higher in children that developed hearing 
loss, whom were subsequently also exposed to an increased number of individual risk factors 
on a daily basis throughout the first 14 days of their neonatal care.  
The proportion of infants receiving ototoxic medication was higher, however, the ototoxicity 
of gentamicin was only evident in accumulation with vancomycin and furosemide. 
Cumulative doses of ototoxic medication increased the risk of audiological harm. Coinciding 
risk factors were also expected to play a role in increasing the risk of hearing loss. The use of 
ototoxic medications in the presence of haemodynamic instability was found to increase the 
likelihood of audiological impairment, supporting this hypothesis.  
It is evident that there is a continuum of exposure to risk factors which lasts beyond the first 
two weeks of life. It could be that there is an initial insult to the ear and then consequent 
exposure exacerbates the damage that has already occurred, particularly in the use of 
aminoglycosides. Suppressed renal function and perfusion necessitate the use of diuretics 
which further exacerbates the ototoxicity of aminoglycosides.  
In conclusion, we found multiple risk factors over a timeline of neonatal care, both 
independent and combined risks which interact to increase the chances of hearing loss in this 
vulnerable population.  
The final chapter will consider implications for research, implications for clinical practice and 
the strengths and limitations of the study.  
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5 Chapter 5: General discussion 
The risk of hearing loss for children born prematurely is widely known and reported by 
developmental outcome studies [1, 4]. The neonatal course of infants born prematurely is 
complex and elucidating individual risk factors for hearing loss is therefore challenging. Ten 
risk factors for impaired hearing were identified by JCIH including: family history of hearing 
loss, congenital infections, craniofacial abnormalities, low birth weight (less than 1500g), 
hyperbilirubinaemia, ototoxic medications, bacterial meningitis, low APGAR scores at 1 or 5 
minutes, assisted ventilation for 5 days or more, and syndromes associated with hearing loss. 
Whilst many of the children with hearing loss were more frequently exposed to the neonatal 
variables amongst these risks in comparison to children that have normal hearing, additional 
risk factors were also evident in this sample of preterm infants. Low gestational age, acquired 
brain injury, PDA and an individual and cumulative risk of ototoxic medication increased the 
outcome of impaired hearing.  
The risk of ototoxic medication to hearing in preterm infants is exacerbated in individuals 
with m.1555A>G which provides a predetermined susceptibility to hearing loss following 
exposure to aminoglycosides. The contribution of aminoglycosides has been unclear in 
previous research, and remains somewhat unclear in this study. A late onset mild hearing 
impairment became evident in one control child, following aminoglycosides in the presence 
of m.1555A>G, although this was not apparent in an older sibling who had also been exposed 
to aminoglycosides. 
The rest of this chapter will consider the implications of the findings in this study, as well as 
limitations and directions for further research. 
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5.1 Implications for research  
5.1.1 Genetic research 
The implications for research surrounding the effect of m.1555A>G to deafness are primarily 
methodological. Results from this study can be used to reflect on previous studies and steer 
future research in the following ways. 
Research has previously found hearing loss in individuals with m.1555A>G following 
exposure to aminoglycosides, however from the current study it is evident that the 
methodology chosen to investigate deafness as an outcome impacts the overall findings. This 
study has revealed flaws in some previous studies which have focussed only on individuals 
with severe to profound deafness [126], used self-reporting of the progression of hearing 
loss [117], self-reported aminoglycoside exposure [141], and used the failure of early 
newborn hearing screens as an outcome measure [124]. The results from this study 
emphasise firstly, the need to include normal hearing children and lower severities of 
impairment including high frequency losses, and not just a subset of children with impaired 
hearing. As a progressive form of hearing loss has been associated with m.1555A>G many 
affected children with a later onset of impairment could have been missed, subsequently 
underestimating not only the age of onset of hearing loss but also the impact of the mutation. 
Secondly, the current study has shown that the timing of monitoring outcome measures is 
influential on the research findings. A newborn hearing screen is completed too early to 
detect a late onset hearing loss as used in previous research. Longitudinal or retrospective 
studies with a complete audiological and pharmacological history are paramount to 
reviewing the causes of hearing loss in a susceptible population. 
In summary, implications for the research of m.1555A>G in children is predominantly 
methodological. Reliance on an early hearing screen is liable to underestimate the influence 
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of m.1555A>G and the impact of aminoglycosides which affects clinical care, this will be 
discussed in section 5.2.1. 
5.1.2 Neonatal research 
From the research explored to date, this appears to be the most comprehensive analysis of 
overlapping risk factors for hearing loss, particularly along a timeline of neonatal care. The 
number of risk factors for hearing loss encountered by children with impaired hearing in the 
first 2 weeks of neonatal care are crucial, but these continue until discharge.  
A strength of this study is the longitudinal nature of recruiting children born over a 5 year 
period, and recruited over a three year period which meant that hearing loss was confirmed, 
whilst changes to clinical care were likely to be minimal. The rates of preterm hearing loss 
are much higher than term born populations but overall prevalence rates are still relatively 
low (0.77% in this study), and to reach adequate sample size recruitment will often need to 
be multicentre and/or over a prolonged period of time to make reliable inferences as to the 
manifestation of hearing loss. The number of children with hearing loss participating in this 
study was at the higher end of the target group, this again is an achievement. 
Some of the discrepancies between the results in this study and previous research could 
surround the reliance on cross sectional data from hearing screening rather than confirmed 
hearing loss from follow up appointments [94]. The inclusion of children with suspected and 
confirmed ANSD is advantageous. Given the uncertainty surrounding diagnosis, excluding 
these children would have reduced the power of the study, and given the lack of discernible 
neonatal differences in characteristics between the ANSD and CHL groups (section 4.2.2), 
exclusion would not have been viable. 
A further strength is the cut off of gestational age (<32 weeks) for study inclusion. The risk 
factors that a very preterm infant is exposed to are very different to those of a term baby 
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and are therefore not comparable in the same ways. Furthermore, maturational differences 
lead to inconsistencies in the relationships between risk factors when comparing babies born 
at the lowest gestations to those born near or at term. Studies including the two as an 
individual group, or making comparisons between a term and preterm group are likely to 
miss influential interactions [65].  
Statistical analyses have incorporated a multitude of variables associated with neonatal care 
and attempted to tease apart complex interactions between these risk factors for hearing 
loss. This again, is a strength of the current study. Previously, a reliance of descriptive and 
univariate analysis has been adopted by studies [30] which does not account for the influence 
of confounding factors and co-dependence between risk factors, therefore limiting the ability 
to apply these results to neonatal practice. 
In summary, future research can be informed by the methodology adopted in this study 
which features many strengths, namely using confirmed hearing impairment, restricting 
inclusion of very preterm infants and considering a breadth of overlapping risk factors which 
has previously been overlooked. 
5.2 Implications for practice 
5.2.1 Genetic practice 
The current study has found one child with m.1555A>G who developed a late onset hearing 
impairment following exposure to aminoglycosides, which may be a progressive loss. Current 
practice does not screen for m.1555A>G prior to the administration of aminoglycosides in 
neonatal care, but is screened for prior to the commencement of paediatric oncology 
treatment. Reliance on the newborn hearing screen could delay diagnosis and therefore 
treatment for children that are not identified as at risk. Furthermore, children with a late 
onset hearing impairment with a history of preterm birth and no family history of deafness, 
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may be assumed to have an acquired loss as a result of neonatal complications rather than 
undergo genetic investigations. 
Based on findings from this study, and previous research into the increased risk of hearing 
loss in those with the mutation following exposure to aminoglycoside antibiotics [117], there 
are several considerations to be discussed. Firstly, taking a family history prior to the 
administration of aminoglycosides has been previously suggested, however due to the 
constraints of providing rapid neonatal care this is not always possible. Furthermore, a mild 
hearing loss is not always obvious, and so a self-reported family history may not provide 
much more detailed information. 
Secondly, a change in first line antibiotics for suspected sepsis in preterm infants could be 
implemented. An alternative option to aminoglycosides is to use cephalosporin agents 
instead. However, an advantage to the use of aminoglycosides antibiotics in preterm infants 
is due to the low drug resistance and cost effectiveness. In comparison, cephalosporin agents 
are less economically viable and there is a potential to lower the effect of the antibiotic and 
increase drug resistance. In a study of paediatric hospital admissions with antibiotic 
administration, children who had received 3rd generation cephalosporin’s were significantly 
more likely to develop extended-spectrum β-lactamase (ESBL) [144]. Since the current study 
did not find a confirmed association between m.1555A>G and aminoglycoside use, a change 
in aminoglycoside protocol would not be recommended. However, a reduction in the use of 
antibiotics may be more appropriate considering 95% of infants that are treated 
prophylactically for sepsis do not in fact have positive blood cultures and are therefore in 
receipt of at least 48 hours of antibiotics unnecessarily [145]. A decrease in exposure would 
reduce the risk of aminoglycoside induced hearing loss in general, as well as benefitting 
carriers of m.1555A>G.  
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Thirdly, the use of rapid screening could be undertaken prior to the administration of 
aminoglycosides in preterm infants that are likely to receive antibiotics within the first few 
hours of life. As observed from the results in this study, aminoglycoside exposure in the 
presence of m.1555A>G can cause a late onset decline in hearing which is preventable 
following screening and the avoidance of aminoglycosides. If there is a threshold effect a 
dose or short course might not have implications for hearing, however testing would still be 
required. Cot side testing of saliva samples is non-invasive and fast; currently taking around 
an hour to process. However, an infant born prematurely is likely to be born unwell, and a 
saliva sample will not be given priority over stabilisation; given that the first dose of 
antibiotics will be administered within an hour of life to treat suspected early onset sepsis, a 
result would be unlikely to be available.  
Lastly, specific antenatal rapid response screening for m.1555A>G in preterm labouring 
women and women showing signs of infection during labour, whose babies are likely to be 
prescribed antibiotics following delivery. The result of which could be available prior to birth 
for avoidance of aminoglycosides in infants of women testing positive for m.1555A>G. This 
is as cost effective as testing babies, but provides a wider time frame for obtaining a result in 
comparison to screening the babies once born. Early screening and detection of individuals 
with the mutation, would also enable follow up audiology assessments which are critical in 
detecting impairment as early as possible to reduce the effect on development. Rapid 
screening would enable alternative antibiotics to be given where possible and for 
identification of at risk patients to be followed up even upon passing their newborn hearing 
screen. This study found a late onset presentation of hearing loss, which, based on previous 
studies, is likely to deteriorate with time. 
Preterm infants are just one group of patients exposed to repeated courses of 
aminoglycosides. As discussed in section 1.3.2, cystic fibrosis patients are also frequently 
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treated with aminoglycosides, and hearing loss following exposure to ototoxic antibiotics in 
the presence of m.1555A>G has been found [120]. The use of pre-treatment screening for 
m.1555A>G in paediatric oncology patients is already in current practice, it would be useful 
to see if this has been cost effective before applying to other areas of patient care, this will 
be discussed further in section 5.4. 
5.2.2 Neonatal care 
Preterm hearing loss is up to 10 times higher than in the term born population. The 
prevention of neonatal hearing loss can only be achieved by understanding the underlying 
relationships between risk factors. This study aimed to investigate those and derived 
individual and coinciding risk factors for hearing loss in preterm infants as expected. 
However, the greatest risk of hearing loss appears to surround the use of medication which 
is consistent along a continuum of neonatal care. There are important implications for future 
neonatal treatment.  
The findings from this study have identified the babies at greatest risk of hearing impairment; 
infants with the highest exposure to risk factors. Therefore, the management of these 
vulnerable babies is dependent on the reduction of exposure to risk factors, one of the most 
commonly presented being ototoxic medication.  
Almost all babies in this study were exposed to at least one dose of antibiotics (100% of 
children with impaired hearing and 91% of children with normal hearing). Interestingly, given 
the high rates of exposure to aminoglycosides, the relative risk of sepsis was much lower; 
confirmed by positive blood culture or NEC in 65% of children with hearing loss in comparison 
to 47% of normal hearing children, yet sepsis was not independently predictive of hearing 
impairment in the presence of aminoglycosides. Therefore, treatment for suspected sepsis 
or prevention of central line sepsis accounted for 35% of children with hearing loss and 44% 
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of normal hearing children in this study. In context, it is also important to consider the rate 
of sepsis progression in preterm infants with an immature immune system for which 
antibiotics are given until sepsis is disproven. Antibiotics are a lifesaving treatment in this 
vulnerable population, which overrides the risk of hearing loss, but it nevertheless is 
important to consider the long term risks of prolonged exposure as well as the palpable 
benefits. 
Gentamicin alone appeared to not increase the risk of hearing loss, yet a cumulative effect 
was found. Vancomycin in particular, was associated with hearing loss in multiple analyses 
and questions arise surrounding the high use of this antibiotic. In a Cochrane review of the 
prophylactic use of vancomycin in infants with a birthweight <1500g, no evidence was found 
to support low dose continuous therapy and therefore recommendations concluded that 
prophylactic use should not be undertaken [81]. Attempts to lessen the impact of ototoxic 
medication on hearing have already been implemented in current practice by the strict 
monitoring of blood levels during courses of treatment of amikacin, gentamicin and 
vancomycin. However, negative effects can be further diminished by minimising exposure to 
all ototoxic medication with short durations, and monitoring for coinciding risk factors, in 
particular furosemide and indicators of haemodynamic instability.  
One marker of haemodynamic instability is raised bilirubin. A previous nationwide study 
found the monitoring and treatment of such to be inconsistent across neonatal units [66], of 
particular interest as a consequence of this study is the sickness line and the commencement 
of early therapeutic intervention. Whilst findings in this study did not indicate a consistent 
association between bilirubin and hearing loss, there were indicators of an underlying role 
(section 4.2.4.4) which corresponds with previous studies. This supports the notion that the 
therapeutic level for the commencement of phototherapy should be lower when infants are 
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exposed to a number of risk factors that compete for binding affinity, therefore lowering the 
risk of hearing impairment when there are likely to be other risk factors present. 
The monitoring of cumulative risk factors could also be addressed in clinical practice. 
BadgerNet provides an electronically accessed summary of daily treatment, however 
diagnoses could be added to the timeline. At present, diagnoses are listed and are not 
cohesive with the daily timeline which would increase the awareness of coinciding risks, 
particularly in relation to comorbidities and associated treatments. Long term medication 
use could be monitored more easily to assess previous exposure such as a running total of 
days or doses, specifically for ototoxic medication. This is also beneficial for future research 
investigating later outcome measures, whereby retrospective methodologies are employed 
for data collection. 
In summary, an integrated approach to future care that utilises daily summaries already in 
clinical practice will reduce the risk of hearing impairment in preterm infants. Prescribing of 
medication especially for suspected sepsis needs to take into account other coinciding risk 
factors. Furthermore, given the predisposition to the ototoxicity of aminoglycosides which 
was discussed in section 5.2.1; a review of current practice surrounding antibiotic prescribing 
in the absence of confirmed sepsis may be required. 
5.3 Limitations 
During the three year study period a number of limitations were experienced during the set-
up of the study, recruitment and data collection which could have impacted on the results. 
This will be discussed in relation to sample size, data collection and analysis. 
5.3.1 Sample size 
The first limitation related to sample size, is the time taken to establish the study and begin 
recruitment. A faster set up time would have enabled a greater length of time to identify, 
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recruit and collect data which would have strengthened the findings of the study. Subsequent 
difficulties with the identification and recruitment of children with hearing loss was a further 
constraint on the study. The target sample size of cases was 30-60 children with hearing loss, 
which was achieved at the upper end. However, one third of children identified with impaired 
hearing were not recruited and this could have affected overall results. 
Children with hearing loss were identified by NHSP, which was thought likely to remove the 
risk of selection bias typically associated with case control studies. However, this could have 
impacted on the findings of the study, specifically, the number of children that were found 
to carry m.1555A>G. Although small numbers were expected, the target mutation was 
thought to be more prevalent in a population of children with impaired hearing who were 
very likely to have received aminoglycosides. However, it appears evident that this study is 
less likely to have captured information on preterm children with a later onset of hearing 
loss. Only 10% of cases in this study passed their initial hearing screen and presented with a 
late onset of impaired hearing, all of whom were identified by clinicians. Whilst the 
prevalence of the mutation in this study fits within the trend of previous studies, it is possible 
that the low number of children with the mutation is due to this under-represented group, 
especially, as the only child identified with m.1555A>G in this study was recruited as a control 
but was later found to have a late onset impairment. Therefore, it is possible that these 
results underestimate the impact of m.1555A>G following exposure to aminoglycosides.  
A further potential source of bias is from the families who did not respond to letters of 
invitation to participate. Follow up strategies to increase responses were employed in this 
study, however, not all of the cases or controls could be contacted, which could have 
introduced an unforeseen bias.  
The identification and recruitment of matched control children was also challenging, and 
reduced the total number of controls enrolled to the study. The children with hearing loss 
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born at the very lowest gestational ages had a fewer number of potential controls to match 
with, given that sex and neonatal unit for which care was received, were also controlled for. 
Due to the low numbers of children to invite to participate coupled with a low response rate, 
it was not possible to recruit five matches for every case. Despite difficulties with 
recruitment, the study had three times the number of control children to cases. Measures 
were taken to control for the lower number of matched children with normal hearing born 
at the lowest gestational ages by adjusting analyses for sex, gestational week, and 
birthweight in statistical analyses. 
This study recruited a higher proportion of male than female infants, whilst this was not a 
significant difference, males have a tendency to be more unwell [23, 24], and this could have 
been reflected in the results. The number of females recruited to the study was too low to 
make comparisons between male and female infants in terms of neonatal treatment. 
In summary, the study experienced predictable difficulties with recruitment that may have 
inadvertently impacted on the overall sample size and results. 
5.3.2 Data collection and analysis 
The design of the study intended to include as many children with confirmed hearing loss as 
possible within the study time frame. However, in order to achieve this, data (particularly 
neonatal information) was collected retrospectively. This was a limitation in itself and will be 
discussed further in terms of audiological, and neonatal data collection. 
Audiology data was collected as soon after the time of consent as possible, however this 
differed between children across sites. As a consequence, there was an age difference 
between the children regarding when the data was collected and ultimately how recent their 
last hearing assessment had been; hearing could have improved or worsened during the 
course of the study. The level of data obtained was also somewhat problematic. Information 
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concerning which hearing tests were used and when, was simplified to encourage response 
rates from clinicians. In this respect, the data might be slightly crude and would have 
benefitted from more in depth information regarding the nature, and onset of hearing loss. 
Furthermore, it was difficult to make conclusions without a firm diagnosis of ANSD for some 
of the children, which is partly accounted for by the challenges surrounding data collection. 
With regard to neonatal data collection, changes in data storage and tracking mechanisms in 
recent years led to difficulty in tracing some of the children’s medical notes. Many children 
were treated in a number of hospitals during the neonatal period, resulting in multiple sets 
of clinical records whereby data needed to be abstracted from several volumes of notes 
across different sites. Inaccessibility to medical notes, especially from neonatal units outside 
of London, was supplemented with data collection from BadgerNet summaries (neonatal 
daily summaries where available), however this is somewhat less accurate and less detailed 
than clinical notes. Therefore, study findings may be underestimated. Medical notes were 
also accessed for data abstraction by the student only. Whilst care was taken in designing the 
data collection proforma to enable data to be accurately transcribed from the clinical notes, 
it is possible that errors could have occurred during this process. This would have been 
reduced by having a second person to check the data transcription, however ethical approval 
had stated only the research nurse should be able to access medical records from outside 
the direct medical team. Owing to the time taken to collect data from clinical notes, it was 
not feasible to have a staff member from each neonatal unit second check data collection. 
Furthermore, as a multi-site study, there are differences in protocol between units. Although 
this was controlled for by recruiting matched controls based on which neonatal unit they 
received the first two weeks of treatment, this may still have had a minor impact, and may 
explain some of the discrepancies in findings between this study and previous research. For 
example antibiotic prescribing across the Trusts in this study ranged in terms of the first line 
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choice of medication, dose per kg and in the number of doses given per day. To reduce the 
differences between sites, data was collected on the number of days of doses in the first 14 
days rather than the amount prescribed, it is therefore slightly more difficult to compare to 
single site research protocols, or studies. 
In addition, it might have been beneficial to collect more information regarding the number 
of drug doses, and dosages for each baby. This would have enabled a calculation regarding 
the total amount of ototoxic medication received, as opposed to the yes/no data collected 
per day and then per week. Certainly for the child with m.1555A>G, greater pharmacological 
data would have provided more accuracy as to the total exposure to aminoglycosides. Whilst 
most medications investigated in this study are given once daily, some may have a 6, 8 or 12 
hourly dosing interval which would potentially underestimate the results reported. Although 
this would have provided a more accurate picture, there would have been a consequent 
relative rise in missing data. As already mentioned it was not possible to access all medical 
notes and therefore the depth of data would have cancelled out the breadth.  
Similarly, peak and trough levels of antibiotics were measured differently across sites, and 
were not available for all children. Therefore, it was not possible to report detailed 
aminoglycoside levels, due to obtainability issues. However, only one infant with hearing loss 
had a reported high level during antibiotic treatment, and it is unlikely that this would have 
influenced the result given the number of other risk factors present.  
Bilirubin measurements were collected as a total serum bilirubin level which was based on 
previous research [4], however toxicity is strongly correlated with unbound bilirubin and 
collecting this may have led to more accurate analysis [146]. Again, this information was not 
available from all sites, and so a decision was made to collect the information that was most 
likely to be available. 
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Associations in this study have found the aetiology of preterm hearing loss to occur across a 
continuum. Inferences from this data are limited by the lack of antenatal data which will also 
influence the outcome of hearing loss. The early use of early ototoxic medication particularly 
vancomycin as a second line antibiotic could have been a consequence of maternal infection 
which in itself is a risk factor for hearing loss. 
A further drawback during data collection was the inability to make any reliable inferences 
as to the role of CMV in this cohort. Symptomatic infants were screened for CMV during their 
neonatal care, and some children with impaired hearing were tested later as part of their 
audiology treatment to investigate aetiology. However, not all children and been tested and 
it was therefore not possible to make comparisons to the normal hearing group. Given the 
currently uncertain impact of CMV on hearing loss which is known to be an independent 
cause of childhood hearing loss, this would have added to current understanding regarding 
hearing impairment in this population. 
A limitation of data analysis was the use of preselected risk factors for multivariate 
regression, which was partly based on results, and partly from current knowledge from 
previous research. There is a chance that this could have introduced bias. It was not possible 
to run an analysis comparing groups of children with ototoxic medication only, 
haemodynamic instability only, ototoxic medication and haemodynamic instability and none 
(section 4.2.7) without introducing a Type 1 error. Only 1.8% of children with hearing loss 
and 4.4% of children with normal hearing did not receive any aminoglycosides or have any 
haemodynamic instability during the first 14 days of their neonatal care; this was too low to 
form a baseline comparison group with which to compare the risk of ototoxic medication and 
haemodynamic instability to the other groups. Whilst this demonstrates the widespread use 
of aminoglycosides, a larger number of children who had not been exposed would have 
increased the power of the analyses.  
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It is also very unlikely that the risk factors are completely independent; relationships are 
complex and difficult to differentiate, and analysis underestimates the relationships despite 
attempts to tease them apart. It was initially thought that critical period was during the first 
14 days but when considering drug induced ototoxicity it appeared this was not the case. 
Collecting data on a daily basis during each diagnosis for example PDA if it occurred during 
weekly data collection (after the first two weeks), would have enabled the observation of 
independent risks to emerge. Daily measurements during critical periods might have been as 
informative as the collection of data for the first 14 days, although as already mentioned this 
would increase the risk of missing data. Most relationships had declined by week 12 although 
at this point a large number of infants had already been discharged.  
In summary, despite incurring a number of limitations associated with sample size and data 
collection, most of which could not be anticipated, these were controlled for as much as 
possible. Given that the results follow similar trends to those of previous studies, it is unlikely 
that the findings have been adversely affected. 
5.4 Future research 
Drug induced ototoxicity is one of the main findings from this study. Given the large number 
of preterm infants treated with ototoxic medication, future research should investigate this 
further. Individuals with m.1555A>G are predisposed to the audiological side effects of 
aminoglycosides, and cumulative aminoglycosides with furosemide have also been 
prominent in the risk of hearing impairment. As a result of the findings in this study, and 
methodological strengths and limitations, the following section will discuss potential avenues 
for further research. 
The ongoing monitoring of the child in this study found to carry m.1555A>G and their sibling 
will be a priority following this study and will inform future research. Long term audiological 
follow up will be required for both children. Whilst m.1555A>G initially appeared benign in 
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this study, a later onset high frequency hearing impairment questions the long term 
audiological outcome. Progressive hearing loss has been associated with m.1555A>G 
following aminoglycosides; therefore it is important to observe the course that this hearing 
loss takes. Furthermore, as the sibling also received aminoglycosides based on previous 
research this would also be expected to result in a hearing impairment, time will tell. 
Follow up of preterm studies that have used the newborn hearing screen as a measure of 
hearing loss in infants with m.1555A>G and a history of aminoglycosides, would also be 
informative, and are understood to be in progress [124]. This would enable a direct 
comparison to the results in this study. Late onset impairments would coincide with our 
findings and would highlight the importance of investigating childhood hearing loss as 
opposed to a failed hearing screen.  
Owing to the small number of children affected by m.1555A>G, a meta-analysis of recent 
preterm literature [123-125], preferably following confirmation of hearing loss, would 
increase power and improve the estimates of the effect. In section 5.2.1, the screening of 
infants or mothers in labour was discussed, however this would require a cost benefit 
analysis requiring greater numbers than we found in this study alone. A systematic review 
including the findings of major studies investigating aminoglycoside induced deafness in 
carriers of m.1555A>G might provide greater clarity. Already in practice is genetic screening 
for m.1555A>G in paediatric oncology. A review of the data surrounding the detection of the 
mutation would also be crucial before implementing in neonatal care. Screening was 
introduced prior to the commencement of aminoglycosides to prevent drug induced 
ototoxicity, an audit would aid cost benefit analysis. 
The addition of other contributing risk factors has also been discussed in section 5.2.1. An 
extension of this research might consider the reason behind aminoglycoside administration 
and the potential for proven sepsis as opposed to suspected sepsis to determine deafness in 
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the presence of m.1555A>G. Hu et al (1991) listed potential sources of infection as well as 
exposure to aminoglycosides [142]. Studies consistently fail to report the type of infection, 
which could also be pivotal in the presentation of hearing loss in these individuals. 
Septicaemia increases bodily demand for energy and could cause mitochondrial inhibition 
and subsequent functional errors. This could not be explored in this study as neither the case, 
nor their sibling, had confirmed sepsis when they were treated with aminoglycosides. As 
hearing loss has become evident following suspected sepsis it is unlikely that the cause is 
septicaemia, however interactions between the aminoglycosides, the mutation and 
increased bodily stress are likely to coexist. 
A wide variety of antibiotics have been reported as ototoxic throughout the literature 
although some are used less frequently now, for example kanamycin. As both children with 
the mutation were treated with two different types of aminoglycoside, it is therefore not 
possible to differentiate between the two as to which was the most ototoxic. Tobramycin has 
previously been deemed less harmful than gentamicin, but given the variation used in 
neonatal care future research could investigate which is most toxic in the presence of 
m.1555A>G. Based on the results discussed in section 4.2.7, cumulative doses of 
aminoglycosides could be pivotal in the manifestation of hearing loss in individuals with 
m.1555A>G. Again, it was not possible to report in this study due to inaccessibility to medical 
notes. Moreover, the potentiation of furosemide to aminoglycosides also found in this study 
should also be measured in future research investigating drug induced ototoxicity and 
m.1555A>G. 
From a neonatal perspective, ototoxic medication, namely vancomycin, was consistently 
associated with hearing loss in this study. Exposure to vancomycin in this study was measured 
in terms of whether it had been received per day or per week during neonatal care. Given 
the direct association with hearing loss, future research should consider the total dosages of 
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vancomycin administered per kg. However, this would also need to be considered relative to 
the exposure and dosages of other ototoxic medications, it was evident in this study that 
cumulative exposure to ototoxic risk factors also increase the likelihood of hearing loss. The 
specific use of vancomycin should also be explored further. It was noted that some of the 
infants in this study were given vancomycin for the prevention of long line sepsis, which a 
Cochrane review of prophylactic vancomycin did not recommend. Furthermore, few of the 
studies included in the review had considered hearing loss as an outcome and no conclusions 
could be drawn regarding later antibiotic resistance [81]. The uncertainty surrounding this 
highlight the need for alternative options to be explored, which would involve cost analysis 
reviews and long term follow up on outcome, specifically in terms of antibiotic resistance. 
Similarly, the long term use of furosemide, which is a fast working diuretic was noted for 
some infants. The cumulative effect of furosemide with aminoglycosides was one of the main 
findings from this study. Changes to clinical practice resulting in the decreased exposure to 
ototoxic medication would warrant a similar review to investigate the consequent reduction 
in hearing loss in preterm infants.  
The relationship between the unanticipated protective effect of ibuprofen and hearing 
impairment should also be explored further. Similarly, indometacin showed a protective 
tendency although this did not reach significance which may be due to the small numbers in 
both groups. This study considered the presence of a PDA and the number of days or weeks 
of exposure to ibuprofen and indometacin only; it may be beneficial to consider the size of 
the duct, velocity of blood flow, time taken for the duct to close and the physiological markers 
of changes in perfusion such as bradycardias, acidosis, apnoea’s and desaturations. As this 
study included an untreated and a medically treated PDA in analyses it is possible that these 
had a lesser clinical impact than a surgically treated PDA which is typically measured in 
previous studies; subsequently influencing the overall findings.  
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One of the limitations of the results from this study was the small number of children that 
had not been exposed to ototoxic medication or haemodynamic instability. Based on 
published literature ototoxicity is likely to be increased as a consequence of haemodynamic 
instability, but with a very small unexposed group it was not possible to make this 
comparison. An extension of this study could investigate the predictive nature of ototoxicity 
in the presence of haemodynamic instability as a primary outcome so that recruitment could 
be made to each group (no exposure, haemodynamic instability only, exposure to ototoxic 
medication only, or exposed to ototoxic medication in the presence of haemodynamic 
instability). Although this would be challenging given the difficulties faced with recruitment, 
this would enable a comprehensive evaluation of these risks in association with hearing loss. 
5.5 Conclusion 
Hearing loss in preterm infants is influenced by a multitude of interacting factors. Ototoxic 
medication presents an increased risk of hearing loss to infants born at less than 32 weeks 
gestation. The impact of ototoxic medication on hearing can be reduced by giving short 
durations, and monitoring for coinciding risk factors, in particular indicators of 
haemodynamic instability. Aminoglycosides in particular, appear to present an increased risk 
when given in the presence of m.1555A>G.  Further research could build upon the results 
from this study to develop a cost benefit analysis for changes to clinical practice with regard 
to genetic screening prior to exposure to aminoglycosides.
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Appendices 
Appendix 1: Prevalence of hearing loss following neonatal care (Publications from 2004-2014) 
Study Definition of hearing 
loss 
Population size Gestational 
age/weight 
Prevalence 
Coenraad et al 
[30], 2010 
ABR >40dB 3316 NICU graduates (>24hr stay)  58/3316  1.75% 
Vella-Brincat et al 
[93], 2011 
OAE failure  
OAE and ABR failure 
2347 NICU admissions (>48hr stay)  153/2347  
30/2347 
6.51% 
1.28% 
Rastogi et al [86], 
2013 
Receiving therapy or 
hearing assistance 
344  <1500g 19/344  5.52% 
Declau et al [19], 
2008  
AABR >35dB 87000 infants   116/87000 0.13% 
Xoinis et al [14], 
2007 
ABR >20dB 4250 NICU infants  95/4250  2.24% 
Synnes et al [147], 
2011 
 >21dB 586 extremely low birth weight infants (ELBW) <800g 50/586  8.53% 
Martinez-Cruz et 
al, [51] 2012 
SNHL (BAEP >45dB) 
AN (TEOAE/DPOAE pass, 
BAEP fail) 
93 extremely low birth weight infants (ELBW) <750g 6/93  6.45% 
Johnson et al 
[125], 2010 
ABR >25dB 256 <2500g 10/256  3.9% 
Robertson et al 
[12], 2009 
ABR >25dB 1279 <28 weeks 
<1250g 
40/1279 3.12% 
Hille et al [28], 
2007 
AABR 2186 infants  <30 weeks and/or 
<1000g 
71/2186 3.2% 
Gopel et al [124], 
2014 
OAE/BAER 7056 NICU infants <37 weeks 
<1500g 
788/7056 11% 
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Bielecki et al [129], 
2011 
TEOAE >30dB 5282 infants  280/5282 5.3% 
 
Dowley et al [15], 
2009 
>60dB 45050 infants  30/45050 0.07% 
Van Dommelen et 
al [22], 2015 
ABR >35dB 18564 NICU infants <32 weeks 403/18546 2.17% 
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Appendix 2: Prevalence of hearing loss following neonatal care in selected groups of infants (publications 2004-2016) 
 
Study Definition of hearing 
loss 
Population size Gestational 
age/weight 
Prevalence 
Amin et al [68], 
2016 
Absent or abnormal 
ABR, normal OAE 
44 with total serum bilirubin >20mg/dL >34 weeks 5/44 11.36% 
Martines et al 
[148], 2012 
ABR >40dB 412 at risk infants  47/412 11.41% 
Martinez-Cruz et al 
[49], 2008 
BAEP >40dB 418  146/272 53.68% 
Morini et al [48], 
2008 
SNHL >20dB 82 NICU infants with congenital diaphragmatic 
hernia 
 40/82 48.78% 
Patra et al [52], 
2006 
Unknown 362 NICU infants  
104 with grade I-II IVH 
<1000g 15/362 
9/104 
4.14% 
8.65% 
Robertson et al 
[71], 2006  
ABR >25 dB 
 
81 NICU infants following severe respiratory 
failure 
>34 weeks 43/81 53.09% 
Yoshikawa et al 
[149], 2004 
Referred following 
AABR and ABR  
226, 102 NICU graduates, 124 healthy newborn 
controls 
 9/226 3.98% 
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Appendix 3: Prevalence of m.1555A>G in neonatal populations (publications from 2010-2014) 
 
Study 
 
Population size Prevalence of m.1555A>G Hearing loss and 
m.1555A>G 
Aminoglycoside exposure 
and m.1555A>G 
Ealy et al [123], 2011 703 NICU infants 2/703 0.28% 0/2 2/2 
 
Gopel et al [124], 2014 7056 preterm infants <37 
weeks gestation <1500g 
12/7056 0.17% 
 
3/12 10/12  
3/3 with HL 
Johnson et al [125], 2010 436 infants with birthweight 
<2500g 
3/436 0.69% 1/3 3/3 
 
Nivoloni et al [139], 2010 8974 newborn infants  
 
0/8974 0 0 0 
Wang et al [138], 2011 14913 newborn infants 
 
18/14913 0.12% 0/18 Not measured 
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Appendix 4: Consultant letter (audiology/neonatal) 
Consultant Letter Version 1; 2 November 2011 
 
 
 
Address 
 
 
Research Study into Hearing Loss and Prematurity 
 
Patient name 
Date of birth 
 
Dear Parent 
 
I am writing to introduce a research study to you and to ask if you would consider 
assisting the research team in working out the relationship between deafness and 
the use of antibiotics after birth on the neonatal unit in babies who were born 
prematurely. This is an important study because it will help us to decide which 
antibiotics to use for newborn babies. 
 
I enclose a letter and leaflet introducing the study from Professor Neil Marlow who is 
a newborn specialist working at University College Hospital and is leading the 
research team. Please read his letter and the information leaflet they designed, to 
help you decide whether you want to join this study. 
     
 
Yours sincerely 
 
 
 
 
Consultant Audiological Physician / Consultant Neonatologist 
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Appendix 5: Parent reply sheet 
Reply Version 2; 9 December 2014 
 
 
Professor Neil Marlow, 
Professor of Neonatal Medicine, 
Institute for Women's Health, 
74 Huntley Street, 
London WC1E 6AU 
 
Are you happy for us to contact you?  Yes   No   
 
If we do not receive a reply, we will contact you to check you have received the 
study information. 
 
 
Your name        ……………………………………………........................... 
 
Your child’s name       ……………………………………………........................... 
 
Your child’s date of birth   ……………………………………………........................... 
 
 
NICU where your child was treated ...………………………………........................... 
 
Your GP’s name and address  ………………………………………........................... 
 
 
Your contact details  
 
Phone number  …………………………………………........................... 
 
Mobile number  …………………………………………........................... 
 
Email address   …………………………………………........................... 
 
How may we contact you (please circle phone number/mobile number/email as 
appropriate)? 
 
 
Alternatively, if you wish to get in touch directly with the study Research Nurse, the 
contact details are: 
 
Kathy Chant 
Institute for Women's Health,      
74 Huntley Street, London WC1E 6AU 
 
Tel: 020 7679 6031 or 07580 219408 
Email: k.chant@ucl.ac.uk 
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Appendix 6: Parent consent form 
Consent Form Version 4; 30 August 2013 
 
 
 
MITOGENT PARENTAL CONSENT FORM 
 
Project ID:                      
REC Number: 12/LO/0005 
 
Name of Principal Investigator: Dr M Bitner-Glindzicz  
                 Please tick 
Yes or No  
 
1. I confirm that I have read and understood the information sheet dated 20 May 2013 for the 
above study and have had the opportunity to ask questions and these questions have been 
answered satisfactorily. 
Yes      No 
2.  I understand that my child’s participation is voluntary and that we are free to withdraw at 
any time, without giving any reason, without affecting my child’s medical care or legal 
rights. 
 
 Yes       No    
         
3. I understand that sections of any of my child’s medical notes may be looked at by 
responsible individuals from UCLH, UCL or from regulatory authorities where it is relevant 
to our taking part in research. I give permission for these individuals to have access to my 
child’s records. 
 
 Yes       No 
4. I agree that the research team can contact my child’s General Practitioner to inform 
him/her if my child is found to have the MitoGent variant. 
 
 Yes       No 
5. I understand that all provided tissue samples (eg. saliva and cheek swabs) will be 
considered a ‘gift’ to UCL.  
 
 Yes       No 
6. 
 
If my child is found to have m.1555A>G during the research I would like to be told this 
information. 
 
  Yes      No 
 
 
7. I agree for my child to take part in the above study. 
 
 
  Yes      No  
 
___________________________ 
Name of Child (print) 
 
 
___________________________  ________________ ________________________ 
  
Name of Parent (print)  Date   Signature 
  
 
___________________________  ________________ ________________________ 
Name of Person taking consent Date   Signature 
 
1 form for Parent; 1 to be kept as part of the study documentation, 1 to be kept with hospital notes 
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Appendix 7: Audiology data collection proforma 
Patient Demographics 
Child’s NHS number  
Sex  
Date of birth  
Referring Hospital  
Date of completion  
 
Audiometric data 
(Please circle) 
Sensorineural Hearing loss 
(SNHL)1 detected? 
YES NO 
Unilateral/Bilateral hearing 
loss 
UNILATERAL BILATERAL 
 
Newborn Hearing Screen 
Passed YES NO 
 
Severity of Hearing Loss*  
Mild Moderate  Severe Profound 
 
Hearing Aids YES NO 
Cochlear Implant YES NO 
Intellectual disability YES NO 
Additional disability YES NO 
 
 
Did the test results fit with Auditory Neuropathy Spectrum Disorder (ANSD)5? 
 
RIGHT Yes No Not recorded 
LEFT Yes No Not recorded 
 
 
Additional information: (please fill in) 
Any known causes of SNHL?  
 
Aetiological tests completed CMV status Y/N 
 GJB2 (Connexin26) Y/N 
 m.1555A>G before this study Y/N 
 MRI/CT of inner ear Y/N 
 Ophthalmology review Y/N 
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Notes  
*Mild hearing loss 21 - 40 dB 
Moderate hearing loss 41 - 70 dB 
Severe hearing loss 71 - 95 dB 
Profound hearing loss > 95dB 
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Appendix 8: Neonatal data collection proforma 
Mitogent study ID –  
Date of birth –  
Variable Value Code 
Sex  0=Male 1=Female 
Gestational age   
Birth weight   
Apgar @ 5 mins   
CRIB – II  Admission temp 
Base excess 
Diagnoses 
Variable Value Code 
 
IVH/PVL  0=None 
1=IVH I-II 
2=IVH with vent distension 
3=Intraparenchymal lesion 
4=Perivent leukomalacia 
Pneumathorax  0=No 1=Yes 
Pulmonary Haemorrhage  0=No 1=Yes 
PDA  0=No 
1=Yes-no treatment 
2=Yes-medical treatment 
3=Yes-surgical 
NEC  0=No 
1=Yes-medical treatment 
2=Yes-surgical drain 
3=Yes-laparotomy 
CLD/BPD  0=No 
1=02 28d off 36w 
2=02 36w <30% 02 LF 
3=02 36w >30% 
HF/CPAP/vent 
Septicaemia (+ve BC) (bug)   
Meningitus (+ve CSF) (bug)   
 
Variable Value Code 
Bilirubin (highest)    
Creatinine (highest)   
Days of ETT   
Days of CPAP   
Days of 02   
Days of Long Line (PIC)   
Days Level 1   
Days Level 2   
Days Level 3   
  
  
1
6
5
 
Mitogent study ID –  
Date of birth – 
           
Amikacin           
Netilmicin           
Gentamicin           
Vancomycin           
Levels NGV           
Furosemide           
Indomethacin           
Ibuprofen           
Inotropes            
Dexamethasone           
Hydrocortisone           
Methylprednisolone           
TSB ↑           
Exchange trans           
Blood transfusion           
Creatinine ↑           
Lactate ↑           
Lowest pH           
Vent – CV           
HFO           
Nitric           
CPAP           
02           
TPN           
Inotropes – dopamine, dobutamine, adrenaline, noradrenaline 
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Appendix 9: Subsidiary sites 
Trust Hospital Local principal investigator 
   
Ashford and St Peter's 
Hospitals NHS Foundation 
Trust 
St Peter’s Hospital Dr Peter Reynolds 
   
Barking, Havering and 
Redbridge University 
Hospitals NHS Trust 
Queens Hospital 
King Georges Hospital 
Dr Wilson Lopez 
Dr Wilson Lopez 
 
Barnet and Chase Farm 
Hospitals NHS Trust 
Barnet Hospital 
Chase Farm Hospital 
Dr Tim Wickham 
Dr Tim Wickham 
 
Barts Health NHS Trust Whipps Cross University 
Hospital 
Dr Nic Wilson 
 Royal London Hospital Dr Divyen Shah 
 Newham University 
Hospital 
Dr Vimala Gopinathan 
   
Brighton and Sussex 
University Hospitals NHS 
Trust 
Royal Sussex County 
Hospital 
Dr Cathy Garland 
 Princess Royal Hospital Dr Cathy Garland 
   
Chelsea and Westminster 
NHS Foundation Trust 
Chelsea and Westminster 
Hospital 
Dr Sabita Uthaya 
   
Colchester Hospital 
University NHS Foundation 
Trust 
Colchester General Hospital Dr Sarah Dalton 
   
Croyden Health Services 
NHS Trust 
Croyden University Hospital Dr Arun Kumar 
   
East Kent Hospitals 
University NHS Foundation 
Trust 
William Harvey Hospital 
Queen Elizabeth, The 
Queen Mother Hospital 
Dr Vimal Vasu 
Dr Vimal Vasu 
 
   
Guy's and St Thomas' NHS 
Foundation Trust 
St Thomas' Hospital Dr Grenville Fox 
   
Herts Community NHS 
Trust 
Community trust Dr Alpana Kulkarni 
   
Homerton University 
Hospital NHS Foundation 
Trust 
Homerton Hospital Dr Narendra Aladangady 
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Imperial College Healthcare 
NHS Trust 
Queen Charlotte's and 
Chelsea Hospital 
Dr Aniko Deierl 
 St Mary’s Hospital Dr Aniko Deierl 
Kent Community Health 
NHS Trust 
Community Trust Dr Raj Nandi 
   
Kings College Hospital NHS 
Foundation Trust 
King's College Hospital Dr Simon Hannam 
   
Kingston Hospital NHS Trust Kingston Hospital Dr Jon Filkin 
   
Maidstone and Tunbridge 
Wells NHS Trust 
Maidstone General Hospital 
Tunbridge Wells Hospital 
Dr Hamudi Kisat 
Dr Hamudi Kisat 
 
Medway NHS Foundation 
Trust 
Medway Maritime Hospital Dr Aung Soe 
   
North East London 
Foundation Trust 
Community Trust Dr Iynga Vanniasegaram 
   
Portsmouth Hospitals NHS 
Trust 
Queen Alexandra Hospital Dr Victor Osei-Lah 
Dr Tim Scorrer 
   
St Georges Healthcare NHS 
Trust 
St Georges Hospital Dr Justin Richards 
   
The Hillingdon Hospitals 
NHS Foundation Trust 
Hillingdon Hospital Dr Michelle Cruwys 
   
The North West London 
Hospitals NHS Trust 
Northwick Park Hospital Dr Richard Nicholl 
   
The Whittington Hospital 
NHS Trust 
Whittington Hospital Dr Nischal Rao 
   
West Middlesex University 
Hospital NHS Trust 
West Middlesex Hospital Dr Didi Ratnasinghe 
 
 168 
  
Appendix 10: Distribution of positive blood cultures between hearing impaired and normal 
hearing groups 
 Hearing loss Normal hearing 
(comparison group) 
Total 
Low pathogenicity 
commensals 
26 50 
 
76 
High pathogenicity 
gram positives 
8 11 
 
19 
Low pathogenicity gram 
negatives 
2 2 
 
 
4 
High pathogenicity 
gram negatives 
4 11 
 
 
15 
Viral 2 3 
 
5 
Fungal 2 1 
 
3 
Total 44 78  
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Appendix 11: Protocol Publication BMC 
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